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The enzyme isoprenylcysteine carboxyl methyltransferase (Icmt) plays an 
important role in the post-translational modification of proteins involved in the 
regulation of cell growth and oncogenesis. Biological studies on the 1st selective 
small molecule inhibitor of Icmt cysmethynil has provided convincing evidence 
that targeting Icmt selectively induces cancer cell death. The consequences of 
Icmt inhibition strongly support the potential of the enzyme as a novel therapeutic 
target for oncogenesis.  In this thesis, structural modifications of cysmethynil 
were undertaken with the aim of identifying compounds that had favorable 
physicochemical profiles, were potent Icmt inhibitors and exhibited in vivo 
efficacy in xenograft bearing animals.  It was hypothesized that previously 
identified indoleamines with Icmt inhibitory and antiproliferative activities were 
appropriate starting “leads” to achieve these objectives.    
Fifty nine novel compounds were synthesized and evaluated for antiproliferative 
activity on a human breast cancer cell line (MDA MB 231). Those with promising 
activities were shortlisted for evaluation of Icmt inhibitory activity. 5-(3-
Diethylaminomethyl-1-octyl-1H-indol-5-yl)-pyrimidin-2-ylamine (4-12) emerged as 
a promising candidate with nanomolar IC50 for inhibition of Icmt, and low 
micromolar antiproliferative activities on a panel of malignant cells. The desirable 
activity profile of 4-12 highlighted the critical role of position 5 on the indoleamine 
scaffold in modulating activity.   
The antiproliferative activity of 4-12 arose from its ability to disrupt the transition 
of prostrate PC3 cells from G1 to G2/M phase in the cell cycle.  4-12 prevented 






these cells. Interestingly, it did not initiate apoptotic cell death but demonstrated 
the induction of autophagy in several malignant cell lines. There was also 
evidence that 4-12 restricted cell migration. These findings showed that 4-12 
affected several processes that are critical in carcinogenesis, namely 
antiproliferation, disruption of cell cycle, induction of autophagy and cell 
migration.  In spite of the diversity of these phenomena, the effects of 4-12 were 
observed over a narrow and recurring concentration range (1-5 µM). Compared 
to cysmethynil which also affected these processes in a qualitatively similar 
manner, 4-12 was more potent by at least a fold magnitude. 
The efficacy of 4-12 was demonstrated in vivo on xenografts induced in 
immunocompromised mice. Animals treated with 15mg/kg and 30 mg/kg of 4-12 
demonstrated statistically significant reduction in tumor volumes with no overt 
weight loss or toxicity. A preliminary pharmacokinetic assessment in mice at the 
same dose range showed that 4-12 was widely distributed into tissues, rapidly 
cleared from the circulation and had a moderately short half-life (1.5 h).    
Taken together, the results presented in this thesis have contributed to a 
better understanding of functionalized indoleamines as Icmt inhibitors and the 
mechanistic basis of their antiproliferative activity. It has also highlighted the 
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CHAPTER 1 Introduction 
1.1 Overview of cancer and its characteristic features 
Cancer is the leading cause of death in the developed world. Considerable effort 
and resources have been directed towards understanding the biology of cancer 
in the hope that this would provide a rational basis for the discovery of novel and 
effective anticancer therapeutics.  In their seminal paper, Hanahan and Weinberg 
described six essential functional capabilities acquired by human cells that drive 
their transformation from a normal to malignant state.1 These “hallmarks” which 
arise from aberrations in normal cell physiology are summarized as follows:  
(i) Self-sufficiency in growth signals: Tumor cells are capable of inducing and 
sustaining their own growth signals, hence reducing their dependency on 
exogenous growth signals from the normal tissue microenvironment. 
(ii) Insensitivity to antigrowth signals:  Tumor cells are capable of circumventing 
antigrowth signaling circuitry within cells, mainly by reducing the activities of 
tumor suppressor genes. 
(iii) Evading cell death: Tumor cell populations expand because of unfettered cell 
proliferation coupled with restricted cell attrition. Cell death is an effective barrier 
to cancer and the ability to acquire resistance to cell death mechanisms is a key 
signature of cancer cells. 
(iv) Unlimited replicative potential: The preceding acquired capabilities (i-iii) by 
tumor cells curtail their responsiveness to growth signals from the environment 
but are not sufficient to drive macroscopic tumor growth. The latter is achieved 






(v) Sustained angiogenesis: Tumors require a constant supply of oxygen and 
nutrients and the concurrent removal of metabolic wastes and carbon dioxide to 
support continued growth. Sustained angiogenesis is thus a necessary 
requirement for tumor development. 
(vi) Tissue invasion and metastasis: 90% of cancer deaths are due to 
metastases. Invasion and metastases allow cancer cells to escape from the 
primary tumor mass and colonize new sites in the body where space and 
nutrients are plentiful.  To achieve this end, tumor cells must first acquired the 
aforementioned capabilities (i-v). 
In 2011, Hanahan and Weinberg proposed two additional hallmarks but assigned 
them as “emerging” capabilities as they have yet to be generalized and 
validated.2   They are deregulated cellular energetics and evading immune 
destruction. Briefly, cancer cells are able to modify cellular metabolism in order to 
effectively support proliferation. Notably, carbohydrate metabolism is diverted 
from mitochondrial oxidative phosphorylation to aerobic glycolysis even though 
the latter is less efficient in generating ATP. Cancer cells however benefit from 
aerobic glycolysis because intermediates arising from this pathway are 
channeled towards the biosynthesis of macromolecules (nucleosides, amino 
acids) that are required for growth.   The other hallmark is antitumor immunity. As 
tumors develop, they develop mechanisms or strategies to evade immune 
detection and limit the extent of immunological killing. The authors also identified 
two enabling characteristics that facilitate the acquisition of core and emerging 






cells with genetic alterations that promote their proliferation and the role of 
inflammation in promoting tumor growth.   
Recognizing the functional capabilities of cancer cells has heralded novel 
therapies that act specifically on enabling capabilities.2 The assumption was that 
if an acquired characteristic is truly essential for the tumor, then inhibiting it would 
surely curtail growth and progression.  Such therapies have been used in the 
clinics, for example inhibitors of VEGF signaling to target angiogenesis and 
EGFR inhibitors to interrupt sustained proliferative signaling. Targeted therapies 
should arguably minimize off-target effects and lessen non-specific toxicity, but 
their clinical responses have sadly proven to be transient.  One reason is that a 
targeted therapy is unlikely to completely shut down the core capability due to the 
presence of partially redundant signaling pathways. Hence, some cancer cells 
would invariably survive and subsequently adapt to the selective pressure 
exercised by the therapeutic agent.  
1.2 Post-translational modification of proteins with CaaX at their C-
terminus 
It is widely recognized that the total number of proteins in the human proteome ( 
> 1 million) greatly exceed the number of genes (  20,000 to 25, 000) in the 
genome.  These estimates indicate that single genes encode multiple proteins 
because there are various mechanisms that allow different mRNA transcripts to 
be generated from a single gene.3  The gene products (proteins) are further 
modified by a slew of post translational modifications which introduce additional 
diversity. These post-translational modifications are covalent processing events 






modifying group to one or more amino acids.4  Examples of post translational 
modifications include phosphorylation, ubiquitination, methylation, proteolysis and 
lipidation.  In lipidation, fatty acids and/or isoprenoid groups are covalently 
attached to selected residues in the protein.   Once modified in this way, the 
protein is rendered more hydrophobic, exhibits greater affinity for cellular 
membranes which in turn affects functionality.   
Protein prenylation – the attachment of isoprenoid groups to proteins –  
involves a series of sequential reactions directed at proteins that have a “CaaX” 
box (cysteine –aliphatic-aliphatic- non-specified amino acid) at their C-terminus . 
Figure 1 provides an overview of the process which starts with the attachment of 
an isoprenoid residue to the invariant cysteine of the CaaX motif.5  Either a 15-
carbon farnesyl or 20-carbon geranylgeranyl residue is attached to the cysteine 
via a thioether linkage by cytosolic enzymes protein farnesyltransferase (FTase)6, 
7 or protein geranylgeranyltransferase-I (GGTase-I).8  The amino acid X in the 
CaaX box varies in its identify from protein to protein and is generally thought to 
determine whether farnesylation or geranylgeranylation takes place.  The 
prenylated protein then moves from the cytosol to the endoplasmic reticulum 
(ER) where it is recognized by an ER-bound protease Rce-1(endoprotease RAS 
converting enzyme 1) 9, 10 which removes the –aaX residue from the C-terminus. 
The prenylated cysteine which is now at the C-terminus is methylated by 
isoprenylcysteine carboxyl methyltransferase (Icmt), another integral ER bound 
enzyme,11, 12 to give the final product in which the C-terminal cysteine is 







Figure 1.1  Post translational modification of CaaX proteins  
 
The modified protein is then directed to its appropriate cellular location which is 
often the cytosplasmic surface of cell membranes where it is involved in 
important biological regulatory events.  This is described in the following section 
using Ras proteins as an example.   
1.3 Ras proteins 
Ras proteins are probably the best known proteins that have the C-terminal CaaX 
motif.  Post-translational prenylation of Ras ensures that it is localized in the 






where it is able to recruit downstream target enzymes. An example is shown in 
Figure 1.2 (adapted from Downward13) which shows the activation of Ras by a 




Figure 1.2 signaling upstream of RAS  
 
Ras is active when bound to GTP and inactive when bound to GDP. In cells, the 
ratio of Ras bound to GTP and GDP is moderated by guanine nucleotide 
exchange factors (GEFs) which increases GTP-bound Ras, and GTPase-
activating proteins (GAPs) which increases GDP-bound Ras.   As shown in 
Figure 1.2, phosphorylation of the receptor tyrosine kinase promotes its 
association with an adaptor protein growth-factor-receptor-bound protein 2 
(GRB2), followed by recruitment of SOS1 protein (a GEF) to the plasma 
membrane where Ras is located as a result of prenylation. The proximity of 
SOS1 to Ras triggers guanine nucleotide exchange and increases GTP-bound 
Ras.  The activated Ras interacts and increases the catalytic activity of several 






involved in cell proliferation and survival.  Examples of Ras-responsive pathways 
are RAF/MAPK (for cell cycle progression) and PI3K/AKT/PDK1(for cell survival, 
cytoskeletal signaling, transcription factor pathways).  
Approximately 30% of human cancers result from mutated or hyperactive Ras 
proteins.13 For this reason, Ras is widely recognized as an important oncology 
target. However, developing small molecule inhibitors against Ras has proven to 
be elusive.  The conventional approach of designing inhibitors to disrupt 
nucleotide binding to Ras has not been fruitful due to the strong (picomolar) 
binding affinity of Ras to guanine nucleotides, which are abundant in the cytosol. 
In contrast, the same strategy has successfully generated small molecule 
inhibitors of ATP binding protein targets primarily because ATP binds weakly (low 
micromolar Km) to its target protein and is thus readily displaced. Inhibiting Ras 
protein expression through the use of antisense oligonucleotides and short 
interfering RNAs (siRNA) are other options of curtailing Ras activity but the 
therapeutic potential of these methods have yet to be demonstrated.  
 In view of the limitations associated with direct methods of apprehending Ras 
activity, attention has turned to indirect approaches. Of these, inhibiting the 
kinases involved in Ras signaling pathways have given good results.  Gefitinib 
(ZD1839, Iressa) which is used clinically for non-small cell lung cancer, inhibits 
the kinase activity of EGFR (epithelial growth factor receptor) which is upstream 
of Ras. Inhibitors acting on downstream effectors such as the components of the 
RAF-MAPK pathway are in the different stages of clinical development. 
Downward has provided an insightful discussion on the targeting of Ras signaling 






localization of Ras at membranes by inhibiting the enzymes involved in the post-
translational prenylation reactions. This has been the topic of several excellent 
reviews14, 15 and will be discussed briefly in the following section.  
1.4 Targeting prenylation and post-prenylation processing enzymes as 
targets in oncogenesis 
1.4.1 Inhibitors of protein farnesyltransferase (FTase) and protein 
geranylgeranyltransferase-I (GGTase-I) 
 
FTase inhibitors (FTIs) were first reported in the early 1990s.16  The choice 
to target FTase over other prenylation/post-prenylation enzymes was prompted 
by the following considerations:  FTase is the first and rate-limiting step in CaaX 
processing, it is soluble and readily purified, and as it processes comparatively 
fewer substrates than RCE1 or Icmt,  FTase inhibitors may be less toxic.5 Since 
2000, four FTIs have been evaluated in clinical trials (Figure 1.3) but sadly, none 
have demonstrated therapeutic efficacy, in spite of outstanding potencies in 
preclinical trials. Several reasons may account for the discrepancy.15 Foremost is 
the realization that in humans, the KRas isoform is most frequently mutated 17and 
that when FTase is inhibited, KRas is prenylated by GGTase1 (“cross-
prenylation”) and remains fully functional.18-21 In addition, patients may not have 
been properly selected for the clinical trials.  Patients with tumors that are 






                  
Figure 1.3 FTIs that have been evaluated in clinical trials (a)  
Lonafarnib 22 (b) Tibifarnib23  (c) L77812324, (d)  BMS214662.24 
 
The disappointing experience with FTIs and reports suggesting that 
inhibition of GGT may benefit a wide array of diseases (such as glaucoma, 
diabetic retinopathy, viral infections, multiple sclerosis and inflammation7, 24 
besides cancer have boosted interest in GGT inhibitors (GGTIs).  Several 
scaffolds have been investigated7, 25 but to date,  only one GGT inhibitor, GGTI-
2418 (Figure1.4), has entered clinical trials,26  
 







1.4.2 Inhibitors of post-prenylation enzymes Rce-1 and Icmt 
Rce-1 and Icmt are downstream to FTase and GGTase1 in the prenylation 
cascade. Both Rce-1 and Icmt are structurally and mechanistically distinct from 
other proteases and methytransferases in the human body,8, 27, 28 which suggests 
that inhibitors of these enzymes are likely to be highly specific in their targeting 
activity . On the other hand, concerns have been raised that since inhibition of 
Rce1/Icmt affect both farnesylated and geranylgeranylated proteins, these 
inhibitors may be more toxic than FTIs and GGTIs.15  
Of the two post-prenylation enzymes, Rce-1 is generally viewed as the 
less attractive target.  Its catalytic mechanism is poorly defined, attempts to 
identify potent and selective inhibitors have not been fruitful and there is a 
prevailing view that Ras and other oncogenic proteins are somehow less 
dependent on the proteolytic activity of Rce1 for cancer growth and 
progression.29 Patent activity in the area of Rce-1 inhibitors have similarly been 
weak.29  
There is more evidence to support Icmt as a viable target for oncogenesis. 
Genetic disruption studies in murine cells showed that ablating Icmt activity had 
profound consequences on oncogenic transformation.30-32 Inhibition of Icmt 
resulted in mislocalization of Ras and loss of cellular transformation ability.33, 34 
Several classes of Icmt inhibitors have been reported but only a few scaffolds 
have been patented.35, 36 These are briefly described in the following paragraphs, 






1.4.3 Substrate-based inhibitors of Icmt 
Outstanding work in this area has been reported by Hrycyna and Gibbs of 
Purdue University.33, 37-43 Their inhibitors are based on two ‘minimal” substrates 
of Icmt : N-acetyl-S-farnesyl-L-cysteine (AFC)44and farnesyl thiopropionic acid 
(FTPA).44 (Figure1.5). Through a series of structural modifications, they 
succeeded in suppressing the substrate profiles of these scaffolds and converting 
them into inhibitors.  
 
Figure 1.5 Structures of minimal substrates of Icmt: AFC and 
FTPA 
 
To develop AFC-based inhibitors, the investigators identified the structural 
elements in AFC that were critical for inhibition (Figure1. 6).  
    







Maintaining the chirality at the α carbon was not critical for inhibition. A 
free carboxylic acid that was not esterified was however, essential. Replacing the 
N-acetyl moiety in AFC with bulkier and more lipophilic groups greatly enhanced 
inhibitory activity. The most promising compound to emerge from these 
investigations was POP-FC in which acetyl has been replaced by 2-
phenoxybenzoyl  (IC50 4.3µM) (Figure 1.7).45   The ortho-orientation of the 
phenoxy group was critical for activity as Icmt inhibition decreased when it was 
shifted to para or meta position.43 Also important was the ether linkage between 
the two rings. Replacing O with CH2 or S (less electronegative atoms) was not 
favored but NH gave acceptable levels of activity.43, 45 Isosteric replacement of 
the amide in AFC with a sulphonamide was not permissible although it was 
argued that the sulphonamide analogs were a step in the right direction because 
of their drug-like character.41 Another interesting observation was that N-
methylation of the amide N in AFC did not adversely affect Icmt inhibitory 
activity.43  
 
Figure 1.7 Structure of POP-FC 
  
Several investigations centered on modifications of the S-farnesyl side 
chain.43 Replacing the C15 farnesyl with shorter (C10 geranyl) or longer (C15  
geranylgeranyl) isoprenoid- side chains diminished inhibitory activity. A derivative 






fragment in the S-farnesyl side chain is known to be susceptible to enzymatic and 
chemical hydrolysis.46 Thus considerable effort was expended in finding a stable 
substitute to this fragment. Replacing the nucleophilic sulphur in AFC with 
sulfoxide resulted in a more potent inhibitor but a sulphur-to-selenium substitution 
gave substrates with larger Km and smaller Vmax values which are characteristic 
of weaker substrates.47 The analog with an all carbon side chain (sulphur 
replaced by methylene) was neither a substrate or inhibitor, implying that while a 
heteroatom in the side chain favored binding to the enzyme,  substrate-like 
properties were uniquely associated with sulphur.  In spite of the apparent need 
for a heteroatom in the side chain, Bergman and co-workers explored the 
possibility of substituting the thioether linkage with a heteroaryl motif, namely 
1,2,3-triazolyl (Figure1. 8). The resulting compounds were weak Icmt inhibitors 
(IC50 10-36 µM) but less lipophilic and presumably more stable.48  
 
Figure 1.8 Example of an AFC congener derived by replacing the 
thioether with 1,2,3-triazole moiety 
 
The most potent inhibitor derived from AFC is POP-3-MB-FC (Figure 
1.9)45  whose design was the outcome of several SAR investigations. Thus, the 
biphenyl chain was introduced because studies with FTase ligands showed that 
the 2nd and 3rd isoprene units in the farnesyl side chain could be replaced by a 






analog33, 35 inspired the inclusion of the isobutenyl side chain and in the same 
way, the phenoxyphenyl residue was introduced because of POP-AFC.45 POP-
3MB-FC inhibited Icmt with an IC50 of 2.5 µM. It altered the subcellular 
localization of GFP-K-Ras in Jurkat T cells, and also inhibited ERK 
phosphorylation and Ras activation.43  
 
 
Figure 1.9 Structure and SAR of POP-3MB-FC 
 
  There are fewer studies on inhibitors derived from FTPA. The most 
promising compound was a triazolyl analog (Figure 1.10) whose design bore 
similarities to modifications made in the AFC-based inhibitors. As described 
earlier, the biphenyl was introduced as an isoprene mimetic. Unlike the AFC-
derived inhibitors, esterification of the carboxylic acid was found to be necessary. 
The triazole ring was explored unsuccessfully as a thioether substitute but greatly 
improved activity when incorporated into the side chain. This compound turned 
out to be a more potent IC50 inhibitor than POP-3MB-FC (IC50 0.8 µM). It inhibited 
the viability of a K-Ras addicted pancreatic cell line PaTu-8902 with an IC50 of 8 








Figure 1.10 Structure of the most promising FTPA-derived Icmt 
inhibitor 
Farnesylthiosalicylic acid (Salirasib) and analogs 
The US Patent RE03968251 describes the anti-cancer potential of 
farnesylthiosalicyclic acid (FTS) and related compounds. Structurally, FTS may 
be viewed as a conformationally restrained analog of the minimal substrate FTPA 
(Figure 1.11). Although FTS inhibited Icmt (IC50 2.6 µM), its effects on Ras may 
not be entirely due to Icmt inhibition. It is proposed that FTS blocks the 
association of Ras with galectins which is required for strong membrane 
association and robust signaling. The galectins have hydrophobic binding 
pockets which accept the farnesyl side chain of prenylated Ras. FTS may 
compete for occupancy of these sites, thereby interfering with galectin-induced 
nanoclustering and the resulting activation of downstream signaling pathways.52, 
53 Modifying the carboxylic acid of FTS by esterification or amidation gave 
compounds with improved growth inhibitory activities on pancreatic cancer cell 
lines but only the amide (R= NH2) reduced levels of active Ras in the cells in the 







Figure 1.11  (A) Relationship between FTS and FTPA. 
(B)Structural analogs of FTS 
1.4.4 Cysmethynil  
The indoleacetamide cysmethynil is possibly the most widely investigated 
Icmt inhibitor to date (Figure 1.12).34, 54 It was identified in a high-throughput 
screen and subsequently found to mislocalize Ras, impair response to EGF 
signaling and reduce anchorage independent growth of colon cancer cells. These 
effects were reversed when Icmt was overexpressed.34 Another study showed 
that cysmethynil did not activate apoptosis as a cell death pathway but enhanced 
autophagy and autophagic cell death in prostate cancer PC3 cells.55 On the other 
hand, cysmethynil induced autophagy and apoptosis in liver cancer HepG2 
cells.30 Interestingly, the ability of cysmethynil to elicit an apoptotic response was 
dependent on the induction of autophagy. Thus when autophagy was suppressed 
(either pharmacologically or through knock down of autophagy-essential 
proteins), cysmethynil-induced apoptosis was not observed in HepG2 cells.30 It is 
not known why cysmethynil induced apoptosis in HepG2 cells but not in PC3 
cells. One proposal was that the two cell lines had different cellular genetic 
and/or epigenetic factors which influenced their cell death pathways.30 Treatment 
of mice harboring PC3 or HepG2 cell-derived xenograft tumors resulted in 






xenografts revealed markers consistent with autophagy induction and cell growth 
arrest.30, 55  
In spite of its promising anticancer potential, cysmethynil is highly lipophilic 
(ClogP 7) and poorly soluble.  These properties are likely to hamper its 
bioavailability and development as a therapeutic agent. Thus, medicinal 
chemistry efforts have been directed towards incorporating drug-like features in 
the cysmethynil scaffold while maintaining or improving potency. To this end, the 
SAR of cysmethynil for Icmt inhibition was explored and several indoleamines 
were identified as promising Icmt inhibitors with comparable activity to 
cysmethynil but greater cell based antiproliferative activities.56, 57 Briefly, the 
amide side chain at position 3 of cysmethynil played a critical role as its absence 
completely removed both Icmt inhibition and cell based growth inhibitory 
activities. However, replacing the amide with a tertiary amino side chain restored 
Icmt inhibition while greatly improving cell based antiproliferative activity.  
Modifications at position 5 afforded the greatest flexibility as only incremental 
changes in both activities were observed when m-tolyl was removed or replaced 
by phenyl, methoxy substituted phenyl or ortho/para-tolyl. Surprisingly, removing 
the  n-octyl side chain of cysmethynil weakened Icmt inhibitory activity but did not 
abolish it completely as observed when the amide side chain was removed. 
Replacing n-octyl with geranyl restored Icmt inhibitory activity, as did the 
isoprenyl analog, which was however a weaker Icmt inhibitor.  Interestingly, 
indoleamines with n-octyl at position 1 could tolerate small, less lipophilic groups 
at position 5 (notably fluoro), while analogs with m-tolyl at position 5 retained 
acceptable Icmt inhibitory activity when combined with the shorter, less lipophilic 






a careful choice of groups at these positions. Figure 1.12 summarizes the 
influence of the different structural features in cysmethynil on Icmt inhibitory 
activity. 
 
Figure 1.12 SAR of cysmethynil for Icmt inhibition 
 
Key lead compounds identified from earlier work on lead modification of 







Figure 1.13 Promising lead compounds identified from earlier work on 
lead modification of cysmethynil.56, 59 1 Log D 7.4 values were estimated on 
ACD Labs/12.0. 2Solubility was determined at pH 7.4, 24 h agitation. 
Tetrahydropyranyl derivatives as Icmt inhibitors 
Several tetrahydropyranyl derivatives were identified as potent Icmt inhibitors by 
Judd et al.58 The lead dimethyltetrahydropyranyl derivative had a low IC50 of 3.5 
µM but  improved upon modification to give a nanomolar inhibitor (IC50 1.3 nM) 
which is  the most potent Icmt inhibitor identified to date (Figure 1.14).  This 
compound caused a dose dependent accumulation of cytosolic Ras in colon 
cancer HCT-116 cells, as would be expected from Icmt inhibition. However, 
unlike a FTase inhibitor (FTI-2628) that was concurrently investigated, the effects 






concentrations (10, 25µM). Cell growth inhibitory activities of the 
tetrahydropyranyl derivative across a range of cell lines with wild-type or mutated 
Ras were also moderate (IC50 0.3-20 µM) and did not compare favorably with 
the FTase inhibitor. For this reason, the authors expressed the view that Icmt 
inhibition may not be as critical as FTase in the proteins such as Ras. 
 Figure 1.14Lead optimization of tetrahydropyranyl derivatives as Icmt inhibitors 
 
1.5 Statement of Purpose 
As described in the preceding section, there is strong support for Icmt as a 
therapeutic target for oncogenesis and consensus on the anti-cancer potential of 
small molecule inhibitors of Icmt. In earlier work done in this laboratory, lead 
modification of cysmethynil was carried out with the objective of identifying 
analogs with greater potencies and improved drug-like profiles. 59, An important 
finding to emerge from that investigation were compounds 1,2 and 3 which were 
comparable to cysmethynil in terms of Icmt inhibitory activity but more potent in 
terms of antiproliferative activities on breast cancer MDA-MB-231 cells (Figure 1-
13). As these compounds are indoleamines and will be protonated at pH 7.4, 
they were expected to be more water soluble than cysmethynil. However, the 






the case. Notably, the most promising compound 1 was still poorly soluble, 
possibly because the polarity associated with the ionizable basic centre was 
nullified by the concurrent increase in molecular weight (cysmethynil 376.5 D, 4-
3: 404.6 D). Clearly, there are gaps in our understanding of how best to carry out 
lead modification in order to align the structural elements required for drug-
likeness and potency.  We hypothesized that the modifications encoded in the 
lead compounds 1-3 are useful starting points which could be further exploited to 
achieve our aim of designing Icmt inhibitors that fulfill the dual requirements of 
potency and drug-likeness. The desired endpoints for drug likeness are arbitrary 
set at a solubility of at least 50 ug/mL for a compound of moderate potency (low 
or submicromolar Icmt inhibitory and cell-based antiproliferative activity) and 
average permeability (PAMPA permeability equivalent to that of known 
compounds ranked in this category ).92 Other criteria would include a molecular 
weight threshold of no more than 500 dalton and acceptable lipophilicity (log P < 
5, log D at pH 7.4 of 3 to 4.5).89 Any potential candidate to emerge from the 
proposed work would also need to be characterized in detail in terms of its 
antiproliferative activity and in vivo activity in animal models.  An understanding 
of how the candidate compound affects the cell cycle, modes of cell death 
(apoptosis, autophagy) and migration of cells  would provide the needed 
elaboration of its antiproliferative activity. If there is justification to proceed further 
with in vivo testing, this should be preceded by estimation of its maximal tolerated 
dose and some understanding of the metabolic susceptibility and other 






CHAPTER 2     Design and Synthesis of Target Compounds 
2.1 Design of Target Compounds 
Seven compound series were designed and synthesized in this report. Series 1 
and 2 were based on the lead compound 1, Series 3 on lead compound 2, and 
Series 4 on lead compound 3. As mentioned in Section 1-9 (Statement of 
Purpose), lead compounds 1 and 2 demonstrated exceptional solubilities (> 100 
µM, pH 7.4, 25oC) but mediocre anti-proliferative and Icmt inhibitory activities 
while the potencies of compound 3 exceeded those of cysmethynil but was 
hampered by its poor solubility. Thus, there is a compelling basis for exploring 
the structure-activity relationships (SAR) of these compounds. The aim is to 
address and if possible, overcome these shortcomings by appropriate design 
approaches.  Series 5, 6 and 7 were modeled after cysmethynil, with 
modifications made to position 5 in Series 5 and the amide side chain in Series 6. 
Series 7 comprised compounds with non-indole scaffolds but with similar 
substituents as cysmethynil.  In all, 90 compounds were reported and of these, 
61 compounds in Series 1, 4, 5, 6 and 7 were synthesized by the candidate, 
while the remaining 29 compounds were synthesized by a post doctoral fellow, 
Dr Yang Tianming.  The latter compounds were also discussed in this chapter to 
provide a complete overview. Figure 1 summarizes the design approaches 







Figure 2.1 Series 1-7: Design approaches. 
2.1.2 Series 1 
The lead structure for series 1 is compound 1 which owes its good solubility (120 
µM, pH 7.4)60 largely to the presence of 5-fluoro (F).  Fluorine is the most 
electronegative of the halogens. The C-F bond is exceptionally strong and 
accounts to a large measure for the metabolic inertness of fluorine. In spite of its 
poor hydrogen bond (H) acceptor properties, F paradoxically participates in 
multipolar interactions of the type C-F--H-N and C-F--C=O. When present in a 
molecule, it is known to favor specific conformations due to its stereo electronic 






ring is planar but  trifluoromethoxyl (CF3O) attached to phenyl is not. In drug 
design, F is the smallest substituent that can replace H with minimal steric 
consequences, but F and O are more nearly isosteric than F and H because of 
size and electronegativity considerations. In Series 1, a “fluorine scan” was 
carried out on lead compound 1 in which F was systematically introduced at 
positions 4, 5, 6 and 7 of the indole ring, with the intent of determining if 
relocating F would affect biological activity (Table 2.1).  The log D7.4 of the 
compounds were estimated and interestingly, found to vary with the position of F 
(for the same tertiary aminomethyl side chain at position 3). As seen from Table 















Table 2.1 Series 1 compounds 
 










-N(CH3)2   1-9 3.8 1-16 3.9   
-N(C2H5)2 1-1 4.2 1-10 4.0 1-17 5.6 1-23 5.6 
N  












1-5 4.5 1-14 4.4 1-20 4.5 1-25 6.0 
N  








1-8 4.4   1-22 4.1 1-26 5.6 
a  Estimated with ACD /Labs Version 12. LogD7.4 of cysmethynil = 6.9. 
Besides varying the position of F, changes were also made to the amino side 
chain at position 3. The following side chains have been investigated in lead 
structure 1 : dimethylamino, diethylamino, piperidinyl, morpholino, 
thiomorpholino, 4-methylpiperazinyl and pyrrolidinyl.56, 59However, the biological 
impact of secondary amino side chains (1-7, 1-8) have yet to be explored and for 






2.1.3 Series 2 
Like Series 1, compounds in Series 2 were based on lead structure 1. Here, the 
n-octyl of 1 was replaced by geranyl (3,7-dimethyl-octa-2,6-dienyl). Geranyl 
differs from n-octyl in being longer (C10), unsaturated and branched.   It has been 
shown that the combination of 5-F and 1-n-octyl in 1 was essential for Icmt 
inhibition.56, 59 Notably, the compound with 5-F and 1-isoprenyl was inactive,59 an 
indication that the small, weakly lipophilic F must be coupled with a more 
lipophilic entity at position 1. The decision to investigate geranyl as a substitute 
for n-octyl in 1 was motivated by several factors, namely that (i) the 1-geranyl 
analog of cysmethynil was as potent as cysmethynil in terms of Icmt and anti-
proliferative activities,56, 59 and (ii) replacing n-octyl with geranyl caused 
lipophilicity to increase by a modest 4 fold (Table 2-2). The tertiary amino side 
chains explored in Series 2 were largely similar to those investigated in Series 1, 
but included two “asymmetrically substituted” tertiary amino groups as seen in 2-











Table 2.2 Series 2 compounds 
     
Cpd 
No 
R1 LogD7.4a Cpd 
No 
R1 LogD7.4a 
2-1 -N(CH3)2 4.4 2-7 
 
5.5 
2-2 -N(C2H5)2 4.6 2-8 
 
6.7 
2-3 - N(CH3)( C3H7-n) 5.3 2-9 
 
4.9 
2-4 - N(C2H5)(C3H7-n) 5.8 2-10 
 
5.3 





5.4    
aEstimated with ACD /Labs Version 12 . LogD7.4 of cysmethynil = 6.9. 
2.1.4 Series 3 
Series 3 is based on lead structure 2 which has the shorter and less lipophilic 
isoprenyl (3-methyl-but-2-enyl) side chain in place of n-octyl. Accordingly, the 
larger, more lipophilic m-tolyl must be present at position 5. In Series 3, 
modifications were made to the amino side chain at position 3 and as seen from 










R1 Log D7.4a Cpd 
No 
R1 Log D7.4a 
3-1 -N(CH3)2 4.8 3-7 
 
6.1 
3-2 -N(C2H5)2 5.0 3-8 
 
7.3 













5.8    
a  Estimated with ACD /Labs Version 12, Log D. LogD7.4 of cysmethynil = 6.9.  
2.1.5 Series 4 
The lead structure for this series was compound 3 which had impressive Icmt 
and antiproliferative activities, but poor solubility (1.1 µM, pH 7.4). Series 4 aims 
to determine if varying the substitution on the 5-phenyl ring of 3 would be a viable 
means of overcoming the solubility problem while retaining good biological 
activity. Thus far, only methyl, methoxy and ethoxy substituents have been 
investigated (Figure 2-2). These compounds showed limited variability in Icmt 







Figure 2.2 Icmt and growth inhibitory IC50 values of compounds 
related to Compound 3.56, 59Growth inhibitory IC50 values were 
determined on human breast cancer MDA-MB-231 cells.  
 
Clearly, substitution of the phenyl ring at position 5 should be explored in greater 
detail and this was undertaken in Series 4 by introducing substituents   that 
differed from the electron-donating (-), lipophilic (+π) methyl and methoxy 
groups of earlier compounds.  Substituents explored were (i) electron-donating (-
) and hydrophilic (-π) hydroxyl, (ii) electron-withdrawing (+), lipophilic (+π) 
fluoro, trifluoromethyl, trifluoromethoxy and nitro groups, (iii) electron-withdrawing 
(-) and hydrophilic (-π) cyano, methylsulfonyl and methylaminosulfonyl groups, 
and (iv) heterocyclic pyridinyl and pyrimidinyl rings and their substituted analogs. 
Table 2-4 lists the structures and Log D 7.4 of the Series 4 compounds. Except for 
compounds with fluoro, trifluoromethyl and trifluoromethoxy groups, the other 
compounds were less lipophilic than compound 3 and may be more water 






properties as depicted in Table 2-4 would provide useful insight into the SAR at 
this position.  








































































2.1.6 Series 5 
Series 5 is modeled after cysmethynil and explores the effect of modifying the 5-
phenyl ring by substitution or replacement with a heteroaromatic ring. In the 
original library that led to the identification of cysmethynil, analogs with different 
substituent’s on 5-phenyl were investigated (Table 2-5). 62 Fluoro and ethoxy 
substituents retained good Icmt inhibitory activities while the other substituents 
were less promising.   
Table 2.5 Icmt inhibitory activities of functionalized cysmethynil analogs 
bearing different substituents on 5-phenyl.62  
 
R1 pIC50 b R1 pIC50b 
m-F 5.62 m-Cl-p-F 5.15 
p-CH3 4.97 m,m-bis-CF3 4.43 




b pIC50 = -log IC50 for inhibition of Icmt 
In view of the promising results obtained with the m-F substituent, fluoro 
regioisomers (o-F, p-F) and other fluorinated groups (CF3, OCF3) were 
investigated in Series 5 (Table 2-6). In addition, nitro and methylsulfonyl were 
selected as representative electron withdrawing (+)/ hydrophilic (- π) and 
electron donating (- ) / hydrophilic (- π) groups respectively.  The impact of 
replacing 5-phenyl with heteroaromatic rings (π deficient pyridine, π excessive 






Table 2.6 Series 5 compounds 
 
 
aEstimated with ACD /Labs Version 12 . LogD7.4 of cysmethynil = 6.9. 
b Substituted in place of 5-phenyl 
2.1.7 Series 6 
Earlier, an analog of cysmethynil with a secondary amide side chain was 
reported to be a slightly weaker Icmt inhibitor than cysmethynil but with 
significantly greater antiproliferative activity. In contrast, the compound with a 
tertiary amide side chain had a profile that was similar to cysmethynil (Figure 2-
3). 
Cpd No R1 Log D 7.4
a 
 
Cpd No R1 Log D 7.4
a 
 
5-1 o-F 6.44 5-7 o-F-p- CH3 6.87 
5-2 m-F 6.36 5-8b 
 
5.1 
5-3 p-F 6.33 5-9 b 
 
5.11 
5-4 o-CF3 7.11 5-10 m-NO2 6.22 
5-5 m-CF3 6.97 5-11 m-CH3SO2 5.49 









Figure 2.3 Icmt and growth inhibitory IC50 values of secondary 
and tertiary amide analogs of cysmethynil. 2, 3  Growth inhibitory IC50 
values were determined on human breast cancer MDA-MB-231(“231”) 
cells.  
 
 In view of these findings, the potential of compounds with a secondary amide 
side chain was explored in Series 6 (Table 2-7). Three of the compounds in this 






































6-3 m-CH3 CO-NH- 
C2H5 







6.2     
a  Estimated with ACD /Labs Version 12. LogD7.4 of cysmethynil = 6.9.  
b  Phenyl 
ring at position 5 is replaced by 3-pyridyl. 
2.1.8 Series 7 
Series 7 explores the potential of non-indole scaffolds that retain the same 
groups (m-tolyl, acetamide, n-octyl) as cysmethynil. Three scaffolds were 
proposed – pyrazole, indazole and azaindole, but finally only the pyrazole and 







Figure 2.4 Series 7 compounds : Functionalized non-indole 
analogs of cysmethynil. Log D7.4 values were estimated with ACD 
/Labs Version 12 . LogD7.4 of cysmethynil = 6.9. 
 
2.2 Chemical considerations 
2.2.1 Series 1 
 
Scheme 2.1 Reagents and conditions: (a) 1-Bromooctane, NaH (60%), DMF, 0 
oC to  rt, overnight;(yield: 80-90%)  (b) Secondary or primary amine, HCHO, 
acetic acid.(yield: 40-60%) 
As shown in Scheme 1, Series 1 compounds were synthesized in 2-steps :N-
alkylation of the indole NH of 4,5,6 or 7-fluoroindoles with 1-bromooctane in the 
presence of sodium hydride as base, and the Mannich reaction to introduce the 






Mannich reaction involves condensation of the primary or secondary amine with 
formaldehyde to form an electrophilic iminium cation which is then attacked by 
the electron rich carbon at position 3 of indole (Figure 2-5). 
 
Figure 2.5 Mechanism of Mannich Reaction 
 
2.2.2 Series 2 
Series 2 compounds were synthesized in the same way as Series 1 compounds, 
except that the alkylation step was carried out with geranyl bromide (Scheme 2-
2). The indole NH was deprotonated in the presence of base (NaH) to give a 









Scheme 2.2 Reagents and conditions: (a) Geranyl bromide, NaH, DMSO, 0 oC 
to  rt;  (b) Secondary amine, formaldehyde, acetic acid. 
2.2.3 Series 3 
The synthesis of Series 3 compounds is outlined in Scheme 2-3. 5-Bromoindole 
was reacted in a Suzuki coupling reaction to introduce the m-tolyl moiety at 
position 5, followed by alkylation of the indole NH to give the N-isoprenyl indole 
intermediate which was then reacted in a Mannich reaction with various amines 
to give the desired product.   
 
Reagents and conditions: (a) 3-Tolylboronic acid, Pd(dppf)Cl2, K2CO3(aqueous), 
1,4-dioxane, microwave, 130 oC, 25min; Yield:55% (b) 1-Chloro-3-methylbut-2-
ene (isoprenyl chloride), NaH(60%), DMF, rt, 4 Yield:87%h; (c) Formaldehyde, 











2.2.4 Series 4 
The synthesis of Series 4 compounds is outlined in Scheme 2-4. 
 
Scheme 2.3 Reagents and conditions (a) 1-Bromooctane, NaH (60%), DMF, 
0oC to rt, overnight; Yield:80-90% (b) Diethylamine, HCHO, acetic acid, RT, 
overnight; Yield:40-60% (c) Boronic acid, Pd(dppf), K2CO3, dioxane, microwave, 
20 min, 100oC. Yield:25-40%. 
 
As in the case of other Series, the same reactions ( N-alkylation of the indole NH, 
Mannich reaction, Suzuki coupling) were involved but carried out in a different 
sequence. Here, since variations were made at position 5, the Suzuki coupling 
reaction on a common intermediate (8) was assigned as the final step.  
The Suzuki coupling reaction is one of the most widely used palladium-catalyzed 
cross-coupling reactions.63 The palladium catalyst used here was 1,1’ 
bis(diphenylphosphino)ferrocene palladium (II) dichloride [Pd(dppf)] in which 
palladium exists in the stable, formal oxidation (II) state and slowly releases 
palladium in the lower (0) oxidation state.  Several commercial palladium 
catalysts  like Palladium(II) acetate Pd(OAc)2, Bis(triphenylphosphine) 
palladium(II) dichloridePdCl2(PPh3)2, Tetrakis(triphenylphosphine)palladium(0)  
Pd(PPh3)4, Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct 
Pd2(dba)3-CHCl3 , also contain palladium in the (II) state.  For example, 






phosphine oxide whereas  [1,1′-Bis(diphenylphosphino) ferrocene] 
dichloropalladium(II), complex with dichloromethane Pd(dppf)Cl2 · CH2Cl2 
generates the Pd(0) specie without the addition of phosphine ligands 
 
Figure 2.6 Provides a schematic representation of the 
mechanism of Suzuki coupling.   
 
The reaction starts with the rate limiting oxidative addition of the functionalized 5-
bromoindole to the palladium (0) complex, generated in situ from Pd(II) in 
Pd(dppf).  The complex  reverts to its Pd(II) state which is then  transmetallated 
with the aryl boronic acid to afford the Pd(Ar)(Ar’) complex.  The latter then 
undergoes reductive elimination with C-C bond formation and concurrent 
regeneration of the catalytically active Pd(0) complex. A base (sodium or 
potassium ethoxide, hydroxide or carbonate) is required to accelerate the 
transmetallation step by promoting the formation of a nucleophilic “ate” complex.  
2.2.5 Series 5 
The compounds in series 5 differ from cysmethynil in the substitution at position 






method for synthesizing cysmethynil was re-examined.34
  
Scheme 2.4 Reagents and conditions: (a) (i) NaBH4, NH2CHO-MeOH, rt (ii) 
KCN, 100 oC;  (b) KOH, t-BuOH, reflux;  (c) m-Tolylboronic acid, Pd(PPh3)4, 
K2CO3, EtOH/toluene, reflux; (d) Octyl bromide, NaH, DMF, rt. 
 
As shown in Scheme 2-5, the method involved reduction of 5-bromo-1H-indole-3-
carbaldehyde by sodium borohydride to give the corresponding alcohol which 
was then reacted in situ with potassium cyanide to give the nitrile. The latter was 
hydrolyzed under basic conditions to give the carboxamide.  Next, Suzuki 
coupling was carried out with m-tolylboronic acid in the presence of a palladium 
catalyst [tetrakis(triphenylphosphine)palladium(0), Pd(PhP)4], followed by N-
alkylation of the indole NH with 1-bromooctane in the presence of sodium 
hydride. When this method was attempted, the reaction was found to be sensitive 
to the quality of potassium cyanide (must be dry and free flowing) and the 
reaction time for hydrolysis to give the carboxamide. Overall, cysmethynil was 
obtained as a semi-solid gum in 15% yield. The method had several 
shortcomings, namely it involved the use of potassium cyanide, gave an low 
overall yield of cysmethynil and most importantly, was not suited for the synthesis 
of Series 5 compounds.  For the latter, a common intermediate, 2-(5-bromo-1-
octyl-1H-indol-3-yl)acetamide (10), should be synthesized and reacted with 
different arylboronic acids to give the final compounds.  Hence, an alternative 






readily executed, with cysmethynil obtained as a white powder in 54% yield. 
Briefly, the reaction started with commercially available 2-(5-bromo-1H-indol-3-
yl)acetic acid which was converted to the primary amide 9 via a coupling 
reaction64 with ammonium chloride in the presence of 1-hydroxybenzotriazole 
(HOBt) and  1-ethyl-3-(3-dimethylamino propyl) carbodiimide (EDC). The reaction 
proceeded smoothly to give the acetamide  9 in 95% yield.  The acetamide was 
then N-alkylated with 1-bromooctane to give 10 and reacted with m-Tolylboronic 
acid in a Suzuki coupling reaction to give cysmethynil.  
 
Scheme 2.5 Reagents and conditions: (a) EDC, HOBT, NH4Cl, DMF, rt; 
Yield:95% (b) 1-Bromooctane, NaH, DMF,0 o C to rt; Yield:85% (c) m-
Tolylboronic acid, Pd(PPh3)4, K2CO3, 1,4 dioxane, MW. Yield:60% 
 
This reaction scheme was adopted for the synthesis of Series 5 compounds. In 
the final step, different arylboronic acids were used to give the desired 
compounds. Unlike Series 4, tetrakis(triphenylphosphine) palladium(0), 
Pd(PPh3)4, was used as the palladium catalyst because it did not interfere with 







Figure 2.7 Mechanism involved in the conversion of carboxylic 
acid to carboxamide by EDC-HOBT coupling 
 
The mechanism of the carboxylic acid to amide conversion is summarized in 
Figure 2-7. The indole carboxylic acid reacts with EDC to give an activated ester 
which reacts with a nucleophile (for example, ammonia) to expel the stable urea 
as leaving group.  However a direct reaction with the nucleophile is usually not 
recommended because it can lead to unwanted side reactions (in particular, 
racemization if there is a chiral centre in the carboxylic acid) which would affect 
yield. HOBT is added to intercept the activated ester before these reactions 
occur. The nucleophilic ammonia then attacks the HOBT ester to give the desired 
carboxamide.   
2.2.6 Series 6 
Series 6 is closely related to Series 5. The main difference is the presence of a 
secondary amide at position 3. Half of the compounds in this series have m-tolyl 
at position 5 while the others have 3-pyridinyl at position 5. The reaction scheme 






N-alkylation with 1-bromooctane and finally Suzuki coupling with either m-
Tolylboronic acid or 3-pyridyl boronic acid   (Scheme 2-7)  
 
Scheme 2.6 Reagents and conditions: (a) EDC, HOBT, primary amine, DIPEA, 
DMF, RT, overnight;  (b) 1-Bromooctane, NaH (60%), DMF,0 oC to rt; overnight; 
Yield:80-90% (c) m-tolylboronic acid or 3-pyridyl boronic acid   , Pd(PPh3)4, 
K2CO3, 1,4 dioxane, MW, 100 oC, 20 min. Yield:60-70% 
 
2.2.7 Series 7 
In Series 7, an attempt was made to replace the indole ring of cysmethynil with 
other  scaffolds – pyrazole, indazole and 7- azaindole, while retaining the 
functional groups (n-octyl, m-tolyl, carboxamide)  present in cysmethynil.  
Scheme 2-8 outlines the reaction sequences involved in the synthesis of pyrazole 
7-1. Briefly, ethyl 2,4,dioxovalerate was reacted with hydrazine hydrate  to form 
the pyrazole ring. The pyrazole NH was then alkylated with 1-bromooctane, 
followed by bromination of the ring which will allow the subsequent Suzuki 
coupling reaction to take place. The ethyl ester was hydrolyzed to give the 
carboxylic acid which was derivatized to the acid chloride with thionyl chloride 
and subsequently reacted with propylamine to give 7-1.  7-2 was synthesized in 
the same way except that the pyrazole intermediate was commercially 








Scheme 2.7 Reagents and conditions: (a) Sodium acetate, acetic acid 60 0C;  
(b) 1-Bromooctane, NaH (60%), DMF,0 o C to  rt; overnight; (c) N-
Bromosuccinimide, CHCl3;  (d) m-Tolylboronic acid, Pd(PPh3)4, K2CO3, 1,4 
dioxane, MW, 100 oC, 20min;  (e) KOH-Methanol, reflux (f) Thionyl chloride, 
amine, TEA, DCM. 
 
The 7-azaindole derivatives 7-3 and 7-4 were prepared by reactions outlined in 












Scheme 2.8 Reagents and conditions: (a)  Dimethylamine, HCHO, acetic acid, 
80oC  (b) CH3I (c) KCN, DMF, 80 0 C,  4 h (d) EtOH-KOH, reflux  (e) EDC, HOBT, 
methylamine  or NH4Cl ,DMF rt;  (f) 1-Bromooctane, NaH (60%), DMF,0 0 C to  rt; 
overnight; Yield:55% (g) m-Tolylboronic acid, Pd(PPh3)4, K2CO3, 1,4 dioxane,MW 
20min, 100oC . Yield:47% 
 
The dimethylaminomethyl side chain was introduced at position 3 of 5-bromo7-
azaindole by the Mannich reaction.  It was then converted to the quaternary 
ammomium with iodomethane to facilitate  displacement by cyanide.  The cyano 
group of 12 was then hydrolyzed to give the carboxylic acid 13 which was 
derivatized to the amide by HOBT/EDC coupling. Subsequently, N-alkylation of 
the azaindole NH and Suzuki coupling were carried out to give the desired 
compounds. 
Scheme 2-9 was proposed for the synthesis of 7-5. Indazole-3-carboxylic acid 
was subjected to HOBT-EDC coupling to give the carboxamide, the formation of 
which was confirmed by MS. The N-alkylation reaction did not proceed as 
expected and the target product was not obtained in spite of many attempts.  The 







Scheme 2-9:   Reagents and conditions: (a) EDC, HOBT, NH4Cl,DMF rt; (b)   1-
bromooctane, NaH (60%), DMF,0 0 C to  rt; overnight; (c) N-bromosuccinimide, 
CHCl3, 4 h (d) m-Tolylboronic acid, Pd(PPh3)4, K2CO3, 1,4 dioxane,MW 20min, 
100oC .  
2.3 Summary 
The syntheses of 59 functionalized indoleamines, indoleamides and 
pyrazole analogs were successfully achieved. Of these compounds, all are novel 
compounds and have not been listed in the SciFinder Scholar when checked on 
6th August 2012. The final compounds were of at least 95% purity when 
evaluated by reversed phase HPLC on 2 different gradient runs.  
2.4 Experimental  
2.4.1 General Experimental Conditions 
Reagents (synthetic grade or better) were obtained from commercial suppliers 
(Sigma-Aldrich Chemical Company Inc, Singapore; Alfa Aesar, MA, USA; 
BioSynth AG, Switzerland; CombiBlocks, SD, USA ) and used without further 
purification.  1H and 13C NMR spectra were recorded on a Bruker DRX 400 
spectrometer. Chemical shifts were reported in parts per million (ppm,) and 
referenced to residual solvents, deuterated CHCl3 (7.23) or DMSO-d6 (2.49) for 
1H spectra and deuterated CHCl3 (c 77.16) and DMSO-d6 (c 39.52) for proton 
decoupled 13C NMR. Coupling constants (J) were reported in Hertz (Hz). Proton 






triplet (t), quartet (q), multiplet (m) and broad (br).  Reactions were routinely 
monitored by thin layer chromatography on pre-coated Merck silica 60 F254 
sheets.  Column chromatography was carried out on Merck Silica Gel (0.040-
0.063 mm mesh). Nominal mass spectra were analyzed on Waters LC-MS with 
electrospray ionization (ESI) as probe or LcQ Finnigan MAT mass spectrometer 
with atmospheric pressure chemical ionization (APCI) as probe. High resolution 
accurate mass spectra were analyzed on Bruker MicroTOF-QII mass 
spectrometer with atmospheric pressure chemical ionization (APCI) as probe.  
Purity of final compounds were verified by reverse phase HPLC.  Microwave 
reactions were carried out on the Biotage® Initiator Microwave Synthesizer. 
NMR, LCMS and purity data of final compounds are given in the Appendix. 
2.4.2 Series 1 Procedure 








     
     
To a stirred suspension of sodium hydride (NaH, 60% dispersion in mineral oil; 
48mg,2mmol) in anhydrous DMF (5 ml) in an ice bath was added dropwise a 
solution of the fluoroindole (1.5mmol) in anhydrous DMF (10 mL) over a period of 
10 min.1-Bromooctane (1.8mmol) was then added dropwise over 5 min and 
reaction mixture allowed to warm to RT and stirred overnight.   The reaction was 
quenched by pouring over ice and extracted twice with ethyl acetate (EtOAc, 






filtered and concentrated under reduced pressure to obtain the crude residue.  
The crude material was purified by flash silica gel column chromatography with 
EtOAc and hexane to give the product as an oil (Yield:  80 -90%).  
 










     
To a stirred solution of the fluoroindole (2mmol) in acetic acid (10mL) was added 
HCHO (0.5mL) and the corresponding amine (4mmol). The reaction mixture was 
stirred at RT overnight, after which it was quenched by DCM (20mL) and water 
(15mL) with pH adjusted to 9 using 1N NaOH.  Extraction with DCM was 
repeated. The combined organic layer was washed with brine, dried (Na2SO4) 
and concentrated under reduced pressure to obtain the crude residue.  The 
crude material was purified by column chromatography (CHCl3-MeOH) to give an 






2.4.3 Series-2 Procedure 
2.4.3.1 Series 2: General procedure for the synthesis of N-substituted 










    






5 was synthesized by Dr Yang following a reported method.65  The mixture of 5-
bromo-1H-indole (5 mmol), 3-tolylboronic acid (5.5 mmol) and Pd(dppf)Cl2 (0.25 
mmol) in 12 mL 1,4-dioxane was added 4 mL aqueous solution of K2CO3 (15 
mmol). The mixture was stirred under argon ( 15 min) and then  heated in a 
microwave reactor at 130℃,  50min. On cooling, the solvent was evaporated, the 
residue extracted with CH2Cl2 (20 mL×3), and the organic layer worked up in the 
usual way. The residue obtained on removal of the solvent was purified by 
column chromatography with EtOAc/hexane as eluting solvents. Yield: 55.0 %. 
1H NMR (300 MHz, CDCl3): δ 2.31 (s, 3 H), 6.47 (s, 1 H), 6.92-7.12 (m, 2 H), 






MHz, CDCl3) δ 21.5, 102.9, 111.1, 119.2, 121.9, 124.4, 124.8, 127.0, 128.2, 
128.3, 128.5, 133.4, 135.2, 138.1, 142.5. 





6 was synthesized by Dr Yang following a reported method.66   To a solution of 5 
(4 mmol) in anhydrous DMSO was added NaH (60% in mineral oil dispersion, 4.8 
mmol) at room temperature. The mixture was stirred (ca 1 h) followed by addition 
of 1-chloro-3-methylbut-2-ene (4.8 mmol) and stirred for another 4 h. Water was 
added to stop the reaction, the mixture was extracted with DCM and the organic 
layer was worked up in the usual way. The residue was purified by column 
chromatography to give an off-yellow oil. Yield: 87.1 %. 1H NMR (300 MHz, 
CDCl3): δ 1.82 (s, 3 H), 1.88 (s, 3 H), 2.48 (s, 3 H), 4.74 (d, J = 6.6 Hz, 2 H), 5.45 
(t, J = 6.9 Hz, 1 H), 6.57 (d, J = 2.4 Hz, 1 H), 7.17 (t, J = 3.3 Hz, 2 H), 7.34-7.43 
(m, 2H), 7.49-7.52 (m, 3H), 7.89 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 18.0, 21.6, 
25.6, 44.2, 101.3, 109.6, 119.4, 119.9, 121.2, 124.4, 126.9, 128.0, 128.2, 128.5, 







2.4.3.4 Series 3:  General procedure for the synthesis of N-substituted 






    
To the mixture of the secondary amine (1.2 equiv.) and 36% aqueous 
formaldehyde (1.2 equiv.) in acetic acid (5 mL) was added a solution of 6 in 
acetic acid (200mg) with temperature maintained at 0 ℃. The reaction mixture 
was stirred at room temperature overnight. The reaction was worked up as 
described in Section 2.4.3.  
2.4.4 Series-4 Procedure 









The method described in Section 2.3.2. was followed. 7 was obtained as an oil in 
80-90% yield. 1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz, 3 H), 1.25-1.29 (m, 
10 H), 1.79 to 1.83 (m 2H,), 4.08 (t, J =7 Hz, 2H), 6.42(dd, J =3 Hz 1 H), 7.09(d, J 








2.4.5.2 Series 4: N-[(5-Bromo-1-octyl-1H-indol-3-yl)methyl]-N-









The method described in Section 2.4.3. was followed. 8 was obtained as an oil in 
40-60% yield. 1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz, 3 H), 1.25-1.4 (m, 
16 H), 1.79 - 1.83 (m 2H), 2.8 (m,4H), 4.08 (t, J =7 Hz, 2H), 4.15 (s,2H), 7.19-7.3 
(m, 2 H), 7.4 (s,1H), 7.70 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 14.06, 22.62, 
24.11, 24.42,  26.58, 26.72, 29.17, 31.59, 31.81, 49.08,  56.92, 58.11,  64.36, 
107.27, 107.45, 110.00, 114.46, 114.49, 119.55, 119.61, 119.11, 123.98, 124.07, 
129.73, 131.79, 131.85.,148.95, 151.37   LC-MS (ESI): m/z 393.11.  [M+H] + 
 
2.4.4.3 Series 4:  General method for the synthesis of diethyl-[5-










A suspension of 8 (0.8mmol), aryl boronic acid (1.25mmol) and 1,1’ 
bis(diphenylphosphino) ferrocene palladium (II) dichloride [Pd(dppf)] (0.05mmol) 
in dry 1,4-dioxane (3 mL) was contained in a microwave reaction tube (20 mL). 
An aqueous solution of K2CO3 (2 mL, 1.5mM) was added, the tube was sealed 
and heated in a microwave reactor for 20 min at 100 °C with stirring. A dark 
colored solution was obtained at the end of the reaction. The mixture was 






washed once with water (20mL), followed by brine, and dried with anhydrous 
Na2SO4. The organic solvent was removed under reduced pressure to give the 
crude product which was purified by column chromatography with CHCl3-MeOH  
as eluting solvents.  Yields varied from 25-40%.  
 
2.4.5 Series 5 Procedure 










To a solution of (5-bromo-1H-indol-3-yl)-acetic acid (1.2mmol) in DMF (6mL) was 
added N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 
(EDC,1.5mmol), 1-hydroxybenzotriazole hydrate (HOBT, 1.5mmol), ammonium 
chloride (2mmol), diisopropyl ethyl amine (0.7mL).  The reaction mixture was 
stirred overnight,  then poured into cold water and extracted twice with EtOAc 
(50mL). Combined organic layers were washed with brine, dried (Na2SO4), 
filtered and concentrated under reduced pressure to obtain the crude product as 
a yellow oil which was purified by flash column chromatography (EtOAc/hexane). 
Fractions (15mL) were assessed by TLC and product containing fractions were 
combined and evaporated under reduced pressure.  9 was obtained as a white 
















To a stirred suspension of sodium hydride (NaH, 60% dispersion in mineral oil; 
2mmol) in anhydrous DMF (5 mL) cooled in an ice bath was added dropwise a 
solution of 9 (1.2 mmol ) in anhydrous DMF (10 mL) over 10 min with stirring. 1-
Bromooctane (1.2 mmol) was added dropwise over 5 min and the reaction 
mixture was allowed to warm to RT and stirred overnight. The reaction was 
quenched by pouring over ice and extracted twice with EtOAc (50mL). The 
combined organic layers were washed with brine and worked up in the usual 
way. The crude product was purified by column chromatography  with EtOAc-
hexane to give 10 as a white solid (Yield:85%) 1H NMR (400 MHz, CDCl3,): δ 
0.85 (t, J =7 Hz, 3 H), 1.25-1.29 (m, 10 H), 1.79 to 1.83 (m 2H,), 3.6 (s,2H), 4.08 
(t, J =7 Hz, 2H), 4.9 (s,2H),  7.05(m 1 H), 7.19-7.29 (m, 2 H), 7.8(s, 1H),;  LC-MS 
(ESI): m/z 364.2 [M+H]+. 









C8H17 Cysmethynil  
The procedure described in Section 2.4.5.3 was followed using m-tolylboronic 






crude material was purified by column chromatography (CHCl3-MeOH) to give 
cysmethynil in 60% yield.    1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 
1.33-1.39 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 2.50 (s, 3 H), 3.80 (s, 2 H), 4.14 (t, J 
= 15 Hz, 2 H), 5.84 (br,1H), 6.17 (br,1H), 7.11 (d, J = 9 Hz, 1 H), 7.21-7.19 (dd-
1H), 7.37-7.45 (m, 2 H), 7.50-7.57 (m, 3 H), 7.83 (s, 1 H); 13C NMR (100 MHz, 
CDCl3): δ 14.1, 21.6, 22.6, 27.0, 29.1, 29.2, 30.3, 31.7, 32.9, 46.5, 108.0, 110.0, 
117.3, 122.0, 124.5.1, 127.3, 127.8, 128.18, 128.64, 133.4, 136.0, 138.3, 142.1, 
174.32; LC-MS (ESI): m/z 377.5 [M+H]+. 
2.4.5.4 Series 5: General Proceudre for the synthesis of 2-(1-Octyl-5-










The procedure described in 2.4.5.3 was followed using the appropriate 
aryl/substituted aryl boronic acid.  Yields varied from 43-68%.  
2.4.6 Series 6 Procedure 










To a solution of (5-bromo-1H-indol-3-yl)-acetic acid (1.2mmol)in DMF (6mL) was 
added EDC HCl (1.5mmol), HOBT hydrate (1.5mmol), the corresponding amine 






overnight after which ice-cold water was added to quench the reaction. The 
mixture was extracted twice with ethyl acetate (50mL) and the combined organic 
layer was worked up in the usual manner. The crude product was obtained as an 
oil and used as such for the next step of the reaction.  











To a stirred suspension of NaH (60% dispersion in mineral oil; 2mmol) in 
anhydrous DMF (5 mL) cooled in an ice bath was added dropwise a solution of 
the 2(5-bromo-1H-indol-3-yl) N-substituted amide (1.5mmol) in anhydrous DMF 
(10 mL) over a period of 10 min with stirring. 1-Bromooctane(1.8mmol) was 
added dropwise over 5 min and the reaction mixture was allowed to warm to RT 
and stirred overnight. The reaction was quenched by addition of ice and 
extracted twice with EtOAC (25mL). The combined organic layers were washed 
with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to 
obtain the crude residue.  The crude material was purified by column 
chromatography with EtOAc-hexane as eluting solvents. Yields varied from 80 to 
90%.  
2.4.6.3 Series 6:  2-(1-Octyl-5-m-tolyl-1H-indol-3-yl)-N-substituted 



















A suspension of the 2-(5-bromo-1-octyl-1H-indol-3-yl)-N-substituted amide ( 
0.8mmol), aryl boronic acid (1.25mmol) and tetrakis(triphenylphosphine) 
palladium(0) [Pd(PPh3)4]  (0.05mmol) in dry 1,4-dioxane (3 mL) was contained in 
a microwave reaction tube (20 mL). An aqueous solution of K2CO3 (2 mL, 
1.5mM) was added, the tube was sealed and heated in a microwave reactor for 
20 min at 100 °C with stirring.  The reaction mixture was worked up as described 
in Section 2.4.5.3. Yields varied from 60-70 %.  












 To  a solution of  2,4-dioxo-pentanoic acid ethyl ester (14mmol) in acetic acid 
(10mL)  was added sodium acetate (15mmol)  and hydrazine hydrate (730uL, 
15mmol). The mixture was heated to 60o C with stirring for 3h. The reaction 
mixture was poured into wet ice, extracted with CHCl3 (25mL x 2) and the 
combined organic layer washed with brine, dried (Na2SO4) and concentrated 
under reduced pressure. The crude product was used for the next step without 
purification. 1H NMR (400 MHz, CDCl3,): δ 1.3 (t, 3 H), 2.40 (s, 3 H), 4.4 (t, 2 H), 





















To a stirred suspension of NaH (60% dispersion in mineral oil, 20mmol) in 
anhydrous DMF (5 mL) in an ice bath was added 5-methyl-1H-pyrazole-3-
carboxylic acid ethyl ester (10mmol) in 10 mL dry DMF under nitrogen cover. 1-
Bromooctane (12mmol) was added dropwise to the stirred solution and  the 
reaction mixture was allowed to warm to RT and stirred overnight.   Reaction was 
quenched by pouring over ice and extracted with ethyl acetate twice (25ml). 
Combined organic layer was washed with brine, dried (Na2SO4) and 
concentrated under reduced pressure to obtain the crude product which was 
used as such for the next step. 
2.4.6.6 Series 7: 4-Bromo-5-methyl-1-octyl 1H-pyrazole-3-carboxylic 













 To a solution of 5-methyl-1-octyl 1H-pyrazole-3-carboxylic acid ethyl ester 
(10mmol) in 100mL CHCl3  was added N-bromosuccinimide (11mmol) and stirred 
for 3h. When no further reaction was observed (determined by TLC monitoring), 






the chloroform layer removed in vacuo to give a red viscous solution. The product 
was purified by column chromatography.  LCMS m/z 347.08 [M+H]+. 
2.4.6.7 Series 7: 5-Methyl-1-octyl 4-m-tolyl 1H-pyrazole-3-carboxylic 












A suspension of the 4-bromo-5-methyl-1-octyl 1H-pyrazole-3-carboxylic acid 
ethyl ester ( 0.8mmol), m-tolyl boronic acid (1.5mmol) and 
tetrakis(triphenylphosphine) palladium(0) Pd(PPh3)4 (0.05mmol) in dry 1,4-
dioxane (3 mL) was contained in a microwave reaction tube (20 mL). An aqueous 
solution of K2CO3 (2 mL, 1.5mM) was added, the tube was sealed and heated in 
a microwave reactor for 20 min at 100 °C with stirring.  The reaction mixture was 
worked up as described in Section 2.4.5.3 The crude product was The crude 
material was purified by column chromatography with EtOAc-hexane as eluting 
solvents.  
 

















5-Methyl-1-octyl 4-m-tolyl 1H-pyrazole-3-carboxylic acid ethyl ester was added to 
a methanolic solution of KOH (28% KOH in methanol, 5mL) and refluxed 
overnight. The solvent was evaporated and the residue extracted with EtOAc. 
The organic layer was processed in the usual manner to give the product which 
was used as such for the next step.  
2.4.6.9 Series 7: 5-Methyl-1-octyl 4-m-tolyl 1H-pyrazole-3-carboxylic 










To a solution of 5-methyl-1-octyl 4-m-tolyl 1H-pyrazole-3-carboxylic acid  (crude, 
from 2.3.2xx)   in  DCM (20mL)  was added thionyl chloride (2 mL), triethylamine 
(1.5 equiv) and propylamine (1.2 equiv). The reaction was monitored by TLC and 
when deemed to be complete, DCM (25 mL) was added to extract the product. 
The combined organic layer was washed with water, dried and concentrated in 
vacuo. The crude product was purified by column chromatography with ethyl 
acetate and hexane as eluting solvents.  1H NMR (400 MHz, CDCl3,): δ 0.65 
(t,3H), 0.85 (t, , 3 H),), 1.10-1.42 (m, 12 H), 1.85 (t, 2 H), 2.2 (s,3H),2.4 (s, 
3H),3.01 (q, 2 H), 4.5 (t, 2H), 5.5 (br,  1 H), 6.65 (m,2H), 7.01 (m,3H),  7.20 (m, 






2.4.6.10 Series 7: 1-Octyl-4-m-tolyl-1H-pyrazole-3-carboxylic acid 
propylamide (7.2) 
1H-Pyrazole-3 carboxylic acid ethyl ester was purchased from Sigma Aldrich and 
reacted by the same procedure as described for 7-1 (Section 2.4.8.2 to 2.4.8.6).  
1H NMR (400 MHz, CDCl3,): δ 0.9 (t, , 3 H),), 1.10-1.42 (m, 13 H),1.6 (p.2H) 1.85 
(t, 2 H), 2.4 (s, 3H),3.3 (q, 2 H), 4.1 (q, 3H), 6.8 (br,  1 H), 7.2 (m,1H), 7.3 (m,1H),  
7.50 (m, 2H),;  LC-MS (ESI): m/z 354.05. [M+H] + 
2.4.7 Azaindole synthesis 








To a solution of 5-bromo-1H-pyrrolo[2,3-b]pyridine in acetic acid (1mmol) was 
added  HCHO (0.5mL) and dimethylamine (1.2mmol). The reaction mixture was 
stirred at RT overnight, after which DCM was added and the mixture cooled down 
to 0o C .  pH was adjusted to 9 with NaOH solution. The organic layer was 





















To crude 11 was added iodomethane, potassium cyanide, DMF and the mixture 
was heated to 80 oC for 4h.  Crude 12 was purified by column chromatography 
using ethyl acetate and hexane as eluting solvents.   Product was used without 
further characterization in the next step.  
To crude 11 was added iodomethane, potassium cyanide, DMF and the mixture 
was heated to 80 oC for 4h.  Crude 12 was purified by column chromatography 
using ethyl acetate and hexane as eluting solvents.   Product was used without 
further characterization in the next step.  









12 was dissolved in methanolic KOH (28% KOH in methanol, 5mL) and refluxed 
overnight. The reaction mixture was cooled to 0 oC and acidified with 4M HCl. 














To  a solution of 13 (1.2mmol)  in DMF (6 mL) was added EDC HCl (1.5mmol), 
HOBT hydrate (1.5mmol), ammonium chloride (2mmol) and diisopropyl ethyl 
amine ( 0.7mL)  and reaction mixture was stirred overnight. Workup was carried 
out as described in Section 2.4.6.1. The crude product was used as such in the 
next step.   
2.4.7.5 Series 7: (5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-yl)-N-methyl 
amide 
To  a solution of 13 (1.2mmol)  in DMF (6 mL) was added EDC HCl (1.5mmol), 
HOBT hydrate (1.5mmol), methylamine solution in methanol  (2mmol, 5 mL as 
well) and diisopropyl ethyl amine  (0.7mL)  and reaction mixture was stirred 
overnight. Workup was carried out as described in 2.4.6.1 The crude product was 
used as such in the next step.   









(5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-yl)-acetamide (1.5 mmol) or (5-Bromo-1H-






bromooctane (1.8 mmol) in the presence of NaH (60% dispersion in mineral oil, 2 
mmol) as described in Section 2.4.2,1. The crude product was purified by column 
chromatography  with EtOAC-hexane as eluting solvent to give the desired 
compound as an oil in 55% yield.  










7-3: R = H
7-4: R = CH3
 
A suspension of (5-bromo-1-Octyl 1H-pyrrolo[2,3-b]pyridine-3-yl)-acetamide ( 
0.8mmol), m-tolylboronic acid (1.25mmol) and tetrakis(triphenylphosphine) 
palladium(0) Pd(PPh3)4 (0.05mmol) in dry 1,4-dioxane (3 mL) was contained in a 
microwave reaction tube (20 mL). An aqueous solution of K2CO3 (2 mL, 1.5mM) 
was added, the tube was sealed and heated in a microwave reactor for 20 min at 
100 °C with stirring.  The reaction mixture was worked up as described in Section 
2.4.4.1.  7-3 was obtained as a yellow oil(47.0 %)  1H NMR (400 MHz, CDCl3,): δ 
0.91 (t, 3 H),1.33-1.42 (m, 10 H), 1.90 (t, 2 H,), 2.45 (s,3H), 3.77 (s, 2 H), 4.3 (t, 2 
H), 5.70 (br,2H), 7.10-7.2 (m,  2 H), 7.3-7.5 (m,3H), 8.05 (s,1H) 8.6 (S,1H), ; 13C 
NMR (100 MHz, CDCl3): δ,14.10 ,  21.58, 22.63 ,26.95, 29.22, 30.45, 31.78, 
33.12,  44.74, 106.41, 119.67.124.52, 125.49,127.89.128.20, 128.89,129.73 






2.4.7.8 Series 7:  N-Methyl 2-(1-0ctyl-5-m-tolyl-1H-pyrrolo[2,3-b] 
pyridine-3-yl)-acetamide (7-4)  
N-Methyl-(5-bromo-1-Octyl 1H-pyrrolo[2,3-b]pyridine-3-yl)-acetamide was 
reacted with m-Tolylboronic acid as described in Section 2.4.4.1. 7-4 was 
obtained as a yellow oil in 40.8 % yield.  1H NMR (400 MHz, CDCl3,): δ 0.91 (t, J 
=15 Hz, 3 H),1.33-1.42 (m, 10 H), 1.90 (t, 2 H,), 2.45 (s,3H), 2.8 (d,3H) 3.77 (s, 2 
H), 4.3 (t, J = 15 Hz, 2 H), 5.70 (br,2H), 7.10-7.2 (m,  2 H), 7.3-7.5 (m,3H), 8.05 
(s,1H) 8.6 (S,1H), ; 13C NMR (100 MHz, CDCl3): δ,14.10 ,  21.60, 22.68 ,26.90, 
26.8, 29.10, 30.45, 31.65, 33.10,  44.69, 106.41, 119.47.124.55, 125.35, 127.75, 
128.12, 128.89,129.71 138.64,139.30, 142.93,147.24, 173.5  LC-MS (ESI): m/z 












CHAPTER 3 Anti proliferative and Icmt inhibitory activities of synthesized 
compounds 
3.1 Introduction 
This chapter describes the screening of the synthesized compounds for their 
growth inhibitory activities on the human breast cancer MDA-MB-231 cells. Half-
maximal growth inhibitory concentrations (IC50 which is the concentration of test 
compound required to reduce cell viability by ½ compared to untreated cells) 
were determined.  Earlier, cell based growth inhibitory IC50 values of cysmethynil 
analogs were found to be well correlated to Icmt inhibition.56 Based on this 
observation, compounds were first evaluated for cell based growth inhibitory 
properties, after which promising compounds were selected for evaluation of Icmt 
inhibition.   
3.2 Experimental 
3.2.1 Evaluation of cell viability by the colorimetric tetrazolium assay 
Growth inhibitory IC50 values were determined on a colorimetric assay based on 
a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl) -2-(4-sulfophenyl)-2H-tetrazolium, MTS]. The assay is 
based on the ability of mitochondrial reductases of viable cells to reduce the 
tetrazolium dye to a purple product called formazan.  Cells use NADPH or NADP 
produced from normal cellular activity to achieve this reduction.  When cells are 
not viable, the reduction does not occur due to insufficient NADPH /NADP.  Thus 
less formazan is formed in non-viable cells. The amount of formazan is monitored 
by its absorbance in the visible range.   In the present investigation, a commercial 






MTS, the kit contains another reagent, phenazine ethosulfate (PES).  When MTS 
is reduced to its formazan, the latter is made soluble in the culture media by PES.  
Thus, there is no need to add DMSO to dissolve the formazan and this simplifies 
the assay protocol to an “add-incubate-measure” format. It also allows the plate 
to be read and returned to the incubator if a longer incubation period is required. 
3.2.2 Determination of growth inhibition by the colorimetric tetrazolium 
assay 
Human breast cancer MDA-MB231 cells were purchased from ATCC (Rockville, 
MD) and grown in Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich, 
Singapore) which was supplemented with 10% fetal bovine serum, 50 µg / mL 
penicillin and 50 µg/mL streptomycin at 37oC, 5% CO2. The cells were sub-
cultured to 80-90% confluency and used within 15-28 passages for the assay. 
Cell viability was assessed with CellTitre 96 Aqueous One Solution (Promega , 
Madison, WI) which contained the tetrazolium salt MTS .  MDA-MB-231 cells 
were seeded at 2400 cells per well in a 96-well plate for 24 h.  Aliquots of test 
compounds (initially prepared as 10 mM stock solutions in DMSO) were added to 
each well and the plates were incubated for 72 h.  The final amount of DMSO per 
well was maintained at 0.5% v/v.  At the end of the incubation period, 20 µL per 
well of MTS solution was added and the plates were incubated for another 4 h 
before absorbance readings were read on a microplate reader (Tecan Infinite 
M200) at 490 nm. Cell viability was determined from the expression: 
               
                                    
                                              
      
Where Absorbance cells + cpd = absorbance of cells in vehicle (media + 0.5% 






vehicle and test compound (to account for absorbance due to test compound at 
490 nm); Absorbance cells + vehicle  =  absorbance of untreated cells and vehicle ; 
Absorbance vehicle = absorbance of vehicle  in the absence of cells. 
% Viability readings for each test compound were plotted against log 
concentration on GraphPad Prism (Version 5.0, GraphPad Software, San Diego, 
CA), with constraints set at ≥ 0 and ≤ 100%. A sigmoidal curve was generated 
from which IC50 was obtained.   At least 3 independent determinations of IC50 
were made using two different stock solutions of test compound. 
3.2.3 Measurement of Icmt activity 
Icmt activity was determined by a method that involved measuring the rate at 
which Icmt (expressed on Sf9 membranes) catalyzed the transfer of a methyl 
group from the methyl donor S-adenosyl methionine (AdoMet, SAM) to the 
substrate, biotin-S-farnesyl-L-cysteine (BFC). BFC is a farnesylated, Rce-1-
protetolyzed substrate of Icmt with a Michaelis-Menten constant (Km) of 2.1 µM  
The biotin in BFC facilitates the isolation of the methylated substrate from the 
reaction mixture due to its affinity for streptavidin. Some of the methyl groups 
donated to the substrate are derived from “hot” SAM, which has tritiated methyl 
groups.  In the assay, the enzyme and test compound are incubated, followed by 
addition of a cocktail containing BFC, “cold” SAM and “hot” SAM. If the test 
compound does not inhibit Icmt, BFC is methylated and the methylated substrate 
will bind to the streptavidin SPA beads. The tritiated methyl group in the 
streptavidin-bound substrate emits β particles that activates the scintillant 
embedded within the beads, causing it to emit light which is then detected in a 






methylated and with fewer β-emitting methyl groups in proximity to the scintillant, 
less light is emitted. Inhibition is quantified by comparing the reduction in light 
emission relative to the control.   The method is convenient as it does not require 
the separation of the bound and free tritiated SAM, which was required in the 
previous protocol carried out in the laboratory.56, 59 Therefore for compounds 
whose IC50 values were re-determined in the present report, variations from 
previously reported values were anticipated.    
3.2.4 Determination of Icmt inhibition by test compounds 
Sf9 (Spodoptera frugiperda ovarian) membranes containing recombinant Icmt 
were provided by Prof PJ Casey (Duke University, NC and Duke-NUS Graduate 
Medical School). S-Adenosylmethionine (SAM), magnesium chloride 
hexahydrate, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) ,  
dithiothreitol (DTT),  farnesyl bromide, cysteine and of biotin N-
hydroxysuccinimide ester (biotin NHS) were purchased from Sigma-Aldrich 
Chemical Company Inc, Singapore [3H] S-Adenosylmethionine and streptavidin 
PVT Scintillation Proximity Assay (SPA) Beads were purchased from 
PerkinElmer (Waltham, MA).  Biotinylated farnesylcysteine (BFC) was 
synthesized as described in Section 3.2.6. Assays were performed in black 384-
well microtitre plates from PerkinElmer. 
A vial of Icmt membrane protein (30g/L) stored at -80C was thawed at 37C 
and placed on ice. The  protein was diluted in assay buffer (70 mM HEPES, 100 
mM NaCl, 5mM MgCl2, 3 mM DTT, pH 7.5) to 0.03g/L and aliquots were added 
to each well (5L/well), followed by 20L of the assay buffer and then test 






DMSO per well was kept at 0.05% v/v.     The reaction was initiated by adding 
5µL of a solution containing BFC (6M), SAM (3M) and 30 Ci/mL [3H] SAM. 
These reagents were stored at -20C and thawed on ice (SAM, [3H] SAM) or at 
room temperature (BFC).  The plate was incubated at 37C for 30 minutes after 
which the reaction was quenched by adding 15 L of a solution comprising SAM 
(150 µM) and streptavidin SPA scintillation beads (20 mg/mL).  After overnight 
incubation at (25 oC), radioactivity was counted (Microbeta Trilux™ , Perkin 
Elmer, Turku, Finland). The degree of inhibition was assessed from the 
radioactivity obtained in presence of test compound compared to that obtained 
from the control sample without test compound.  Two independent 
determinations were made for each test compound.  
 
3.2.5 Statistical analysis 










3.2.6 Synthesis of biotin-S-farnesyl-L-cysteine (BFC). 
 
Scheme 3.1 Reagents and conditions: (a) NH3, MeOH, 0oC, 3 h  25oC, 2 h; 
(b) Biotin NHS, Hepes pH 12, DMSO, 3h, rt.  
 
S-Farnesyl-L-cysteine was synthesized following the method of Brown et al.68 To 
a solution of cysteine (175mg,1mmol) in 7M ammonia solution in methanol (5mL) 
was added trans,trans-farnesyl bromide (285mg, 271µl, 1mmol) at 0oC. The 
mixture was stirred for about 3 h at 0oC and then for 2 h at 25oC.  Solvent was 
removed under reduced pressure and the residue was partitioned between 1-
butanol (20mL) and water (40mL). The organic layer was separated, dried 
(anhydrous Na2S04) and removed in vacuo. The residue was dissolved in 
methanol (20mL) and washed twice with hexane (2x 20mL). The methanol layer 
was evaporated under reduced pressure to give a white waxy solid. Yield: 60% 
(195mg) 1H NMR (400 MHz, CD3OD): δ 1.6 (s, 6 H),1.65 (s,3H), 1.70 (s, 3 H), 
1.9-2.3 (m, 8 H), 2.80 (m, 1 H), 3.15 (m, , 1 H), 3.2-3.4 (m,4 H), 3.75 (m, , 1 H),  
5.15 (m, 2 H), 5.30 (m, 1 H), 13C NMR (100 MHz, CD3OD) δ 16.27, 16.44, 17.91, 
26.04, 27.59, 27.95, 30.42, 33.46, 40.89, 41.01, 55.04,121.14, 125.25, 125.59, 







The method of Baron, R. A et al69 was followed for the synthesis of BFC. To a 
large excess of S-farnesyl-L- cysteine (1.5mmol,500mg) was added a solution of 
biotin N-hydroxysuccinimide ester (Biotin NHS) (0.75mmol 255mg) in 5ml of 
DMSO.  1M Hepes (pH 12, 2 mL) was added to the mixture which was then 
stirred for 3 h at room temperature. The solvent was removed under reduced 
pressure and the residue was partitioned between 1-butanol and water. The 
butanol layer was evaporated under reduced pressure and the resulting residue 
was dissolved in methanol and purified by reverse phase preparative HPLC on a 
Phenomenex column (Luna 5 μm C18 (2) 100 Å 150 x 21.2 mm) with solvent 
gradients of 5% to 95% acetonitrile in water containing 0.1% trifluoroacetic acid 
(TFA). Settings were run-time 18 min and flow rate 20 mL/min. Fractions 
containing the desired product were lyophilized to give a fluffy white solid. Yield: 
165mg (20%). 1H NMR (400 MHz, CD3OD): δ 1.5 (m, 2 H), 1.55-1.85(m, 14H), 
1.90-2.2(m, 8H), 2.2-2.45(m, 2H), 2.7 (m, 2H), 2.85-3.10(m, 2H),  3.10-3.40(m, 
4H), 3.85 (s, 1 H), 4.25-4.35 (m, 1 H), 4.4-4.52(m, 1H), 4.55-4.62(m, 1H), 5.05-
5.18(m, 2H), 5.20-5.30(m, 1H). 13C NMR (100 MHz, CD3OD) δ 14.87, 16.39, 
24.51, 25.35, , 26.40, 27.96, 28.12, 28.79, 32.06, 35.06, 36.88, 39.21, 39.45, 
51.87, 55.56, 60.25, 61.84, 120.17, 123.74, 124.06, 130.71, 134.89, 139.14, 
164.75, 175.72, 174.75. LC-MS (ESI): m/z 552.29. [M+H]. + 
3.3 Results 
 
3.3.1 Series 1: Growth inhibitory and Icmt inhibitory activities 
Table 3-1 gives the growth inhibitory IC50 values of Series 1 compounds on 






in Table 3-1) was found to be 7.50 µM which agreed well with an earlier reported 
value (7.2 µM).1 Similarly, the IC50 of cysmethynil (27.4 µM) did not differ 
markedly from an earlier reported value (21.8 µM). The results showed that 
changing the position of fluorine on the indole ring while retaining the same 
amino side chain had little impact on antiproliferative activity. This was evident 
from the limited variation in IC50 values of these compounds with N,N-
diethylamino, 1-piperidinyl, 4-methylpiperazin-1-yl side chains.   Compounds with 
the 4-morpholinomethyl (1-3, 1-12, 1-19) and 4-thiomorpholinomethyl (1-4, 1-13) 
side chains were consistently inactive which lend further support to the view that 
the position of F was not an important factor. Limited solubilities were also 
associated with the morpholino and thiomorpholino side chains.  Compounds 
with secondary amino side chains (1-7, 1-8, 1-21, 1-22, 1-26) have IC50 values 





















4F 5F 6F 7F 
Code IC50 (µM) a Cod
e 
IC50 (µM) a Cod
e 
IC50 (µM)a Code IC50 (µM)a 
-N(CH3)2   1-9 8.48 (0.64) 1-16 6.24 
(0.36) 
  




7.50 (1.09) 1-17 9.14 
(0.07) 



















































  1-22 5.88 
(0.25) 
1-26 6.22 
a  Mean (± SD) of n =3 separate determinations. IC50 of 1-23 to 1-26 were 
averaged from 2 determinations.  b Compound 1-10 = Lead compound 1. IC50 of 
1 was previously reported to be 7.2 µM. 56 IC50 of cysmethynil was found to be 







Icmt inhibitory activities were determined for selected compounds, namely 1-8, 1-
10 (lead compound 1), 1-16, 1-22 and 1-26 (Figure 3-1). 1-10 was reported to 
inhibit Icmt with IC50 of 4.1 µM56  which agreed well with the present finding of 
4.83 µM.  The IC50 of cysmethynil was 1.90 (0.27) µM in the present report and 
1.50 µM in an earlier report.56 It is apparent from the IC50 values that none of the 
compounds were more potent than cysmethynil in terms of Icmt inhibition 
although they fared better than the lead compound 1-10. However, as only 2 
determinations were made, it was not possible to establish the statistical 




Figure 3.1 IC50 for inhibition of Icmt by selected Series 1 
compounds (average of 2 determinations) 
 
3.3.2 Series 2: Growth inhibitory and Icmt inhibitory activities 
As seen in Table 3-2, replacing the n-octyl side chain of lead compound 1 (1-10, 
IC50 7.50 µM) with geranyl (2-2, IC50 6.27 µM) did not affect growth inhibitory 
activities. This was evident from IC50 values of several octyl-geranyl compound 
pairs with the same amino side chain, namely 1-9 and 2-1; 1-11 and 2-6; 1-14 
and 2-9; 1-15 and 2-11. As in Series 1, the morpholino (2-7) and thiomorpholino 
(2-8) analogs demonstrated weak antiproliferative activities which could not be 






Table 3.2 Growth inhibitory IC50 values of Series 2 compounds on MDA-MB-
231 cells 







R1 IC50 (µM) 
a 










2-3 -N(CH3)(C3H7-n) 8.44 2-9 
 
10.2 










7.20    
 a Average of 2 determinations except for those with SD where n=3 
determinations were made. b No inhibition at highest test concentration (50 µM) 
 
 Icmt inhibitory IC50 of 2-2 was determined and found to be 4.05 µM, which was 
comparable to the n-octyl analog 1-10 (4.83 µM). It would appear that for 
compounds with the same amino side chain,  the n-octyl –geranyl replacement 







3.3.3  Series 3: Growth inhibitory and Icmt inhibitory activities 
 
Series 3 is characterized by the presence of the shorter, less lipophilic isoprenyl 
side chain at position 1. A m-tolyl ring was maintained at position 5 and variations 
were made to the tertiary amino side chain. The results showed that replacing the 
N,N-diethylamino side chain of the lead compound 2( 3-2 in Table 3-3) with other 
tertiary amino groups did not markedly affect antiproliferative activity. Exceptions 
were the morpholino and thiomorpholino side chains which as before, resulted in 
compounds with significantly weaker activities. It was noted that the IC50 of 3-2 
(6.99 µM) was almost twice that reported earlier  (3.8 µM).56  This difference 
notwithstanding, the IC50 for Icmt inhibition (2.67 µM) of 3-2 was closely aligned 
to that reported earlier (2.40 µM).56 The IC50 for Icmt inhibition of 3-3 was also 





















R1 IC50 (µM) 
a Cpd 
No 
R1 IC50 (µM) 
a 
3-1 -N(CH3)2 11.8 (0.5) 3-7 
 
19.1 (4.0) 









8.52 (1.74) 3-10 
 
7.78 





8.37    
a  Mean (± SD) of n =3 separate determinations. IC50 of 3-6, 3-9, 3-10 were 
average of 2 determinations.  b Compound 3-2 = Lead compound 2. IC50 of 2 was 
previously reported to be 3.8 µM.56     c No inhibition at highest test concentration 
(50 µM).  
 
3.3.4 Series 4: Growth inhibitory and Icmt inhibitory activities 
Series 4 is based on lead compound 3 (4-1 in Table 3-4). The cell based growth 
inhibitory IC50 of 4-1 on MDA-MB-231 cells was found to be twice higher than a 
previously reported value (7.90 µM versus 3.60 µM).56 On prostate PC3 cells, 
IC50 of 4-1 was again found to exceed the previous value ( 6.31 µM versus 4.0 






operator variations. In view of these findings, the Icmt of 4-1 was re-determined 
and found to be about 3 times higher than the previously reported value (2.18 µM 
versus 0.7 µM).  It may be that the identification of 4-1 as a potential lead was 
erroneous to start with. In any case, 18 derivatives of 4-1 had been synthesized 
and these compounds were evaluated for antiproliferative activities on MDA-MB-
231 and PC3 cells (Table 3-4).  
The results showed that the IC50 values of the two malignant cell lines were 
significantly correlated (Spearman rho 0.667, p =0.002 (2-tailed), n=19; Pearson 
correlatin 0.826, p = 0.0001 (2-tailed), n =19). Substitution of the phenyl ring with 
substituents of different lipophilicities (+/- π) and stereoelectronic (+/- ) 
properties did not appear to markedly affect antiproliferative activity which 
remained within a narrow range (5.6 µM to 15 µM for IC50 MDA-MB-231 and 4.7 µM to 
18 µM for IC50 PC3). For instance, the m-CH3 to m-NO2 substitution resulted in 
compounds (4-1, 4-9) that had largely the same antiproliferative activities  in spite 
of the contrasting stereoelectronic character of the substituents. On the other 
hand,  the m-CH3 to m-OH exchange adversely affected activity, with the OH 
analog 4-17 having the least antiproliferative activity among the investigated 
compounds. OH is electron donating like CH3, but unlike it, OH is less lipophilic 
and a H bond donor. The latter may be detrimental for activity but would need to 
be confirmed with related groups like amino which is also a H bond done and 
found within the same Craig Plot quadrant as OH. Mention should be made of the 
methanesulfonyl analog 4-10 which has the most promising activity among the 5-






Table 3.4 Growth inhibitory IC50 values of Series 4 compounds on human 
breast cancer MDA-MB-231, human prostrate cancer PC3 cells and IC50 for 
inhibition of Icmt 
 
 
Cpd No R1 MDA-MB-231 
 IC50 (µM) 
a 
PC3 IC50 (µM) 




7.90 (1.72) 6.31 (0.20) 2.18 
4-2 
 
7.03 (0.81) 7.28 (2.57) 2.56 
4-3 
 
6.71 (0.21) 6.25 (0.67) 1.61 
4-4 
 
6.69 (0.13) 9.66 (2.62) 1.28 
4-5 
 
6.53 (0.49) 6.81 (0.53) 2.61 
4-6 
 
7.17 (0.06) 11.19 (2.48) Not done 
4-7 
 
5.50 (0.81) 5.84 (0.31) 1.75 
4-8 
 
5.14 (0.67) 5.88 (0.44) 0.96 
4-9 
 
6.51 (0.98) 7.29 (0.85) Not done 
4-10 
 
5.56 (0.58) 4.74 (1.31) 1.72 
4-11 
 
6.26 (0.17) 9.79 (1.94) Not done 
4-12 
 








11.05  8.47 (1.31) 1.58 
4-14 
 
2.52 (0.77) 1.92 (0.22) 1.63 
4-15 
 
3.85 (0.19) 5.74 (0.32) 2.26 
4-16 
 
10.85  6.11 (0.16) 2.45 
4-17 
 
14.9 (0.9) 18.1 (1.9) 5.43 
4-18 
 
7.25 (0.61) 10.4 (0.9) 1.40 
4-19 
 
10.24  6.48 (0.17) 1.71 
a  Mean (± SD) of n =3 separate determinations except for Icmt IC50 values which 
were the average of 2 separate determinations.   
Another modification that was investigated in Series 4 was the 5-phenyl to 
heteroaromatic ring substitution. As seen from Table 3-4, three heteroaromatic 
rings were introduced at position 5: 3-pyridinyl (4-7), 3-pyrazolyl (4-11) and 5-
pyridimidinyl (4-13). Of these, the pyridinyl analog 4-7 fared best (based on 
average IC50 values on the 2 malignant cell lines). Substitution of the pyridine ring 
with fluoro (4-8) and dimethylamino (4-14) gave varied responses, with little 
change in IC50 for the fluoro analog but a surprising 2-fold improvement in activity 
for the dimethylamino analog.  The pyridimine ring of 4-13 also benefited from 
substitution. Both the amino (4-12) and cyano (4-15) analogs   were at least twice 
as potent as 4-13.  Of the two approaches – introducing different substituents on 
5-phenyl and phenyl to heteroaromatic replacement – the latter was obviously the 
more promising approach, with 4-12 and 4-14 identified as the most potent 
compounds so far.  Figure 3-2 shows representative plots of % viability versus 












Figure 3.2 Representative plots of % viability versus 
concentration of (a) cysmethynil and (b) 4-12 on human breast cancer 
MDA-MB-231 cells.  
  
Next, the Icmt IC50 of the Series 4 compounds (except 4-6, 4-9, 4-11) were 
determined. 4-12 was found to be the most potent Icmt inhibitor, with IC50 of 0.78 
µM. A representative % Icmt activity versus concentration plot is depicted in 
Figure 3-3.  Disappointingly, 4-14  had only mediocre Icmt inhibitory activity in 
spite of its impressive antiproliferative properties.  Besides 4-12, only one other 
compound (4-8) had nanomolar IC50 for Icmt inhibition (0.96 µM) even though its 
antiproliferative activity was not impressive. However, the poorly active OH 
analog 4-17 was also the least potent Icmt inhibitor. In view of these lapses in 
correlation, it was not surprising to find that Icmt  inhibitory IC50 values were only 
correlated to antiproliferative IC50 values on the Pearson but not Spearman 







































Figure 3.3 Representative % Icmt activtiy versus concentration of 






Table 3.5 Correlation analysis of IC50 values from antiproliferative assays on 
MDA-MB-231 and PC3 cells  and Icmt IC50 on Series 4 compounds (n =16) 
 IC50 MDA MB 231 vs IC50 Icmt IC50 PC3 vs IC50 Icmt 
Pearson correlation 0.751 0.729 
p (2-tailed) 0.001 0.001 
Spearman rho 0.344 0.188 
p (2-tailed) 0.192 0.485 
 
3.3.5 Series 5: Growth inhibitory activities 
In this series, changes were made at position 5 while maintaining the same 
acetamide side chain at position 3.   In this respect, Series 4 and 5 were similar, 
except that in Series 4, it was the diethylaminomethyl side chain that was kept 
constant. However, Series 5 proved to be a disappointment. Most of the 
compounds had IC50 values that were comparable to cysmethynil (IC50 27.4 uM), 
except for 5-5 and 5-10, whose  IC50 values though lower than cysmethynil, still 
fell short of expectations. Hence, none of the compounds were evaluated for Icmt 
inhibition.  
ICMT  cysmethynil









































aAverage of 2 determinations. b No inhibition at highest test concentration (50 µM) 
3.3.6 Series 6: Growth inhibitory activities 
The lead compound for Series 6 was 6-1 which was previously found to have an 
IC50 of 4.7 µM on MDA-MB-231 cells.56  Re-determination using a resynthesized 
sample of 6-1 found that IC50 to be significantly higher at 28.5 µM.  Only one 
other N-methylamide 6-2 had a determinable IC50 (23.1 µM) while the IC50 values 
of the other compounds (also poorly active) could not be determined due to their 
poor solubilities.  The Icmt inhibitory activities of these compounds were not 
determined. 
Cpd No R1 IC50 (µM) 
a Cpd No R1 IC50 (µM) 
a 
5-1 o-F 29.5 5-7 o-F-p- CH3 23.1 
5-2 m-F 26.6 5-82 
 
31.4 
5-3 p-F 29.5 5-9 b 
 
32.3 
5-4 o-CF3 37.5 5-10 3-NO2 17.2 
5-5 m-CF3 14.8 5-11 p-CH3SO2 No 
inhibitionb 













R1 R2 IC50 (µM) 
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a  Average of 2 determinationsb No inhibition at highest test concentration (50 µM) 
.  c 5-Phenyl is replaced by heteroaromatic ring. 
3.3.7 Series 7: Growth inhibitory activities 
Series 7 compounds were non-indole analogs of cysmethynil. They were 
evaluated for antiproliferative activities on MDA-MB-231 cells and found to be 
poorly active. Their Icmt inhibitory activities were not determined. 
Figure 3.4 Growth inhibitory IC50 values of Series 7 compounds 








An earlier study on the SAR of cysmethynil as Icmt inhibitor ranked the 
functionalities in terms of their importance to Icmt inhibition and proposed that the 
most critical group was the acetamide at position 3, followed by the lipophilic n-
octyl and lastly the m-tolyl at position 5.56  The key findings were summarized in 
Figure 1-12, which is reproduced in Figure 3-5.  
 
Figure 3.5 SAR of cysmethynil as an Icmt inhibitor 
 
Unlike the earlier study, the test compounds in the present investigation were 
evaluated initially for antiproliferative activities, after which a selected few were 
investigated for Icmt inhibition. This approach was adopted because several 
problems were faced in setting up the  Icmt assay and to minimize delay, the 
antiproliferative assays were carried out first.   Antiproliferative and Icmt inhibitory 
IC50 values were earlier found to be correlated,56  and this was further confirmed 
in Series 4 (Table 3-5). 
From Series 1, it was apparent that relocating the 5-F (present in lead structure 
1) to other positions (4, 6 and 7) had minimal impact on antiproliferative activity 
even when the diethylamino side chain was replaced by other tertiary amino side 






activity. The morpholino and thiomorpholino side chains were however 
recognized as poor choices not only in Series 1 but in Series 2 and 3 as well. 
Series 2 showed that the n-octyl to geranyl substitution was well tolerated in 5-
fluoro indoleamines, even in analogs with different tertiary amino side chains. 
The same was true for the n-octyl to isoprenyl substitution that was made in 
Series 3. The IC50 for Icmt inhibition was determined for selected compounds 
from Series 1-3 (1-8, 1-16, 1-22, 1-26, 2-2, 3-3) and found to be close to that of 
their respective lead compounds (1-10, 3-2). The absence of a “rugged” SAR 
terrain for both antiproliferative and Icmt inhibitory activities suggested that the 
lead compounds were optimal in their respective classes, but should there be a 
need to address metabolic or physicochemical liabilities of these compounds, the 
findings from Series 1-3 may be applied. 
Series 4 compounds were by far the most interesting in the present investigation. 
Contrary to previous expectations, modifications at this position did influence 
antiproliferative and Icmt activities, with several compounds found to be more 
potent than the lead structure 3 (4-1). The 5-phenyl to heteroaromatic substitution 
on the scaffold was particularly promising. The 2-aminopyridiminyl analog 4-12 
combined potent (nanomolar) Icmt inhibition with strong antiproliferative activities 
on both MDA-MB-231 and PC3 cells.  The substituted pyridines 4-8 and 4-7 were 
also noteworthy and excelled in either Icmt inhibitory or antiproliferative activity, 
but not both.  There was less certainty as to the type of substituents (electron 
donating or withdrawing, lipophilic or hydrophilic, H bonding or non-H bonding) 
that favored activity, mainly because of the limited number of compounds 






Series 5-7 were based on cysmethynil and investigated the indoleacetamides 
with different substituents at position 5 (Series 5), secondary versus primary 
amide side chains (Series 6) and replacing the indole core altogether (Series 7). 
Disappointingly, none of these variations improved antiproliferative or Icmt 
inhibitory activity (determined for Series 5) to any significant extent. The 
secondary amides of Series 6 were noticeably less soluble, even with a more 
polar 3-pyridyl at position 5.  Pyrazole and azaindole scaffolds bearing the same 
functional groups as cysmethynil were also not promising. Figure 3-6 
summarizes the SAR deduced in this chapter. 
 
Figure 3.6 Summary of SAR deduced from Series 1-7 
 
3.5 Summary 
The antiproliferative activities of Series 1-7 compounds were determined on the 
malignant breast cancer MDA-MB-231 cells. Except for modifications at the 5-
phenyl position (Series 4), changes embodied in the other series had minimal 






Series 4 resulted in the identification of a 2-aminopyrimidin-5-yl analog 4-12 as 








CHAPTER 4 : Investigations on the antiproliferative activity of compound 4-
12 
4.1 Introduction 
Compound 4-12   was identified in Chapter 3 as the most promising 
analog from the present investigation in terms of antiproliferative activity and Icmt 
inhibition.  In this chapter, the antiproliferative activity of 4-12 was explored in 
detail, in order  to address the following questions. First, it was of interest to 
determine if 4-12 would retain activity on a wider range of malignant cell types, 
and importantly to if it affected viability of non-malignant cells. Second, there was 
a need to understand how 4-12 arrested the proliferation of malignant cells and if 
the antiproliferative activity of 4-12 was complemented by induction of cell death.  
Third, tissue invasion is an acquired capability of cancer cells and the ability to 
halt cell migration is a desired attribute of an anti-cancer agent. It was of interest 
to determine if this property characterized 4-12.    
To investigate these questions, the following experiments were carried 
out. The growth activities of 4-12 were determined on two additional malignant 
cells - human hepatocellular carcinoma HepG270  and human pancreatic MIA-
PACA II cells.  In total, 4-12 was evaluated on a panel of 4 malignant cells 
(prostate PC3, breast MDA MB 231 in Chapter 3).  It was also evaluated on non-
malignant human lung fibroblast cells IMR90 to assess if it acts selectively on 
malignant cells.  To supplement the antiproliferative evaluation, a clonogenic 
assay was carried out to assess if a representative malignant cell (PC3) retained 
reproductive capacity after treatment with 4-12. As for the 2nd question, an 






to determine if the key checkpoints (G1/S, G2/M) were disrupted by 4-12 in a 
concentration dependent manner. Cell death may be induced by different 
mechanisms – necrosis, apoptosis, autophagy and in this chapter, these options 
were explored for 4-12 on representative malignant cell lines.  The effects on cell 
migration were determined by a “scratch” assay, which is a preliminary method 
for the analysis of this phenomenon. 
4.2 Experimental Methods 
4.2.1 Determination of cell viability  
The method described in Section 3.2.2 was followed. Human hepatocellular 
carcinoma HepG2 and human pancreatic cancer MIA PACA II cells were 
obtained from ATCC (Rockville, MD).  They were grown in DMEM (high glucose,  
Invitrogen) supplemented with 10% FBS, 50 µg/ mL penicillin and 50 µg/mL 
streptomycin, 37oC, 5% CO2  until they reached 80-90% confluency, after which 
they were subcultured. Passage numbers were kept within 7-14 passages for 
both cell types.  
The growth inhibitory activity of 4-12 on IMR90 cells was carried out by Miss 
Christina Wong, a final year student, Department of Pharmacy, NUS. Briefly, 
human lung fibroblast IMR90 cells were purchased from ATCC (Rockville, MD) 
and grown in Eagle’s Minimal Essential Media (EMEM, Sigma Aldrich, 
Singapore) at 37oC, 5% CO2. The media was supplemented with 10% fetal 
bovine serum (heat treated), 100 mg / L penicillin-G and 100 µg/mL streptomycin.  
Cells were subcultured at 80-90% confluency and used within 4-10 passages 






4.2.2 Colony formation   
A flask (75 cm3) of PC3 cells in media (DMEM high glucose, 10% fetal bovine 
serum, 50 µg/ mL penicillin, 50 µg/mL streptomycin) was grown to 80-90% 
confluency. The media was removed by pipetting and the cell layer washed with 
1x PBS (5 mL).  An aliquot of trypsin (1 mL, 0.25%trypsin-EDTA (1x)-phenol red, 
Invitrogen) was added to the plate, tapped gently for even distribution and 
incubated at 37oC, 5% CO2 for 1 min. The plate was quickly viewed under the 
microscope to confirm that cells have rounded up.  Media (10 mL) was then 
added and the cell suspension transferred to a falcon tube (15 mL). An aliquot 
(10 µL) was transferred to a hemocytometer for cell counting. The suspension 
was then diluted to give the desired seeding concentration of 1000 cells per well 
in a 6-well plate.  After seeding, the plate was gently tapped to help cells spread 
out within the wells. Plates were then incubated for 2 h (37 oC, 5% CO2) for cell 
attachment to take place. The media was removed with a pipette, the cell layer in 
the well washed with PBS and replaced by  a solution of the test compound in 2 
mL of DMEM (containing 5% FBS, instead of 10% FBS).  Test compounds were 
prepared in DMSO stock solutions. The final concentration of DMSO in the well 
was 0.05% v/v. Control plates were also prepared in which no test compound 
was added but with DMSO maintained at 0.05%. The plates were incubated (37 
oC, 5% CO2) for 2 weeks. After this time, media was removed from the plates by 
pipetting, carefully rinsed with PBS, followed by addition of methanol-acetic acid 
(3:1) solution (1 mL per well) to fix the cells to the floor of the well.  After 5 min at 
room temperature (25oC), the solution was removed and crystal violet solution 
(0.5% v/v in methanol) was added to the plate for 15 min at 25oC. The plate was 






dot/patches on the plate which were visible to the naked eye. Each test 
compound was investigated at 5 concentrations and on three separate 
occasions.    
4.2.3 Cell cycle analysis by flow cytometry 
PC3 cells were seeded at 100 000 cells/mL per well in 6-well plates with media 
DMEM (high glucose, 10% FBS, 50 µg/ mL penicillin, 50 µg/mL streptomycin) 
and incubated (24 h, 37oC, 5% CO2) to allow cell attachment after which they 
were treated with test compound (in DMEM, high glucose, 5% FBS, 50 µg/ mL 
penicillin, 50 µg/mL streptomycin) for 48 h.  Final volume of DMSO per well was 
0.05% v/v.  Control wells (without test compound) were similarly treated. After the 
specified time, supernatant in the well was collected; the cell pellet was 
trypsinized as described in Section 4.2.2, combined with the supernatant and 
pelleted by centrifugation (150 g, 5 min). After rinsing  the pellet twice with ice-
cold 1xPBS, the cells were suspended in 0.3 mL PBS, to which was added 
dropwise and with gentle shaking,  cold  ethanol (0.7 mL)  to give a final 
concentration of 70% ethanol.  The cell sample was then kept at 4oC overnight 
after which it was centrifuged (150 g, 5 min), the supernatant was removed, the 
pellet rinsed with cold PBS and re-suspended in a solution of  100 µg/mL 
propidium iodide (PI, Sigma Aldrich, Singapore) and 0.1 mg/mL ribonuclease A 
(Sigma Aldrich, Singapore) in PBS (500 µL). The suspension was kept in the 
dark for 1 h, 25oC (room temperature) before being analyzed for distribution in 
the G1,S, G2/M phases on a FCS500 flow cytometer (Beckman Coulter, CA) 
using the FlowJo software (http: http://www.flowjo.com/)  Each test compound 






4.2.4 Determination of apoptosis 
The Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, Franklin Lakes, 
NJ) was used. PC3 cells were seeded at 65 000 cells per well in 6-well plates 
with DMEM (high glucose, supplemented with 10% FBS) as media. Plates were 
incubated (24 h, 37oC, 5% CO2) for cells to attach and then treated with test 
compound (prepared in same media but with 5% FBS) for 48 h.  Final volume of 
DMSO per well was 0.05% v/v.  After the specified time, the supernatant in the 
well was collected, the cell pellet was trypsinized (Section 4.2.2), combined with 
the supernatant and pelleted by centrifugation (150g, 5 min). The pellet was 
rinsed twice with cold 1x PBS and suspended in the proprietary binding buffer 
(1x) to give a concentration of 10 6 cells per mL.   An aliquot (100 µL) of the 
suspension containing 10 5 cells was transferred to the FACS tube (5 mL) to 
which was added Annexin V-FITC solution (5 µL) and propidium iodide (PI) 
solution (5 µL). The solution was gently vortexed, incubated in the dark for 15 min 
at room temperature (25oC), afterwhich was added 400 µL of the binding buffer 
(1x).  The sample was analyzed immediately or no later than 1 h,  in which case it 
should be kept in ice and protected from light. Analysis was carried out on a 
FCS500 flow cytometer (Beckman Coulter, CA) using the FlowJo software (http: 
http://www.flowjo.com/). Controls comprised untreated cells, cells exposed to 
Annexin V-FITC only, and cells exposed to PI only. Each test compound was 
evaluated at 4 concentrations. Only 1 determination was made per concentration.  
4.2.5 Western Blot analysis 
MDA MB231, PC3 and HepG2 cells were seeded at 65 000 cells/mL per well in 
6-well plates with DMEM (high glucose, supplemented with 10% FBS, 50 µg/ mL 






5% CO2) for cells to attach and then treated with test compound (prepared in 
same media but with 5% FBS) for 24 h or 48 h. Final volume of DMSO per well 
was kept at  0.05% v/v.  After the specified time, the supernatant was removed 
from the well by pipetting, the cell pellet was trypsinized (Section 4.2.2), and 
pelleted by centrifugation (150 g, 5 min) and stored in -20oC. Samples were 
thawed and cells lysed by adding RIPA (radioimmunoprecipitation assay lysis 
buffer, Thermo Scientific, Rockland, IL) (50 µL) , kept in ice for 30 min and 
sonicated for 1 min in an ice bath. Samples were centrifuged (13 000 g, 5 min, 
4oC) to remove cell debris. The supernatant was stored as aliquots at -80oC and 
used when required. At the time of use, samples were thawed and protein 
content determined using the BCA®Protein Assay reagent (Thermo Scientific, 
Rockland, IL). The volume of the lysate was adjusted with deionized water to 
normalize protein content to 10-20 µg per mL . To this was added Laemmli 
buffer(4x) and heated to 100oC for 5 min to denature the protein. The samples 
were resolved by 12% SDS-PAGE gel electrophoresis at 100V for 90 min. The 
resolved proteins were transferred to polyvinylidene diflouride(PVDF) 
membranes (Bio-Rad, Singapore) using transfer buffer at 100V for 120 min. 
Membranes were then treated with 5% blocking buffer (5% non-fat milk and 0.1% 
Tween-20 in PBS) and probed with the specific antibody(GAPDH, LC3) by 
incubating  the membranes in blocking buffer containing the antibody at 4oC 
overnight. After washing the membranes in PBS containing 0.1% Tween 20 
(PBST), the membranes were probed with secondary antibodies (horseradish 
peroxidise anti mouse IgG, Pierce, USA) in blocking buffer at room temperature 
for 1 h. They  were then washed with PBST and developed using an enhanced 






Detection Kit, GE, Healthcare, UK).  Immunoblots were viewed using the 
ImageQuant RT-ECL imager (GE Healthcare) and the image captured with the 
ImageQuant TL software. Antibodies were obtained from the following sources: 
GAPDH (Cell signaling technology, USA), LC3 (Abgent, USA).  Test compound 
was evaluated at 3 concentrations with 2 repeats for each concentration.  
4.2.6  Immunofluorescence 
Cover slips were placed into the base of each well in a 24-well plate.  PC3 cells 
were seeded at 10 000 cells/mL per well in media (DMEM Hi-glucose, 10% FBS, 
50 µg/ mL penicillin, 50 µg/mL streptomycin) and incubated for 24 h. After this 
time, cells were attached as a layer onto the exposed face of the cover slip. The 
media was carefully removed from the well without disrupting the cell layer on the 
cover slip.  Test compound in DMEM (high glucose, 5% FBS) was added and 
incubated for 24 h or 48 h.  DMSO concentration was kept at 0.05 % per well, 
including control wells.  At the end of the incubation period, media was removed, 
wells were washed thrice with PBS, followed by addition of chilled PBST ( 200 
µL) per well for 10 min to permeabilize the cells. Cells were then fixed with 4% 
paraformaldehyde (300 µL), incubated for 15 min, and washed with cold PBS (3 
times) to remove the fixing solution. To the cell layer fixed on the cover slip in the 
well was added 100 µL of anti-LC3 in PBST (1: 1000). The plates were kept at 
4oC overnight after which each well was washed 3 x  with cold PBS. Rhodamine 
Red-X secondary antibody (Jackson Immunoresearch Laboratories, West Grove, 
PA) was added, incubated (2 h, 25oC) and removed by washing with PBS (3 
times). The cover slips were carefully removed from the wells and mounted onto 






Olympus fluorescent microscope fitted with the appropriate excitation and 
emission filters.  
4.2.7 In vitro “Scratch” assay  
PC3 cells were seeded at 100 000 cells per well in a 6-well plate in media 
(DMEM, high glucose, 10% FBS, 50 µg/ mL penicillin, 50 µg/mL streptomycin) 
and incubated (37oC, 5% CO2) for 36 hours until confluent. The cell monolayer 
was scraped in a straight line with a 1 mL pipette tip to create a “scratch” which 
was also marked at the bottom of the plate with a marker pen. The media was 
removed from the well which was then washed with PBS. Test compound in 2 mL 
DMEM (high glucose, 5% FBS) was added to each well (DMSO concentration of 
0.05% v/v per well) and the plates were incubated at 37oC, 5% CO2.  Control 
wells with PC3 monolayers were similarly treated. Scratches of approximately the 
same size were made on control and treated wells.  Photographs of the 
scratched surfaces in wells were taken with a microscope fitted with a camera at 
the start of incubation and after 24 h.  Magnification was kept constant at 40x for 
all acquired images. These were further analyzed by downloading the images 
into a powerpoint file and measuring (on-screen) the distances between one side 
of the scratch and the other. For each “scratch”, four or five distances were 
measured across the length of the scratch in the initial (0 h) image and these 
same distances were monitored after 24 h. Each compound was tested at 3 






4.2.8 Statistical Analysis 
Data was analyzed for statistical significance by one-way ANOVA followed by 
Dunnett post-hoc test on IBM SPSS Version 19 (Chicago, IL). p < 0.05 was taken 
as the criterion for significance.  
4.3 Results 
4.3.1 4-12 reduces viability of HepG2 and MIA PACA II cells 
4-12 reduced the viability of HepG2 and MIA PACA II cells in a concentration 
dependent manner, in the same way  as that observed on MDA-MB-231 and PC3 
cells (Section 3.3.4). Representative concentration response viability curves 
obtained for 4-12 on the 4 malignant cell lines are shown in Figure 4-1A.  The 
close overlap of the curves reveal that 4-12 maintained the same level of potent 
activity on all the cell lines, as reflected in its IC50 values which varied within a 
narrow range of 1.6 -2.6 µM  (Table 4-1). 
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Figure 4.1 Concentration versus % viability plots of (A) 4-12 and 







Cysmethynil and selected Series 4 compounds (4-1, 4-10, 4-18, 4-19) also 
demonstrated concentration-dependence in their antiproliferative activities.  
Antiproliferative IC50 values of cysmethynil on PC3, MDA-MB-231 and HepG2 
agreed well with those reported by others.30 Cysmethynil was equally potent on 
the tested malignant cells and this was also true for the Series 4 compounds.  
None of the latter compounds were more potent than 4-12 on the panel of 
malignant cells. 
4-12 was also evaluated for its effects on the viability of the non-malignant 
human lung fibroblast IMR90 cells. Disappointingly, the non-malignant IMR90 
cells were almost as susceptible as PC3 and MDA MB 231 cells to 4-12, but 
slightly less responsive (1.5 x) when compared to HepG2 and MIA PACA II. The 
same was true for cysmethynil, 4-1 and 4-10, all of which failed to discriminate 












Table 4.1 Cell viability IC50 values of 4-12, cysmethynil and other Series 4 




















































































a Mean (±SD) of at least 3 determinations or mean of 2 separate determinations.b From Table 3-4 
4.3.2 4-12 arrests the cell cycle of PC3 cells at the G1 phase  
Inhibition of CaaX proteins is expected to impact cell cycle progression. The Icmt 
inhibitors cysmethynil, 3-2 and 4-1 were previously reported to disrupt the cell 
cycle of PC3 and MDA-MB-231 cells at the G1 phase. G1 arrest was observed 






4-1).55, 59  These investigations were carried out by fluorescence activated cell 
sorter analysis (FACS) using flow cytometry.  In a subsequent study,30   
cysmethynil (25 µM) was shown to similarly arrest HepG2 cells at the G1 phase 
after 48 hours of incubation. When incubation was extended to 72 hours, a 
significant increase in the sub-G0 phase, indicative of substantial cell death, was 
observed.   
Briefly, at the G1 phase, cells exhibit high levels of biosynthetic activity in 
preparation for DNA synthesis which occurs in the subsequent S phase. Cells 
rigorously monitor their cellular environment during this period and depending on 
the signals received, will proceed with the next phase of the cycle and proliferate, 
be forced out of the proliferative cycle into the  quiescent Go phase from which 
they may later reemerge,  or permanently relinquish their proliferative potential by 
entering into a post-mitotic state, for instance by acquiring differentiation traits.1  
Cancer cells normally acquire insensitivity to anti-growth signals arising from the 
G1 phase. Most if not all of the antigrowth signals involve the retinoblastoma 
protein (pRb) which when hypophosphorylated, blocks proliferation by 
sequestering and altering the function of E2F transcription factors that control the 
genes required for G1 S progression. In cancer cells, pRb is 
hyperphosphorylated which causes it to dissociate from the E2F/Rb complex 
thereby activating E2F and promoting the transcription of genes involved in 
proliferation.  Consistent with the findings of G1 arrest in PC3 and HepG2 cells, 
cysmethynil reduced cyclin D1 and phosphorylated pRb levels.30, 55   
A range of concentrations encompassing the IC50 of 4-12 were incubated with 






G1, S and G2 phase.  For comparison, cysmethynil was investigated under 
similar conditions but at higher concentrations in line with its IC50. The results are 
tabulated in Table 4-2, and representative figures are given in Figure 4-2.   
Table 4.2 % Cells in G1 and G2 phases of PC3 cells treated with 4-12 and 
cysmethynil (48 h incubation)  
 % Cells in G1 phase a % Cells in G2 phase b 
Control 2 47.17 (1.94, 6) 27.94 (5.26,5) 
0.8 µM 4-12 52.92 (2) 24.22 (2) 
1.0 µM 4-12 59.98 (2) c 26.99 (2.77,3) 
1.5 µM 4-12 53.84 (2.78, 3) 22.16(8.66,3) 
2.0 µM 4-12 66.45 (2)c 11.20 (2)c 
12.5 µM Cysmethynil 53.0 (2) 27.87 (2) 
15.0 µM Cysmethynil 51.63 (2) 37.21 (2) 
17.5 µM Cysmethynil 51.83 (2) 26.85 (12.28, 3) 
20.0 µM Cysmethynil 54.85 ( 2) 32.07 (2) 
a Mean values (SD where applicable, number of determinations).  No SD is 
reported for 2 determinations.b Cells treated with media (0.05 % v/v DMSO) in the 
absence of test compound. c Significantly different (p < 0.05) from control G1 or 
G2 phase (1-way ANOVA, Dunnett 2-sided post hoc).  
 
It can be seen from Table 4-2 that compared to the control untreated cells,  4-12 
increased cells in the G1 phase while decreasing cells in G2 phase, changes 
which were indicative of a G1 arrest. These changes were significant for the 
highest concentration of 4-12 tested (2.0 µM). Cysmethynil had previously been 
reported to cause G1 arrest in PC3 cells59 but this was not readily observed here 
(Table 4-2). Although an increase in the G1 population was evident in 
cysmethynil treated cells, there was no corresponding decrease in G2 phase and 







Figure 4.2 Representative figures showing the DNA content 
analysis of PC3 cells after 48 h incubation with vehicle (media + 
0.05% v/v DMSO), 4-12 and cysmethynil  at stated concentrations.   
 
4.3.3 4-12 inhibits colony formation of PC3 cells 
The ability of cells to propagate and form colonies (defined as a cluster of at least 
50 cells) is an indication of its reproductive capability.71 when cell death occurs, 
cells lose their reproductive integrity and ability to proliferative indefinitely.  The 
clonogenic (or colony formation) assay is widely used to detect cells that retain 
the capacity to reproduce after treatments that cause reproductive death such as 
ionizing radiation or cytotoxic agents.  Essentially, the assay tests the ability of 
individual cells in a population to undergo “unlimited” division.   
The effects of 4-12 and cysmethynil on colony formation of PC3 cells were 






µM for cysmethynil.  The results are shown in Figure 4-3. In the case of 4-12, 
colony formation was evident only  at the lowest concentration of 1 µM and not at 
higher concentrations (1.5 to  3 µM). Colony formation was observed with 15 µM 
cysmethynil but not at higher concentrations (17.5 to  25 µM). These were 
encouraging results as they demonstrated the ability of both compounds to 
abrogate the reproductive capabilities of PC3 cells at concentrations that were 
close to their IC50 values. In the case of 4-12, colony formation was clearly 
inhibited at 1 µM.  
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Figure 4.3 Photographic images of PC3 cells treated with 
different concentrations of 4-12 and cysmethynil.  
4.3.4 4-12 does not induce apoptotic cell death of PC3 cells 
Since 4-12 caused a replication block at the G1 phase of the cell cycle of PC3 
cells and limited the reproductive capability of this cell line in the clonogenic 
assay, the next step was to determine if it causes  programmed cell death since 
stalling the proliferation of cancer cells will lead to a “cellular crisis” and  the 
initiation of apoptosis.72 For therapeutic efficacy, diminished proliferation would 
be complemented by an increase in the rate of attrition of cells, namely induction 
of cell death. Cysmethynil has been reported to trigger apoptosis in HepG2 cells 
but not in PC3 cells.30, 55 Cell death by autophagy was however observed in both 
cell types.30, 55  The contrasting apoptotic response of PC3 and HepG2 was 
attributed to differences in their cellular genetic or epigenetic background.30 In 
this section, 4-12 was investigated for its effects on apoptotic cell death in PC3 
cells using a commercial kit based on dual staining by Annexin V and propidium 






cells undergoing early apoptosis. As a result, phosphatidylserine molecules 
normally located in the inner surface of the membrane are translocated to the 
outer membrane leaflet. The exposed phosphatidylserine residues interact 
strongly and specifically with Annexin V in the presence of calcium.73  By 
conjugating Annexin V with a fluorescent tag (fluorescein isothiocyanate, FITC), 
the binding of Annexin V to the membrane surface can be monitored. The kit 
includes propidium iodide (PI) which binds to cellular DNA of necrotic cells. In 
these cells, the cellular membranes are completely compromised and thus 
permeable to PI.  The combination of Annexin V-FITC and PI allows 
differentiation of cells into 3 phases: normal cells (Annexin V -, PI -), early 
apoptosis (Annexin V +, PI-), and late apoptosis /necrosis (Annexin V+, PI+). 
These phases are observed in the lower left quadrant, lower right quadrant, and 
upper left and right quadrants respectively in the FACS diagram of cells double 
stained with Annexin V and PI.   
Apoptosis was investigated by double staining of PC3 cells with Annexin V and 
PI at different concentrations of 4-12 and cysmethynil after 48 h.  Only one 
independent determination was carried out for both compounds and thus the 
results should be regarded as preliminary. Nonetheless, cysmethynil was not 
found to induce apoptosis, in keeping with earlier findings on PC3 cells. Induction 
of apoptosis was also not observed for 4-12 (Table 4-3, Figure 4-4).  Over the 3-
fold concentration range of 4-12 investigated, the proportion of normal cells 
showed limited variation from control untreated cells,  the proportion of apoptotic 
cells showed small increases and % necrotic cells remained largely unchanged 






Table 4.3 Distribution of normal, apoptotic and necrotic PC3 cells treated with 







%   
Necrotica 
Control b 90.1 0.361 9.56 
4-12        
0.4µM 93.6 1.45 4.95 
0.8µM 91.8 1.31 6.85 
1.0µM 90.4 0.71 8.84 
1.2µM 91.6 0.93 7.43 
    Cysmethynil 
   12.5µM 92.1 0.92 6.94 
15.0µM 90.6 1.14 8.28 
17.5µM 89.7 1.96 8.33 
20.0µM 90.7 1.23 8.06 
22.5µM 89.6 1.21 9.14 
a  Determined from one analysis only b Cells treated with media (0.05% v/v 






Figure 4.4 Representative figures showing FACS analysis of 
normal, apoptotic and necrotic PC3 cells after 48 h incubation with 
vehicle (media + 0.05 % v/v DMSO), 4-12 and cysmethynil at stated 
concentrations. Lower left quadrant = normal cells; Lower right 




4.3.5 Effect of 4-12 on PC3 autophagic cell death 
Autophagy as a cell death mechanism has been widely investigated.2, 30, 74-79 
Autophagy involves the degradation and recycling of proteins and intracellular 
components in response to nutrient deficiency in cells. There is still considerable 
discussion on the role of autophagy in cancer and whether the therapeutic 
response of anticancer drugs should be to induce or inhibit autophagy. The 
general consensus is that the role of autophagy in tumorigenesis is context 






order to promote tumor growth. As the  tumor matures, autophagy  may be 
induced to supply nutrients to proliferating cells which may be experiencing 
cellular stresses like hypoxia and nutrient deprivation.79  Autophagy protects 
some cancer cells against anticancer therapy by blocking apoptotic pathways 
(“protective autophagy”) in which case drugs that inhibit autophagy would be 
beneficial. On the other hand, drugs that induce autophagy would be desirable in 
tumors with fundamental defects in the apoptotic machinery.  
Investigations with cysmethynil have shown that it induced autophagic cell death 
in PC355  and HepG230  cells.  It was further demonstrated that cysmethynil 
induced apoptosis in HepG2 cells as well and that both autophagic and apoptotic 
cell death in HepG2 were evoked through the specific inhibition of Icmt.30 
Moreover the robust autophagic response induced by cysmethynil led to 
apoptotic cell death, indicating that autophagy did not merely serve in a pro-
survival or cytoprotective capacity.30  
The earlier sections have shown several similarities between 4-12 and 
cysmethynil with respect to their effects on the cell cycle (G1 arrest) and absence 
of apoptosis in PC3 cells.  It was of interest to determine if these similarities 
would extend to the induction of autophagy in PC3 cells.  Earlier, 3-2 and 4-1 
were shown to cause autophagic cell death in PC3 and MDA MB 231 cells over a 
range of concentrations at one time point (48 h).59 In view of their structural 
resemblance to 4-12, the same outcome was anticipated for 4-12.  In this section, 
the effects of 4-12 on autophagy was investigated in greater detail.  First, the 
autophagic biomarker LC3II was monitored on three cell lines (PC3, MDA MB 






(24h, 48 h).  Second, autophagy was investigated by cell-based 
immunofluorescence analysis of LC3 aggregation in 4-12 treated PC3 cells after 
48 h of incubation.  
Briefly, autophagy begins with the isolation of double membrane-bound 
structures inside an intact cell.78 As these structures elongate and mature, they 
recruit microtubule-associated protein 1 light chain 3 (LC3) on their surfaces. The 
elongated membranes sequester cytoplasmic proteins and organelles 
(mitochondria, Golgi apparatus) and form autophagosomes. These subsequently 
fuse with lysosomes to become autolysosomes which carry out the task of 
degrading the sequestered contents and making them available for recycling.  
One assay for autophagic cells is to detect the presence of membrane bound 
LC3 on autophagosomes. Before attaching to the pre-autophagosomal 
structures, LC3 is ubiquitinated to give LC3-1 which resides in the cytosol. When 
autophagy is induced, some LC3-I is conjugated to phosphatidylethanolamine to 
give LC3-II, which associates tightly with the autophagosomal membrane.80, 81 
Hence, immunoblotting of LC3 results in two bands, LC3-I and LC3-II.  On SDS-
PAGE, LC3-I migrates faster than LC3-II.  Increased production of LC3-II and its 
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Figure 4.5 shows representative immunoblots of LC3-I and LC3-II from 4-12 
treated cells (PC3, MDA MB 231, HepG2) at 24 h and 48 h time points. 4-12 
was investigated at 1, 2.5 and 5 µM on (A) MDA MB 231 and (B) PC3 cells. 
On HepG2 cells (C), it was investigated at lower concentrations of 0.2 and 
0.5 µM.  Also included are plots obtained with  cysmethynil at various 
concentrations ,and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) 
which acts as the house keeping  protein. Immunoblots were obtained from 2 
independent repeats.  
 
  4-12 increased the content of LC3-II of MDA MB 231 and PC3 cells at 1, 2.5 
and 5 µM at both time points (24 h and 48 h). As the intensities of these blots 
were not analyzed by densitometry, it was not possible to comment on 
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concentration or time dependent effects.  Visual inspection indicated that less 
LC3II accumulated at the lower concentration of 1 µM compared to the higher 
concentrations at both time points.  The intense LC3II band observed at 1 µM 4-
12 in treated MDA MB 231 cells after 48 h may be an aberration because a less 
intense band was observed at 2.5 µM on the same blot. LC3-II bands were 
detected in HepG2 cells treated only with 0.5 µM but not 0.25 µM 4-12.  These 
bands were observed at both time points.   
Previously, cysmethynil was demonstrated to increase LC3II content in PC3 and 
MDA MB 231 cells at 25 µM after 48 h of incubation whereas limited LC3 II was 
observed at 10 µM.59  Figure 4-5 shows that LC3-II accumulation was evident in 
MDA MB 231 cells treated with cysmethynil at 20  and 22.5 µM,  but not at 17.5 
µM for both time points. These results were in keeping with those reported 
earlier. On the hand, negligible LC3II were observed from cysmethynil treated 
PC3 cells. HepG2 cells were treated with lower concentrations (12.5, 15 µM) of 
cysmethynil and LC3II accumulation was evident after 48 hours but not 24 h.    
Immunofluorescence assay 
The induction of autophagy by 4-12 was further investigated by using cell-based 
immunofluorescent analysis  to detect autophagosomes. PC3 cells were stained 
with fluorescence tags for in vitro cell imaging. The cell nucleus was stained blue 
by DAPI while LC3 protein was stained red by anti-LC3 and rhodamine-red 
tagged secondary antibodies.  Figure 4-6 shows that in control untreated cells, 
the blue fluorescence of the nuclei predominated. When cells were treated with 
4-12, punctate LC3-positive (red) vacuoles were observed at 2.5 and 5 µM.  












Figure 4.6 Analysis of LC3 aggregation in (A) 4-12 and (B) 
cysmethynil treated PC3 cells (48 h). Fluorescent microscopy 
analyses of PC3 cells labeled with DAPI (blue) and rhodamine red 
secondary antibodies against LC3 (red) are shown. 
 
4.3.6 4-12 inhibits cell migration in the in vitro scratch assay  
The in vitro scratch assay is a simple and inexpensive method to study cell 
migration in vitro. It involves creating an artificial gap (scratch or wound) on a 
confluent cell monolayer and determining if a particular “treatment” (for example, 
presence of a test compound, varying media components) would affect the 
natural tendency of the cells at the edge of the scratch to migrate inwards and 
close the gap.82 Images are taken at the start of the experiment and at specific 
time points thereafter to assess the rate at which the cells migrate to effect 






not meant to replace other well established methods for chemotaxis like the 
Boyden chamber or microfluidics-based systems, as no chemical gradient is 
established in the scratch assay.82  
The scratch assay was carried out on PC3 cells in the presence of 1.5, 2.0 and 
2.5 µM 4-12, with images captured at the start of the experiment (0 h) when the 
scratch was created and 24 h later. (Figure 4-7)  Four distances were marked out 
across the gap initially on each plate (0 h) and these same distances were 
measured after 24 h.  As shown in Figure 4-7, the gap was breached in the 
control (untreated) well after 24 h. In the case of wells treated with 4-12, the gap 
remained “open” at 2 and 2.5 µM but closed to some extent at a lower 
concentration of 1.5 µM.  The measured distances between the gaps in treated 











Figure 4.7 Images of scratches from 4-12 treated wells at the 
start of the experiment (0 h) and after 24 h. The images were taken at 























































Figure 4.8 Average distances between edges of scratches (±SD, 
n= 3) in control wells and wells containing different concentrations of 
4-12. Measurements were made at 0 h and 24 h after scratch was 
created.  
 
The experiments were concurrently run with cysmethynil at 17.5, 20 and 22.5 µM.  
As seen from Figures 4-9 and 4-10, the gap closed to some degree in the 
presence of 17.5 and 20 µM cysmethynil after 24 h, but remained open in cells 
treated with 22.5 µM cysmethynil. Thus, these experiments highlighted the 
potential of 4-12 and cysmethynil to inhibit cell migration at concentrations that 















Figure 4.9 Images of scratches from cysmethynil treated wells at 
the start of the experiment (0 h) and after 24 h. The images were 
taken at the same magnification (40x) and downloaded to a 




Figure 4.10 Average distances between edges of scratch (±SD, 
n= 3) in control wells and wells containing different concentrations of 
cysmethynil. Measurements were made at 0 h and 24 h after scratch 





















































Several important observations have emerged from the investigations described 
in this chapter. Foremost was the observation that 4-12 retained almost the same 
level of antiproliferative activity across a panel of diverse malignant cell lines. 
This was evident from the narrow range of IC50 values (1.6 to 2.6 µM) derived 
from the different cell lines. The cells in the panel have different Ras status - PC3 
cells have wild type Ras, MDA-MB-231 cells83  and MIA-PACA-II cells harbor 
mutated K-Ras,84  and  HepG2 cells have high levels of mutated N-Ras70, but 
these differences did not appear to have any overt influence on the 
antiproliferative activity of 4-12.  Unfortunately, 4-12 was equally active in 
curtailing the proliferation of the non-malignant IMR90 cells, with no more than a 
1.6 fold difference between the IC50 values of IMR90 and MIA Paca II cells which 
was more susceptible to 4-12. Cysmethynil was equally non-selective in its 
antiproliferative activity although it was reportedly well-tolerated when 
administered to healthy animals.30, 55  The apparent non-selective action of 4-12 
would need to be confirmed on a wider panel of non-malignant cell lines. 
The antiproliferative activity of 4-12 was traced to its ability to arrest the cell cycle 
at the G1 phase.  In PC3 cells incubated with 2 µM 4-12 for 48 hours, significant 
changes were observed in the proportion of cells in G1 (increased) and G2 
(decreased) compared to control untreated cells. G1 arrest is normally 
associated with changes in specific molecular marker proteins such as cyclin D1, 
p27 and phosphor-Rb.  Wang et al55 showed that cysmethynil-induced G1 arrest 
of PC3 cells was accompanied by elevated levels of p27, reduced cyclin D1 






to determine if its G1 arrest is accompanied by similar changes in these 
regulatory proteins. 
4-12 was observed to arrest the colony forming capabilities of PC3 cells.  The 
implication was that 4-12 not only arrested proliferation of these cells but also 
effectively curtailed their reproductive capability over time. In other words, PC3 
cells were essentially killed by the compound.  Cell death may be evoked by 
several mechanisms and in the case of 4-12, autophagic-induced cell death was 
found to play a prominent role. 4-12 increased the levels of the autophagosomal 
marker LC3-II in 3 malignant cell lines (PC3, MDA MB 231, HepG2). It also 
induced aggregation of LC3 protein in vesicular structures characteristic of 
autophagosomes.  By contrast, preliminary assessment by dual staining with 
Annexin-V and PI showed limited apoptotic cell death in 4-12 treated PC3 cells.   
Another pertinent observation related to the ability of 4-12 to promote cell 
migration as seen from the in vitro scratch assay. Although not directly linked to 
cell viability and proliferation, several processes related to cell migration like 
angiogenesis are hallmarks of carcinogenesis. Thus, further investigations should 
be initiated to confirm the inhibitory effects of 4-12 on cell migration.   
In the experiments described in Sections 4.3.3, 4.3.4 and 4.3.5,  different 
concentration ranges were investigated for cysmethynil and 4-12. Cysmethynil 
was investigated at a higher concentration range (15 µM – 25 µM) in keeping 
with its higher antiproliferative IC50. 4-12, on the other hand, was investigated at 
lower concentrations (1 µM – 5 µM) for the same reason.  The non-overlapping 
concentrations could have made comparisons between the two compounds 






The narrow concentration intervals employed in several of the experiments, could 
however have been improved upon by using concentrations equivalent to ½ 
logarithm dilutions.   
4.5 Taken together, the present chapter has provided preliminary evidence 
that 4-12 affected several processes that are critical in carcinogenesis, namely 
antiproliferation, disruption of cell cycle, induction of autophagy and cell 
migration.  In spite of the diversity of these phenomena, the effects of 4-12 were 
observed over a narrow and recurring concentration range (1-5 µM). Compared 
to cysmethynil which also affected these processes in a qualitatively similar 
manner, 4-12 was clearly more potent by at least a fold magnitude. However, 
unlike cysmethynil for which there is a good (if still incomplete) understanding 
between Icmt inhibition and tumor progression, much less is known for 4-12.  
Notably, it has not been shown that Icmt inhibition by 4-12 led to mislocalization 
of Ras or impaired epidermal growth factor signaling, as have been 
demonstrated for cysmethynil. Neither is it known if the autophagy induced by 4-
12 is linked to apoptosis as reported for cysmethynil.  Icmt inhibition by 
cysmethynil has been linked to reduced signaling along the m-TOR pathway 
which is activated in cancer cells through growth factor receptors. 78 It is not 
known if this applies to 4-12 as well. Clearly further investigations are required to 
confirm the present findings and to address the current gaps in our knowledge of 
4-12. Summary 
4-12 was found to retain the same level of antiproliferative  activity on a panel of 
diverse malignant cell types of different Ras status.  However, it lacked selective 
activity as it affected the viability of the non-malignant IMR90 cells to the same 






arrest.  4-12 also curtailed the reproductive integrity of PC3 cells, which was 
indicative of cell death. Investigations revealed that 4-12 induced autophagic cell 
death in several malignant cell types. There was less convincing evidence that it 
induced apoptosis.  4-12 inhibited in vitro cell migration and should be 
investigated for its effects on angiogenesis.  4-12 and cysmethynil shared many 
similarities in their activity profile but the effects of 4-12 were observed at a 5 to 






CHAPTER 5 In vivo evaluation of 4-12 in mice bearing xenografts induced 
with human heptocellular carcinoma HepG2 cells 
5.1 Introduction 
 This chapter describes investigations aimed at demonstrating the in vivo 
efficacy of 4-12 on xenografts induced by human heptocellular carcinoma HepG2 
cells in immunocompromised mice. Before this evaluation could be carried out, 
two experiments on 4-12 were required. The first involved determining the 
maximal tolerated dose (MTD) of 4-12 in mice in order to establish the dose 
range to be administered in the xenograft experiments.  Once proposed 
concentrations of 4-12 were identified, the next step was to confirm that mice 
receiving these doses would achieve concentrations in plasma that were 
comparable to the in vitro IC50 of 4-12. In this way, appropriate doses of 4-12 
could be delivered to the xenograft bearing animals for in vivo evaluation. An 
attempt to identify the possible metabolites of 4-12 in rat was also described in 
this chapter.  
5.2 Experimental Methods 
5.2.1 Determination of maximal tolerated dose (MTD) 
Approval for the experimental protocol was obtained from the SingHealth 
Institutional Animal Care and Use Committee (Application number 
#2011/SHS/688).  Experiments were carried out on female Balb/c mice (6-8 
weeks old, 20-22 g) obtained from the Biological Resource Centre, Agency for 
Science, Technology and Research, Singapore. Animals were kept under 
controlled environmental conditions (19-26°C, relative humidity <70%, 12h dark-






Animals were given free access to water and standard feed. They were randomly 
assigned to 10 groups with 2 animals per group. Five groups were assigned for 
the determination of MTD of 4-12 and the remaining groups for cysmethynil.  4-
12 was investigated at the following doses:   10, 20, 50 and 100 mg/kg. In the 
case of cysmethynil, doses were 20, 50, 100 and 200 mg/kg.  The test compound 
was administered intraperitoneally using a 23G gauge needle to the animal in a 
volume of vehicle that was tagged to the body weight, namely 0.2 mL for 20 g 
animal and so on. The vehicle was formulated from ethanol, PEG 400 (Sigma 
Aldrich) and 5% dextrose (Sigma Aldrich) in the ratio 1:6:3. The test compound 
was first dissolved in ethanol, PEG400 was added and the solution was vortexed, 
followed by 5% dextrose and further vortexing. The solutions were freshly 
prepared before administration.  For the determination of MTD, one group of 2 
animals received the vehicle without test compound. Another group of 2 animals 
received the lowest dose of test compound by IP injection and were observed for 
45 min. If they did not show signs of toxicity (vomiting, vocalization, hunched 
posture, shivering, decreased activity, immobility or moribund state), another 
group of 2 animals were given the next higher dose and the process was 
repeated until all the doses were tested.  Animals in each group were observed 
for 24 hours thereafter.  
5.2.2 Pharmacokinetic study 
Experiments were carried out on female Balb/c mice (6-8 weeks old, 20-22 g) 
obtained from the Biological Resource Centre, Agency for Science, Technology 
and Research, Singapore and maintained under similar conditions as described 
in 5.2.1.  4-12 was tested at two doses of 10 mg/kg and 25 mg/kg which were 






following time points thereafter : 5 min, 15 min, 45 min, 1.5 h, 3 h, 8 h, 24 h and 
48 h. Cysmethynil was tested at 20mg/kg and 100 mg/kg in a similar manner and 
blood was withdrawn at the same time points.  
12 mice were used for each dose. They were divided into 4 groups of 3 mice. All 
the mice received the test compound prepared in the vehicle described in 5.2.1. 
The volume administered was tagged to the animal’s weight (for example, 0.2 mL 
for 20 g and so on). Collection of blood was staggered as follows: blood was 
withdrawn at 5 min and 3 h for the 1st group of mice, 15 min and 8 h for the 2nd 
group, 45 min and 24 h for the 3rd group, 1.5 h and 48 h for the 4th group.  For the 
1st time point, blood was drawn from the sub-mandibular vein using a 21 G gauge 
needle. For the final time point, the animal was anaesthesized with an anesthetic  
mixture comprising   ketamine (0.1mL,  100mg/kg), diazepam (0.1mL, 5mg/kg) in 
saline (0.8 mL). Each mouse was given 0.2 mL of the mixture (IP)and blood was 
withdrawn by cardiac puncture. The blood was collected in EDTA-coated tubes, 
centrifuged at 15800 g for 10 min at 4oC and stored at -20oC until analyzed.  
Naive blood samples were also collected from 4 untreated animals 
(submandibular route) to obtain the calibration curves required for LCMS 
quantification.  
Samples for the calibration curves were obtained as follows: To a microcentrifuge 
tube was added the naïve plasma sample (45 µL), internal standard (20 µL) and 
test compound (5 µL). The internal standard was cysmethynil (50 µg/mL ) for 4-
12, and 4-12 (50 µg/mL) for cysmethynil. The test compound was added over a 
range of concentrations which were 2 µg/mL to 200 µg/mL for 4-12, and 2µg /mL 






shaking on a plate shaker for 5 min, after which ice cold methanol (150 µL) was 
added, shaking continued for another 15 min and then centrifuged (15800 g, 4oC, 
15 min). The supernatant was transferred to an autosampler vial and an aliquot 
(10 µL) was injected into an LC/MS/MS instrument for analysis. In order to 
assess variations due to instrument fluctuations, calibration was repeated twice 
during the period of analysis. Appendix 5: Table 5-1 to Table 5-4 lists the 
calibration curves for 4-12 and cysmethynil, and % accuracy of the 
determinations based on comparisons of the expected and experimentally 
determined concentrations of spiked samples.   In the case of samples from 
treated animals, the procedure was the same except that 50 µL of plasma was 
added to the micro centrifuge tube and the test compound (5 µL) was omitted.   
The instrument used for analysis was a Shimadzu UFLC system 
(Shimadzu Scientific Instruments, Columbia, MD),  with the Waters X-Terra  C18 
column (4.6 X 50mm,  5µM) maintained at an oven temperature of 30 °C and  
coupled to a QTRAP 3200 triple quadruple mass spectrometer (Applied 
Biosystems, Foster City, CA). Instrument control and data acquisition were 
performed using Applied Biosystems software Analyst 1.4.2.   The mobile phase 
comprised (A) 10 mM ammonium formate in 0.1 % formic acid and (B) 
acetonitrile, run on gradient mode. Flow rate was 0.6ml/min, and a 20 µl injection 











Plasma concentration from three mice were obtained at each time point and the 
mean value was plotted against time to give a plasma concentration versus time 
plot for each dosing regimen. Pharmacokinetic parameters were calculated by 
WinNonlin (Standard Version 5.0.1,Pharsight, Sunnyvale, CA) using non-
compartmentalized analysis for  PO dosing.  
5.2.3 In vitro metabolite structure identification 
The test compound was incubated with rat liver microsomes for 45 min, after 
which aliquots were analyzed by LC/MS/MS for the presence of metabolites.  The 
incubation studies were carried out by Miss Luo Wen Xia of the Drug 
Development Unit, NUS. LC/MS/MS analysis and proposal of likely metabolites 
were carried out by the candidate. Briefly, the test compound was incubated with 
pooled rat liver microsomes (BD Gentest Corp, Woburn, MA)  in a mixture (final  
volume 500 µL) comprising the following : rat liver microsomes (7.5 µL of 20 mg 
microsomal protein  to give final concentration of  0.3 mg microsome protein/mL), 
test compound (2.5 µL of 1 mM test compound in acetonitrile  to give final 
concentration of 10 µM) and phosphate buffer (440 µL of 0.1 M, pH 7.4, 
containing 1 mM EDTA). The mixture was preincubated for 5 min at 37oC in a 

















































NADPH (freshly prepared in phosphate buffer) to give a final concentration of 
1mM NADPH in the mixture. Aliquots of 50 µL were withdrawn immediately on 
addition of NADPH (time 0) and 45 min later.   On removal of the sample, 
reaction was quenched by addition of chilled methanol (100 µL). The mixture was 
then centrifuged at 10,000 g to remove the protein and the supernatant was 
analyzed by LC-MS-MS .  
Liquid chromatography was performed on an Agilent 1200 series HPLC system 
interfaced with a QTRAP 3200 triple quadruple mass spectrometer (Applied 
Biosystems, Foster City, CA). Instrument control and data acquisition were 
performed using Applied Biosystems software Analyst 1.4.2.   Separation was 
carried out on a Phenomenex Luna C18 column (50 x 2.0 mm, 3 μM) with 10 mM 
ammonium formate in 0.1 % formic acid (mobile phase A) and acetonitrile 
(mobile phase B) as eluting solvents, run on gradient mode, details of which are 
as follows:  
Step Total time 
(min) 
Mobile Phase A 
% 
Mobile Phase B % 
0 0 98 2 
1 2 98 2 
2 8 2 98 
3 10 2 98 
4 10.2 98 2 
5 11 98 2 
 
Column temperature was maintained at  50oC, injection volume was 10 µL and 
flow rate 400 µL /min. The mass spectrometer was operated in the turbo spray 
mode with positive ion detection. The optimized instrument parameters were 






Nebulising gas (N2) 40-60;  turbo ion spray gas (N2) 50; collision gas (argon) 
medium; dwell time 200 ms.  
Full scan spectra of 4-12 and cysmethynil were first obtained, after which 
Extracted Ion chromatogram (XIC) spectra were derived  based on predicted 
metabolites. Metabolite peaks that had total ion current of 1 x 10 5 counts per 
second (cps) or more were shortlisted and the product ion spectra were obtained 
by adjusting the declustering potential (V) and collision energy (eV).  
5.2.4 Evaluation of in vivo activity on  xenograft bearing mice 
Approval for the experimental protocol was obtained from the SingHealth 
Institutional Animal Care and Use Committee (Application number 
#2011/SHS/688).  HepG2 cells were grown in DMEM and 10% FBS until near 
confluence and then harvested after trypsinization.  Cells (1 x 107) were mixed 
with Matrigel (BD Biosciences, Catalog No.354234) to achieve 40% Matrigel in 
the final mixture. The cell preparation was injected subcutaneously Into the flanks 
of female immunodeficient SCID mice (6-8 weeks old, 20-22g). When tumors 
were palpable (100–200 mm3), the animals were randomly assigned to 5 groups 
of 8 mice each, namely (i) a control group which received vehicle IP, on alternate 
days; (ii)two groups that were given 75 mg/kg and 150 mg /kg cysmethynil 
respectively (IP, on alternate days);  and (iii) two groups that received 15 mg/kg 
and 30 mg/kg 4-12 respectively (IP, daily).  Fresh stock solutionswere prepared 
daily or on alternate days for each dose regimen (for example, 7.5 mg/mL stock 
for dose of 75 mg/kg). The vehicle was ethanol-PEG400-dextrose solution as 
described in 5.2.1. The animals were monitored daily for changes in their general 
appearance, weight and tumor volume. Tumor volume was calculated using the 






measured with a digital vernier caliper and reported to 2 decimal places. The 
shorter of the 2 distances was taken as width.  The mice were monitored for 25 
days after which they were euthanized with CO2,, the tumors removed by 
dissection and weighed. Animals were also euthanized (before Day 25) if they 
showed any of the following characteristics : tumor volume > 2 cm 3;  tumor 
ulceration, infection or inflammation; ruffled fur, hunched back appearance or 
inappetent state;  10% or more body weight loss over 24 h or 20% body weight 
loss over one week moribund or pre-moribund state.  
5.2.5 Statistical Analysis 
Tumour volume and tumor weight data were analyzed by One-way 
ANOVA with Dunnett post-hoc on IBM SPSS Statistics Version 19.0 (Chicago, 
IL). p-values <0.05 were considered significant.  
5.3 Results 
5.3.1 Maximal tolerated dose of 4-12 and cysmethynil in Balb/c mice 
4-12 was well tolerated at 10, 20 and 50 mg/kg but at 100 mg/kg, one of the 2 
mice died within the 45 min observation period.  The animals were monitored for 
the next 24 h, and during this time, no morbidity was observed.  In the case of 
cysmethynil, it was well tolerated at all doses (20mg/kg to 200 mg/kg) and no 
deaths were observed. 
5.3.2 Pharmacokinetic evaluation of 4-12 and cysmethynil in Balb/c mice 
In view of the results obtained for the maximal tolerated doses of 4-12 and 
cysmethynil, a decision was made to evaluate 4-12 at 10mg/kg and 25 mg/kg, 






plasma concentration with time for the two doses of 4-12. 4-12 was not detected 
after 24 h and 48 h. 
 
Figure 5.1 Mice plasma concentrations of 4-12 at various time 
points. 4-12 was administered at 10mg/kg and 25 mg/kg IP. Each data 
point was obtained from 3 animals.  
 
The plasma data was analyzed assuming non-compartmentalized 
pharmacokinetics.  Table 5-1 lists some apparent  pharmacokinetic (PK) 










































Table 5.1 Apparent pharmacokinetic parameters of 4-12 and cysmethynil 
derived from WinNonLin software based on non-compartmental model 
Parameters 4-12 Cysmethynil 
10mg/kg 25 mg/kg 20 mg/kg 100 mg/kg 
Cmax (ug/mL)1 17.9 17.4 210 1162 
Tmax (h)2 0.25 0.75 0.75 0.75 
AUC all 
(µg.h/mL)3 
24.63 40.81 843 7692 




721 1185 52.9 79.9 
Clearance 6 
(mL/h/kg) 
400 604 23.7 13 
1 Peak concentration in plasma. 2 Time at which peak concentration was 
observed. 3 Area under the time-concentration curve. Indicates drug exposure 4 
Half life which is the time for the concentration in plasma to be reduced by half. 5 
Indicates how widely compound is distributed in system. 6 Indicates how rapidly 
compound is extracted from the circulation and eliminated 
 
As seen from Table 5-1, the  PK parameters of 4-12 given at 10mg/kg or 25 
mg/kg did not differ markedly. The peak concentration in plasma (Tmax) was 
achieved within an hour. 4-12 had a large volume of distribution exceeding 
volume of blood (ca 70 mL/kg), suggesting that it was extensively distributed into 
tissue compartments like muscle and fat and not restricted to the circulation by 
binding to plasma proteins. Its clearance from the systemic circulation was rapid 
and 4-12 was estimated to have a moderately short half life (< 3 h).85 In view of 
these findings, it may be necessary to administer 4-12 more frequently to animals 








Figure 5.2 Mice plasma concentrations of cysmethynil at various 
time points. Cysmethynil was administered at 20mg/kg and 100 mg/kg 
IP. Each data point was obtained from 3 animals.  
 
 Figure 5-2 shows the change in plasma concentration with time for the two 
doses of cysmethynil. Plasma was collected from animals dosed with 20 mg/kg 
up to 24 h only because cysmethynil could not be detected in plasma beyond this 
time. For animals dosed with 100 mg/kg, plasma collection continued up to 48 
hours. The different plasma collection time points (24 h for 20mg/kg and 48 h for 
100 mg/kg) could have led to some differences in their PK parameters (notably 
the half life which was longer (4.3 h) for the higher dose compared to the lower 
dose (1.6 h) .   
The apparent PK parameters of 4-12 and cysmethynil were compared at 
20mg/kg and 25 mg/kg respectively. One obvious difference was noted in the 
volumes of distribution of the two compounds.  The average volume of blood in a 
mouse is 70 mL /kg and volumes of distribution that are close to or less than this 





































plasma protein binding.85 Volumes of distribution that approach (or exceed) the 
volume of body water (700 mL/kg) indicate that the compound is distributed 
throughout the blood and tissues. Thus, it is deduced that cysmethynil (53 mL/kg) 
was largely restricted to the blood stream by plasma protein binding, whereas 4-
12 (721 mL/kg)  was distributed throughout body water (blood and tissues) with 
limited binding to plasma proteins.  The clearance of the two compounds also 
differed.  4-12 was rapidly cleared in contrast to cysmethynil which had a slow 
clearance. Half lives were however comparable (< 1 h) as it is deteremined by 
volume of distribution and clearance (half life = volume of distribution/ clearance). 
A caveat on the interpretation of these results is that the plasma-time curves 
spanned different time periods, namely 8 h for 4-12 and 24 h for cysmethynil, and 
this difference could have influenced the magnitude of the PK values.  
Another limitation is that cysmethynil and 4-12 may have different plasma protein 
binding capacities. Only the unbound compound is pharmacologically active and 
thus a comparison of free fraction of the compound in plasma versus time would 
have provided a more meaningful interpretation of the results. 
Figures 5-1 and 5-2 include a horizontal line which corresponds to the in vitro 
IC50 of 4-12  (1.70µM) and cysmethynil (22.0µM). For both compounds, the lines 
were below the estimated Cmax values, which implied that plasma levels 
associated with antiproliferative activities were attained for both compounds. As 
mentioned above, plasma levels of free compound (and not total compound) 






5.3.3 In vitro metabolite identification 
Profiles of the major metabolites of 4-12 and cysmethynil were obtained by 
microsomal incubation followed by LC/MS/MS analysis. Based on the structures 
of the compounds, phase I metabolites were predicted, such as metabolites 
arising from hydroxylation, dihydroxylation or demethylation. Each of these 
metabolites would result in a characteristic molecular ion (for example +16 for 
hydroxylation, -14 for demethylation) and if these were found in the extracted ion 
chromatogram (XIC) of the compound, the MS/MS product ion spectrum 
(daughter spectrum) of each component was extracted.   In the case of 4-12, four 
metabolites were proposed based on the presence of molecular ions which were 
not found in the microsomal control sample. The metabolites arose from mono-
hydroxylation (A, MH+16), dihydroxylation (B, MH+32) and deethylation (C, MH-
28).  Another metabolite D had a mass difference of 30 from 4-12 and was 
proposed to result from hydroxylation and conversion of a terminal methyl to an 
aldehyde (CH3 CHO). Table 5-2 lists these metabolites (A-D) and their 
retention times on the mass ion spectrum. The daughter spectrum of each 
metabolite was derived and an attempt was made to assign the fragments arising 
from the metabolite. 
Table 5.2 Proposed metabolites of 4-12 based on LC/MS/MS analysis 




4-12 Parent MH+ 408.4 5.946 
A Hydroxylation MH++16 424.2 5.146 
B Dihydroxylation MH++32 440.2 4.572 






D Hydroxylation + oxidation 
of CH3 to CHO 
MH++30 438.0 4.816 
 
Figure 5-3 shows the daughter ion spectrum of the oxygenated /hydroxylated 
metabolite A. Loss of the diethylamino moiety gave a fragment 351.2 which 
retained the oxygen-containing /hydroxyl group. Further fragmentation could not 
reveal where the oxidation has occurred. It could have occurred on the octyl side 
chain 1 or arose from N-oxidation of the pyrimidine ring.  
Figure 5.3 Product ion spectrum of metabolite A. The “-O” 
symbol indicates the addition of mass 16 to the specie. Exact site of 
addition in molecule is not known.   
      
 
In the case of metabolite B, the daughter ion spectrum closely resembled that of 
metabolite A. The fragment with mass 367.2 was again observed and attributed  
to concurrent oxygenation and loss of the diethylamino side chain (367.2).  
However, the identity of metabolite B could not be established from the 






Figure 5.4 Product ion spectrum of metabolite B .  The “-O” 
symbol indicates the addition of mass 16 to the specie. Exact site of 
addition in molecule is not known.   
 
 
Figures 5-5 depicts the product ion spectra of metabolites C and D. No 
characteristic fragments could be assigned to the daughter fragments of either 
metabolite. It is proposed that metabolite C is due the deethylation of the 
diethylamino moiety. The mass of metabolite D suggested the presence of an 
oxygen-containing/ OH group (+16) and a carbonyl containing group which may 
have originated from a methyl to aldehyde (CH3 CHO) conversion. This could 
have occurred on the n-octyl side chain as a similar transformation had been 
reported for octyl-containing compounds. 86 As metabolites C and D  were 
observed at lower intensities (< 106 cps) than A and B, they may be minor 











 +Q1: 4.665 to 4.816 min from Sample 57 (D1-3-FS) of 20120505-Cm-812-metID.wiff (Turbo Spray), subtracted (4.214 to 4.665 min and ... Max. 2.3e5 cps.
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 +Q1: 5.769 to 5.869 min from Sample 58 (A1-3FS) of 20120505-Cm-812-metID.wiff (Turbo Spray), subtracted (5.618 to 5.719 min and 5... Max. 6.3e5 cps.











































The same procedure was used to propose the metabolites of cysmethynil.  The 
extracted ion chromatograms of cysmethynil showed 4 mono-oxygenated / 
hydroxylated metabolites (A-D) at different retention times (Table 5-3). 
Table 5.3 Proposed metabolites of cysmethynil  based on LC/MS/MS analysis 
Component Description Molecular Ion m/z Retention 
time(min) 
cysmethynil Parent MH+ 377.3 8.158 
A Hydroxylation MH++16 393.3 7.870 
B Hydroxylation MH++16 393.3 7.580 
C Hydroxylation MH++16 393.3 7.347 







Analysis of the daughter ion spectra showed that oxygenation /hydroxylation 
occurred on the aromatic scaffold of metabolites A-C. These metabolites showed 
similar fragments arising from the loss of the amide (CONH2) residue (348.3), 
and partial loss of the n-octyl side chain and the CONH2 residue (250.2). The 
retention of oxygen /OH in these fragments was evident from their masses. In the 
case of D,  the fragment with mass 348.3 was also observed in the daughter ion 
spectra but the mass of the  fragment corresponding to partial loss of n-octyl and 
CONH2 (234.4) was compatible with the absence of oxygen/OH in the ring 
scaffold. The implication was that the oxygen-containing/OH group was attached 
to the n-octyl side chain of metabolite D, unlike the other metabolites A-C where 
the OH was attached to the aromatic rings.  Hydroxylation of n-octyl in other 
chemical entities have been reported by others 86 Figure 5-7 depicts the 
extracted ion chromatograms of the metabolites A-D and Figure 5-8 shows the 
daughter spectra derived from the metabolites.  Figure 5-9 summarizes the 






Figure 5.7 Extracted ion chromatograms of m/z 393.30 (MH+16)+ 

















Figure 5.8 MS-MS Daughter ion spectra of metabolites A-D of 
cysmethynil.  
(a) Metabolite A 
 







 +EPI (393.30) Charge (+0) CE (35) CES (2) FT (20): Exp 3, 7.580 min from Sample 5... Max. 9.9e6 cps.

































333.5209.2 264.2 350.869.0 393.3281.2257.3181.3 358.1213.7
 +EPI (393.30) Charge (+0) CE (35) CES (2) FT (20): Exp 3, 7.870 min from Sample 5... Max. 9.5e5 cps.

























































Figure 5.9 Summary of metabolites derived from microsomal 







5.3.4 Effect of  4-12 on mice bearing human hepatocellular carcinoma 
HepG2 xenografts  
 
4-12 was dosed daily at 15 mg/kg and 30 mg/kg to xenograft-bearing mice for 25 
days. These doses were less than the apparent maximal tolerated dose of 4-12 
(100 mg/kg). Daily dosing was carried out because the pharmacokinetic 
investigation (4-12 at 10 mg/kg and 25 mg/kg, Section 5.3.2) showed that 4-12 
was rapidly cleared from blood. Cysmethynil was investigated at 75 mg/kg and 
150 mg/kg which were lower doses than that used in an earlier report (100mg/kg 
and 200 mg/kg).2  It was dosed on alternate days as it was cleared at a slower 






Of the 8 mice that received 15 mg/kg 4-12, one animal died during the treatment 
period (Day 24). Three deaths were recorded in mice receiving the higher dose of 
30 mg/kg 4-12 (Days 4, 8, 22).  In the case of mice treated with cysmethynil, 3 of 
the 8 animals died for each dose regimen (Days 6, 24 for 75 mg/kg; Days 8, 10, 
22 for 150 mg/kg). The control group saw 1 death which occurred on Day 23. The 
deaths were not anticipated, with the animals found dead in their cages 
overnight.  None of the animals were put down due to censored events.   
The body weights of the mice were monitored throughout the treatment period.  
As seen from Figure 5-10 A, mice treated with 4-12 lost weight within the 1st 
week, with significant losses observed at the higher dose (30 mg/kg) on Days 5 
and 7.  Thereafter, the animals regained weight and no significant loss was 
observed by the 25th day. Weight loss was observed up to Day 11 for cysmethynil 
treated animals at both doses but like 4-12, animals showed good weight 
recovery by the 25th day.   
Figure 5.10 Changes in body weight (grams) of xenograft-bearing 
mice treated with vehicle (Control), 4-12 (A) and cysmethynil (B) at 
indicated doses. Weight (Wt) was expressed as % of initial weight 
(Wo) at Day 0.  Error bars indicate standard deviation. Sam: change 8-
12 to 4-12 




































































Evidence of in vivo efficacy of 4-12 was derived from the change in tumor volume 
in treated animals. Figure 5-11 shows the time dependent changes in relative 
tumor volumes of animals dosed with 4-12. Significant reduction in tumor volume 
was evident from Day 5 onwards for animals receiving 30 mg/kg and Day 7 
onwards for animals receiving 15 mg/kg (p < 0.05, 1-way Anova, Dunnett post-
hoc). There were aberrations on Days 9 (30 mg/kg) and 15 (15 mg/kg) where the 
reductions in volumes were not statistically significant.  
HEPG2 Xenograft study



































Figure 5.11 Changes in relative tumour volume of xenograft-
bearing mice treated with vehicle (Control) and 4-12 at 15 mg/kg and 
30 mg/kg. Relative tumor volume = (volume at nth day / volume at Day 
0) x 100%.  Reduction in tumor volume was significant from Day 5 and 
Day 7 onwards for animals dosed with 30mg/kg and 15 mg/kg 
respectively (p < 0.05, 1-way ANOVA, Dunnett post-hoc). On Days 9 
(30mg/kg) and 15 (15 mg/kg), relative tumour volumes were not 







Figure 5-12 shows the time dependent changes in relative tumor volumes of 
animals dosed with cysmethynil.  The reductions in tumor volume were significant 
for 150 mg/kg treated animals on Days 11 and 13. Thereafter, tumor volumes 
increased steadily up to the end of the treatment period. Although smaller tumor 
volumes were recorded for animals receiving 75 mg/kg, reductions were not 
statistically significant.  
 
HEPG2 Xenograft study



































Figure 5.12 Changes in relative tumour volume of xenograft-
bearing mice treated with vehicle (Control) and cysmethynil at 75 
mg/kg and 150 mg/kg. Relative tumor volume = (volume at nth day / 
volume at Day 0) x 100%.   Reduction in tumor volume was significant 
on Day 11 and Day 13 for animals treated with 150 mg/kg. (p < 0.05, 







After 25 days, the tumors were excised and weighed. As seen in Figure 5-13, 
reductions in tumor volumes were observed for all treatments but only those 
derived from 4-12 treated animals showed significant weight loss compared to 
control (p = 0.024 for 15 mg/kg, p = 0.01 for 30 mg/kg).   
 
Figure 5.13 Weights of tumors excised from control and treated 
animals after 25 days treatment. * indicates significant reduction in 
weight of tumor compared to control. (p < 0.05, 1-way ANOVA, 
Dunnett post-hoc).  
 
5.4 Discussion 
In earlier reports, cysmethynil was investigated at 100mg/kg and 200mg/kg in 
mice bearing xenografts induced by prostate cancer PC3 and hepatocellular 
carcinoma HepG2 cells.30, 55 It was well tolerated (dosing by IP administration, 
alternate days for 28 days) and a reduction in tumor volume was observed at the 
end of the study period. The same protocol was followed in this chapter except 
that cysmethynil was administered at lower doses of 75 mg/kg and 150 mg/kg.  
Reductions in tumor volumes and (final) tumor weights were noted in treated 
animals, with greater reductions observed in animals receiving the higher dose. 


























However, tumor volume reductions were statistically significant only for animals 
on the higher dose (150mg/kg) and for a short period midway (Days 13,15) in the 
treatment period. As deaths were observed in the cysmethynil treated animals (3 
deaths out of 8 mice, at both dose regimens), the smaller animal cohort may 
have affected the statistical analysis.    Taken together, cysmethynil is generally 
well tolerated in healthy mice. Its maximal tolerated dose exceeded 100 kg/kg 
and in xenograft bearing animals, those that survived with reduction in tumor 
volumes were healthy and maintained their weights after an initial period of 
weight loss.  
Compared to cysmethynil,  4-12 demonstrated greater efficacy on the xenograft 
model. It reduced tumor volumes at all test doses (15 mg/kg, 30 mg/kg), the 
reductions were sustained and statistically significant from Days 5 and 7 to the 
end of the study period, and there were indications of dose dependency in tumor 
size reductions.  The apparent maximal tolerated dose of 4-12 was 100 mg/kg 
but its in vivo effects were demonstrated at lower concentrations (15mg/kg, 30 
mg/kg). At these doses, animals remained healthy and maintained their weights 
after an initial period of weight loss.  
In Section 4.3.1, mention was made of the non-selective action of 4-12 on 
malignant cells, as seen from its similar IC50 values on non-malignant IMR90 
cells and various other malignant cell types. The observation that 4-12 could 
control tumor growth in the xenograft model without overt mortality in test animals 
suggests that assessment of selectivity based on in vitro antiproliferative 
activities may not always provide a complete picture if derived from only one cell 






The potency and efficacy of 4-12 as a potential anti-cancer agent has been 
demonstrated in this report. 4-12 inhibited Icmt and curtailed proliferation of 
malignant cells at low micromolar /submicromolar concentrations. In vivo, its 
efficacy on the xenograft model was evident at 15 mg/kg.  Aside from these 
desirable attributes, lead compounds must demonstrate drug-like properties if 
they are to progress further in development. A back-of-the-envelopment 
assessment of 4-12 based on the widely cited Rule of five (Ro5) criteria for drug-
likeness87  shows that it passes muster. 4-12 has a molecular weight of 407.3, 2 
hydrogen (H)-bond donor and 5 H-bond acceptor groups.  Its ClogP (6.6) is out of 
the Ro5 range, but as it has protonable groups, its lipophilicity would vary with pH 
and in this context, log D 7.4 may be a better predictor. Ideally, logD7.4 should fall 
within 1 and 3 to achieve a good balance of solubility and permeability for oral 
absorption.88   The estimated log D7.4 of 4-12 (3.54) marginally exceeded the 
optimal range. The polar surface area of 4-12 was estimated to be 60 Å2  which is 
near  optimal for compounds targeted for oral administration.89  4-12 has a high 
count of rotatable bonds (15) which exceeds  exceeding the threshold set by 
Verber et al89  (≤ 10) for good bioavailability in compounds.  A recent report 
indicated that correlation between oral exposure and number of rotatable bonds 
was less stringent and compounds with 15-20 rotatable bonds may still give 
acceptable exposure.90 
In order to go beyond these theoretical assessments of drug-like character, 
others in the candidate’s laboratory have undertaken detailed physicochemical 
characterization of 4-12.  Properties investigated were solubility, permeability and 
aggregate forming tendency.60  The results are summarized in Table 5-4 with 








Table 5.4 Summary of physicochemical and in vitro metabolic data of 4-12 
and cysmethynil 
 4-12 Cysmethynil 
ClogP a 6.6 7.0 
Log D 7.4a 3.5 6.9 
Solubility  (µM) b 155.9 (±6.4) 1.14 (±0.1) 
PAMPA Pe  (x 10-6 cm/s)2 14.2 (±1.4) Nilc 
Dynamic light scattering count rate (kcps)d at 
concentrations of  
-10 µM 










Estimated Half-life (min) from in vitro rat 
microsomes 
11.3 (±0.4) 44.8 (±8.0) 
Estimated Intrinsic Clearance  (µL/min/mg) 
from in vitro rat microsomes 
204.0 (±9.0) 53.6 (±9.0) 
 
a Estimated with ChemDraw Ultra 12.0  (ClogP) and  ACD/Labs 12.0  (log D 7.4). 
b Determinations were made at pH 7.4, 24 h (solubility) or 16 h (PAMPA Pe) 
agitation. Mean (SD) of 3 separate determinations. c Could not be determined 
under existing experimental conditions. d Mean count rates (kilocount per sec) 
from 3 separate determinations at 10 µM or 1 µM test compound (1% DMSO, 
potassium phosphate buffer 5 mM pH 7.4).   
 
Solubility was determined on Multiscreen  solubility filter plates from Millipore in 
phosphate buffer pH 7.4 (1% v/v DMSO) at 25oC with agitation for 24 h.60 






assay (PAMPA) at pH7.4 with lecithin-dodecane as the simulated cellular 
barrier.60 At pH 7.4, 4-12 was at least 100 x more soluble than cysmethynil. Its 
solubility (156 µM or 64 µg/ mL) was close to the minimum accepted drug 
solubility (50 µg /mL) for a compound with “average” potency and permeability91  
It is premature to comment on the clinical potency of 4-12 but its permeability as 
assessed by effective permeability (Pe) was 14.2 x 10-6 cm/s which  exceeded 
that of verapamil (10.2 x 10-6 cm/s, determined under similar conditions) which is 
normally used as a high permeability standard.92  The higher Pe of 4-12 suggests 
above average permeabilityThe permeability of cysmethynil could not be 
determined by the present method because its low solubility limited its analysis in 
the donor and receiving compartments of the PAMPA plates.60  
Table 5.4  includes determinations of dynamic light scattering by 4-12 and 
cysmethynil at two concentrations.60  These determinations were undertaken to 
assess the aggregate-forming tendencies of the compounds and they were  
prompted in part by the amphipathic nature of both compounds (lipophilic n-octyl 
side chain combined with polar amide/ tertiary amine). These features may 
promote formation of micelles and of greater concern, soluble colloidal 
aggregates which are widely associated with promiscuous behavior, such as 
non-specific inhibition of enzymes93-96 Compounds that form soluble or colloidal 
aggregates normally exist as particles of 30-1000 nm in diameter which are 
detectable by light scattering.97   Aggregators exhibit significant increases in 
aggregate formation with relatively small increases (2-3 fold) in concentration.98   
As seen from Table 5-4, cysmethynil caused a 7 fold increase in light scattering 






2-fold increase for the same change. 4-12 may thus have a lower tendency to 
form aggregates compared to cysmethynil.  
A preliminary assessment of the pharmacokinetics of 4-12 and cysmethynil was 
carried out in mice to assist in the dosing schedule for the in vivo xenograft 
experiments. Both compounds have broadly similar half-lives but very different 
volumes of distribution and clearance values. The more lipophilic and poorly 
permeable cysmethynil had a smaller volume of distribution suggestive of marked 
plasma protein binding. The more permeable and water soluble 4-12 was widely 
dispersed in body water and tissues and thus have a larger volume of 
distribution. Further support for the different pharmacokinetic profiles of 4-12 and 
cysmethynil came from investigations on the metabolic stabilities of these 
compounds when incubated with rat microsomes (Appendix5: figure 5-3,5-4 and 
table 5-9,5-10).99 Both compounds were deemed to be metabolically more stable 
than midazolam which was determined under similar conditions. Half lives and 
intrinsic clearance values estimated from the incubation period (45 min) 
supported the view that 4-12 was more rapidly cleared than cysmethynil.  The 
metabolites arising from rat microsomal metabolism were analyzed and some 
marked differences were evident. Cysmethynil was largely mono-hydroxylated on 
the aromatic scaffold and the n-octyl chain, whereas hydroxylation of 4-12 was 
confined to the n-octyl side chain. There was evidence of N-dealkylation of the 
tertiary amino side chain.   
5.5 Summary 
The findings in this chapter have provided evidence that 4-12 was effective in 






pharmacokinetic characteristics of 4-12.  It was found to have a large volume of 
distribution in treated mice, to be rapidly cleared  from the systemic circulation 
and to possess  a relatively short half life of < 1 hour.  Metabolites of 4-12 
predicted from rat microsomal incubation experiments point to the presence of 
hydroxylated metabolites, an N-dealkylated metabolite and a less well defined 







CHAPTER 6 Conclusion and Future Work 
The investigations reported in this thesis were undertaken with the objective 
of identifying potent and drug-like anticancer agents with Icmt inhibitory activity.  
Previous investigations59 have identified three indoleamine lead compounds (1-3) 
that were structurally related to cysmethynil and with more potent antiproliferative 
activity than cysmethynil. These compounds served as starting points for 
structural modification in the present study.  Using conventional medicinal 
chemistry approaches, 7 compound series were designed and synthesized. The 
modifications included fluorination of the indole ring, substituting the m-tolyl or 
tertiary amino side chain with other rings/ functionalities, replacing the indole core 
with other scaffolds and replacing the n-octyl side chain with prenyl side chains. 
Only Series 4 which involved modifying the m-tolyl ring, gave promising results.  
The SAR derived from the antiproliferative activities of the other compound series 
were generally “flat”, with most compounds retaining the same level of activity as 
the leads 1-3. A summary of the SAR findings are presented in Figure 6-1, which 









Figure 6.1 Summary of SAR for antiproliferative activity derived 
from Series 1-7. 
 
The most promising compound to emerge from Series 4 was 4-12, which 
differed from lead 3 in having a 2-aminopyrimidin-4-yl ring in place of m-tolyl at 
position 3 of the indole scaffold. 4-12 was a potent Icmt inhibitor (IC50 0.78 µM) 
with good antiproliferative activity (IC50 1.6-2.6 µM) across a panel of diverse 
malignant cells (prostate PC3, breast MDA MB 231, pancreas MIA Paca II, liver 
HepG2). In view of its potency, various aspects of its antiproliferative activity 
were investigated in detail and compared with cysmethynil.  In summary, 4-12 
was found to arrest the cell cycle of prostate PC3 cancer cells at the G1 phase.  
When incubated with PC3 cells over 2 weeks, it prevented colony formation in 
the clonogenic assay indicating that the treated cells have lost their reproductive 
capacity. 4-12 did not show detectable apoptosis but there was evidence that it 
induced autophagic cell death.  It may inhibit cell migration as seen from the 
failure of cells to breach the scratch induced in wells containing monolayers of 
PC3 cells.  In spite of the diversity of these phenomena, the effects of 4-12 were 






Cysmethynil also affected these processes in a qualitatively similar manner but at 
concentrations that were at least 10 x higher. The similarity in their mechanistic 
profiles is quite remarkable and suggest that it may arise from their shared ability 
to inhibit Icmt.  G1 cell cycle arrest and autophagy are modulated by m-TOR 
signaling. Two CaaX proteins (Ras, Rheb) are known to regulate mTOR 
signaling. Impaired Ras activity due to Icmt inhibition would have a positive 
impact on autophagy (induction) and a negative impact on the cell cycle (G1 
arrest).2 Cysmethynil has been widely investigated for its effects on signaling 
pathways that are involved in this proposed scheme.55 4-12 should also be 
investigated as the findings would further support Icmt as a druggable anticancer 
target.  
4-12 showed convincing in vivo efficacy on a mouse xenograft model at 
moderate doses of 15 mg/kg and 30 mg/kg, administered daily for 25 days by 
intraperitoneal injection. It was well tolerated in the animals in spite of the 
intensive dosing and showed significant reductions in tumor volumes and final 
tumor weights.  The frequent dosing of 4-12 was prompted in part by its 
pharmacokinetic profile. 4-12 was rapidly cleared from the systemic circulation, 
besides being extensively distributed in tissues and body water.  On the other 
hand, cysmethynil experienced slower rates of clearance and its distribution was 
largely limited to blood, suggesting strong plasma protein binding. The different 
pharmacokinetic profiles are traced to structural and physicochemical differences 
in the two compounds. 4-12 has an ionizable tertiary amine and a polar 
aminopyrimidine ring, unlike cysmethynil which has a non-ionizable amide moiety 
and several lipophilic entities in its structure. It might be useful to determine if 4-






the limited number of active leads available for this aggressive malignancy. 
Moreover 4-12 was earlier shown to curtail proliferation of MIA PACA cells at a 
reasonably low IC50 of 1.60 µM.  The effects of 4-12  on metastasis and 
angiogenesis should be further explored. 4-12 was reported by others to have a 
good solubility-permeability balance in contrast to cysmethynil which had poor 
solubility and permeability. The lipophilic character and poor permeability 
associated with cysmethynil  would account for the strong protein binding and 
limited distribution. With the more polar yet permeable 4-12, the situation could 
be reversed.  Experimental confirmation by  protein binding experiments would 
be in order. 
Notwithstanding the promising results obtained with 4-12, there are several areas 
that merit further investigation, some of which have been surfaced in earlier 
chapters. Foremost is the need to illustrate that Icmt inhibition by 4-12 leads to 
mislocalization of Ras and impaired epidermal growth factor signaling. Without 
this evidence, the role of Icmt inhibition in the antiproliferative activity of 4-12 
wouldl remain speculative. Other mechanistic aspects of 4-12 like its effects on 
mTOR signaling, G1 arrest should be confirmed and elaborated in additional 
investigations. Another aspect that was not addressed in this thesis is the toxicity 
of the 4-12 in particular, and the indoleamine scaffold in general. 4-12 is a 
cationic amphiphilic entity because it is protonated at pH7.4 and has a lipophilic 
octyl side chain.  Such entitites are associated with phospholipidosis which 
involves excessive accumulation of phospholipids in cells leading to dysfunctional 
phospholipid metabolism and mitochondrial function.100  Drug-induced 
phospholipidosis is related to the dose and duration of treatment and is normally 






consequences of this phenomena are unknown, it merits attention.  The potential 
of cationic amphiphiles like 4-12 and other Series 4 compounds in inducing 
phospholipidosis should be clarified.  The structure of 4-12 may also predisposed 
it to interactions with the hERG (human ether a-go-go related gene) protein 
leading to cardiotoxicity. hERG inhibitors generally possess a basic entity which 
is protonated at pH7.4 and aromatic residues capable of π- π interactions, 101 
features which are present in 4-12.  Screening for hERG inhibition would be 
necessary if the compound is to be considered for further development. 
Notwithstanding its potency, efficacy and druglike physicochemical profile, 4-12 
has potential toxic liabilities and this underscores the need to pursue other 
scaffolds associated with Icmt inhibition.  
In conclusion, the results presented in this thesis have contributed to a 
better understanding of functionalized indoleamines as Icmt inhibitors and the 
mechanistic basis of their antiproliferative activity. It has also highlighted the drug 
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Appendix 1.1 Series 1: 
 
Diethyl-(4-fluoro-1-octyl-1H-indol-3-ylmethyl)–amine (1-1)  Yellow oil. Yield: 
200mg  60.1 %. 1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H),1.10 (t, J 
=15 Hz, 6 H), 1.33-1.42 (m, 10 H), 1.85 (t, 2 H, J = 15 Hz), 2.7 (q,4H),3.95(s,2H) , 
4.1(t, 2 H), 6.8 (m,  1 H), 7.1 (m,2H), 7.20 (S,1H); 13C NMR (100 MHz, CDCl3): δ 
11.38, 14.06, 22.62, 26.95, 29.73, 29.17, 30.12, 31.75, 46.36,  46.70, 48.43, 
104.22, 104.41, 105.63, 105.66,109.42, 116.83,117.03, 121.61,121.62, 
128.11,138.88, 139.00,156.06, 158.51.  LC-MS (ESI): m/z 333.42. [M+H] +. 
 
4-Fluoro-1-octyl-3-piperidin-1-ylmethyl-1H-indole (1-2)  Yellow oil. Yield: 
210mg 60.8 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.33-1.42 
(m, 12 H),1.49(t,2H), 1.7(q 4H),  1.85 (t, 2 H,), 2.6 (br,4H),3.95(s,2H), 4.1(t, 2 H), 
6.8 (m,  1 H), 7.1 (m,2H), 7.20 (S,1H); 13C NMR (100 MHz, CDCl3): δ 14.06, 
22.62, 23.88, 25.24, 26.95, 29.16, 30.09, 31.75, 44.82, 46.77, 53.43, 
53.77,104.43,104.62, 105.77, 105.80,107.08, 117.12,117.30, 121.71,121.79, 







4-Fluoro- 3-morpholin-4-ylmethyl-1-octyl-1H-indole (1-3) Yellow oil Yield 
180mg 51.8%. 1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.33-1.42 
(m, 10 H), 1.85 (t, 2 H,), 2.6 (dd,4H),3.3(dd,4H), 3.95(s,2H), 4.1(t, 2 H), 6.8 (m, 1 
H), 7.1 (s,1H), 7.20 (m,2H); 13C NMR (100 MHz, CDCl3): δ 14.08, 22.62 ,26.95, 
29.16, 30.12, 31.75, 46.67, 53.12,  53.43, 54.06, 67.06,104.32,104.51, 105.60, 
105.63, 108.82,108.85, 116.99,117.19, 121.76,121.83, 127.81,138.97, 
139.08,156.10, 158.55.  LC-MS (ESI): m/z 347.62. [M+H]. +  
 
4-Fluoro -1-octyl-3-thiomorpholin-4-ylmethyl-1H-indole (1-4) Yellow oil Yield: 
195mg,  53.7 %. 1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.33-1.42 
(m, 10 H), 1.85 (t, 2 H,), 2.5-3.0 (m,10H), 3.95(s,2H), 4.1(t, 2 H), 6.8 (m,  1 H), 
7.1 (s,1H), 7.20 (m,2H); 13C NMR (100 MHz, CDCl3): δ 14.08, 22.62 
,26.98,28.00, 28.10, 29.16, 30.12, 31.75, 46.67,53.45, 54.41, 54.51, 
82.27,104.30,104.51, 105.48, 105.61, 108.99,109.03, 117.02,117.22, 
121.73,121.81,  127.71, 138.97, 139.08, 156.09, 158.55.  LC-MS (ESI): m/z 




4-Fluoro-3-(4-methyl-piperazin-1-ylmethyl-1-octyl-1H-indole (1-5) Yellow oil. 
Yield: 160mg ,44.4 %..1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 
1.33-1.42 (m, 10 H), 1.85 (t, 2 H,), 2.28 (s, 3H), 2.5-2.85 (m,8H), 3.95(s,2H), 






14.06, 22.62 ,26.98, 29.16, 30.12, 31.75, 45.91, 46.67, 52.34, 53.44, 54.71, 
54.80, 54.97, 104.30,104.48, 105.55, 105.58,108.73, 117.02,117.21, 
121.68,121.76, 127.98,138.91, 139.03, 156.09, 158.55.  LC-MS (ESI): m/z 360.5. 
[M+H]. +  
 
4-Fluro-1-octyl-3-pyrrolidin-1-ylmethyl-1H-indole (1-6) Yellow oil. Yield: 34.7 
%.115mg.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.33-1.42 (m, 10 
H), 1.85 (t, 2 H,), 2.10 (br, 4H), 3.35-3.45(br,4H), 4.1(t, 2 H), 4.5(s,2H), 4.7 
(br,1H), 6.8 (m,  1 H), 7.1 (m,2H), 7.8 (s,1H); 13C NMR (100 MHz, CDCl3): δ 
14.06, 22.57,23.04 , 26.87, 29.10, 30.03, 31.71, 47.15, 49.31, 51.89, 
100.86,105.27, 105.46, 106.57,106.60, 116.29,116.48, 122.48,122.56, 




Cyclohexyl-(4-fluoro-1-octyl-1H-indol-3-ylmethyl)–amine (1-7) Yellow oil. 
Yield: 145mg 40.4 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.33-
1.42 (m, 10 H), 1.5 m 4 H,), 1.8 (br, 6H) 2.2(br,2H),2.8 m, 1H) 4.05(t, 2 H), 
4.4(s,2H), 6.8 (m,  1 H), 7.1 (m,2H), 7.6 (s,1H); 13C NMR (100 MHz, CDCl3): δ 
14.06, 22.60,24.64, 25.17, 25.45, 26.00 ,26.93, 29.16, 30.10, 30.18, 31.74, 






122.15,122.23, 130.30,138.71, 138.83,155.59, 158.02  LC-MS (ESI): m/z 359.5. 
[M+H] .+  
 
Cyclopentyl-(4-fluoro-1-octyl-1H-indol-3-ylmethyl)–amine (1-8) Yellow oil. 
Yield: 185mg ,53.6 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.33-
1.42 (m, 10 H), 1.45 to 2.0 (m 8H), 3.35-3.45(br,4H), 4.1(t, 2 H), 4.2(s,2H), 6.8 
(m,  1 H), 7.1 (m,2H), 7.2 (s,1H); 13C NMR (100 MHz, CDCl3): δ 14.06, 
22.57,23.04 ,26.87, 29.10, 30.03, 31.71, 47.15, 49.38, 51.96, 101.00, 105.27, 
106.47,106.60, 116.47,116.58, 122.47,122.56, 132.37,138.58, 138.69,155.20, 
157.62  LC-MS (ESI): m/z 345.23. [M+H]. +  
 
 
1-(5-Fluoro-1-octyl-1H-indol-3-yl)-N, N-dimethylmethanamine (1-9).  Yellow 
oil. Yield: 71.1 %.1H NMR (300 MHz, CDCl3): δ 0.86 (br, 3 H), 1.25-1.28 (m, 10 
H), 1.81 (br, 2 H), 2.28 (s, 6 H), 3.58 (s, 2 H), 4.05 (t, J = 6.9 Hz, 2 H), 6.90-6.96 
(m, 1 H), 7.10 (s, 1H), 7.16-7.22 (m, 1 H), 7.30 (d, J = 9.3 Hz, 1H). 13C NMR (75 
MHz, CDCl3) δ 14.0, 22.5, 29.1 (2C), 30.1, 31.5, 31.7, 45.0 (2C), 46.5, 54.2, 
103.9, 109.8, 111.0, 128.5, 129.0, 132.8, 141.9, 161.0. IT TOF-HRMS calculated 
for (C19H30FN2 + H+) 305.2393, found 305.2282. Elemental analysis: calc./found 







N-Ethyl-N-((5-fluoro-1-octyl-1H-indol-3-yl)methyl)ethanamine (1-10). Yellow 
oil. Yield: 46.1 %.1H NMR (300 MHz, CDCl3): δ 0.86 (t, J = 6.6 Hz, 3 H), 1.10 (t, J 
= 6.9 Hz, 6 H), 1.28 (br, 10 H), 1.80 (br, 2 H), 2.57 (q, J = 6.9 Hz, 4 H), 3.74 (s, 2 
H), 4.04 (t, J = 6.9 Hz, 2 H), 6.93 (t, J = 9.0 Hz, 1 H), 7.11 (s, 1H), 7.17-7.22 (m, 
1H), 7.34 (d, J = 9.6 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 11.7(2C), 14.0, 22.5, 
26.9, 29.1 (2C), 30.1, 31.7, 46.4 (2C), 47.8, 104.4, 109.4, 109.9, 111.2, 128.9, 
132.8, 155.9, 159.0. IT TOF-HRMS calculated for (C21H34FN2 + H+) 333.2706, 




  5-Fluoro-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole (1-11). Yellow oil. Yield: 
75.8 %.  1H NMR (300 MHz, CDCl3): δ 0.86 (t, J = 6.9 Hz, 3 H), 1.24-1.28 (m, 10 
H), 1.42 (d, J = 4.5 Hz, 2 H), 1.59 (t, J = 5.4 Hz, 4 H), 1.80 (br, 2 H), 2.45 (br, 4 
H), 3.65 (s, 2 H), 4.04 (t, J = 7.2 Hz, 2 H), 6.93 (t, J = 8.1 Hz, 1 H), 7.11 (s, 1H), 
7.17-7.22 (m, 1H), 7.35 (d, J = 1.5 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 
11.7(2C), 14.0, 22.5, 24.2, 25.8 (2C), 26.9, 29.1 (2C), 30.1, 31.7, 46.5, 53.8, 54.1 
(2C), 104.4, 109.7, 109.9, 110.5, 129.0, 132.7, 155.9, 159.1. IT TOF-HRMS 
calculated for (C22H34FN2 + H+) 345.2706, found 345.2620. Elemental analysis: 







4-((5-Fluoro-1-octyl-1H-indol-3-yl)methyl)morpholine (1-12). Yellow oil. Yield: 
88.5 %.  1H NMR (300 MHz, CDCl3): δ 0.87 (t, J = 6.9 Hz, 3 H), 1.24-1.28 (m, 10 
H), 1.80 (t, J = 6.3 Hz, 2 H), 2.48 (br, 4 H), 3.64 (s, 2 H), 3.69-3.72 (m, 4 H), 4.04 
(t, J = 7.2 Hz, 2 H), 6.94 (t, J = 8.7 Hz, 1 H), 7.07 (s, 1 H), 7.18-7.22 (m, 1H), 7.37 
(d, J = 9.9 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 14.0, 22.5, 26.9, 29.1 (2C), 
30.1, 31.7, 46.5, 53.4, 53.9 (2C), 67.0, 104.5, 109.8, 110.2, 128.5, 128.9, 132.9, 
156.0, 159.1. ESI-LCMS calculated for (C21H32FN2O + H+) 347.25, found 347.10. 
Elemental analysis: calc./found (C, H): 72.80, 9.02 ⁄ 73.05, 8.73.  
 
4-((5-Fluoro-1-octyl-1H-indol-3-yl)methyl)thiomorpholine (1-13). Yellow oil. 
Yield: 91.4 %.   1H NMR (300 MHz, CDCl3): δ 0.87 (t, J = 6.6 Hz, 3 H), 1.25-1.29 
(m, 10 H), 1.80 (br, 2 H), 2.69 (br, 4 H), 2.73 (br, 4 H), 3.66 (s, 2 H), 4.04 (t, J = 
6.9 Hz, 2 H), 6.94 (t, J = 8.1 Hz, 1 H), 7.05 (s, 1 H), 7.18-7.26 (m, 1H), 7.35 (d, J 
= 8.1 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 14.0, 22.5, 26.9, 28.0 (2C), 29.1 
(2C), 30.1, 31.7, 46.5, 54.3, 54.7 (2C), 104.5, 109.8, 110.4, 128.5, 128.9, 132.7, 
155.9, 159.0. ESI-LCMS calculated for (C21H32FN2S + Na+) 385.20, found 







5-Fluoro-3-((4-methylpiperazin-1-yl)methyl)-1-octyl-1H-indole (1-14). Yellow 
oil. Yield: 56.4 %.1H NMR (300 MHz, CDCl3): δ 0.86 (t, J = 6.6 Hz, 3 H), 1.24-
1.28 (m, 10 H), 1.79 (br, 2 H), 2.27 (br, 4 H), 2.45 (br, 7 H), 3.64 (s, 2 H), 4.03 (t, 
J = 6.9 Hz, 2 H), 6.92 (t, J = 8.1 Hz, 1 H), 7.06 (s, 1 H), 7.16-7.20 (m, 1H), 7.36 
(d, J = 8.4 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 14.0, 22.5, 26.9, 29.1 (2C), 
30.1, 31.6, 45.9, 46.4, 52.8 (2C), 53.3, 55.0 (2C), 104.5, 109.8, 110.7, 128.6, 
128.8, 132.8, 155.9, 159.0. ESI-LCMS calculated for (C22H35FN3 + H+) 360.28, 
found 360.20. Elemental analysis: calc./found (C, H): 73.50, 9.53 ⁄ 73.66, H 9.42. 
 
5-Fluoro-1-octyl-3-(pyrrolidin-1-ylmethyl)-1H-indole (1-15). Yellow oil. Yield: 
67.0 %.1H NMR (300 MHz, CDCl3): δ 0.86 (t, J = 6.6 Hz, 3 H), 1.24-1.28 (m, 10 
H), 1.80 (br, 6 H), 2.62 (br, 4 H), 3.81 (s, 2 H), 4.04 (t, J = 6.9 Hz, 2 H), 6.93 (t, J 
= 8.7 Hz, 1 H), 7.17-7.22 (m, 2H), 7.30 (d, J = 9.6 Hz, 1 H). 13C NMR (75 MHz, 
CDCl3) δ 14.0, 22.5, 23.4 (2C), 26.9, 29.1 (2C), 30.1, 31.7, 46.5, 50.1, 53.8 (2C), 
104.1, 109.8, 111.1, 128.3, 128.9, 132.7, 156.0, 159.1. ESI-LCMS calculated for 
(C21H32FN2 + H+) 331.25, found 331.15. Elemental analysis: calc./found (C, H): 
76.32, 9.45 ⁄ 76.28, 9.23. 
 
 (6-Fluoro-1-octyl-1H-indol-3-ylmethyl)–dimethyl-amine (1-16) Yellow oil. 
Yield: 205mg ,67.2 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.33-
1.42 (m, 10 H), 1.85 (t, 2 H, J = 15 Hz), 2.6-2.9 (m,6H),3.75(s,2H), 4.1(t, 2 H), 6.8 
(t,  1 H), 6.9-7.1 (m,2H), 7.60 (t,1H); 13C NMR (100 MHz, CDCl3): δ 14.06, 






95.87, 107.57, 107.81,110.62, 120.46, 120.56,124.94, 127.72,136.34, 
136.46,158.67, 161.03. LC-MS (ESI): m/z 305.4. M+H]. + 
 
Diethyl-(6-fluoro-1-octyl-1H-indol-3-ylmethyl)–amine (1-17) Yellow oil. Yield: 
190mg 57.2 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.10-1.42 
(m, 16 H), 1.85 (t, 2 H), 2.7 (q,4H),3.9 (s,2H), 4.1(t, 2 H), 6.8 (t,  1 H), 6.95 
(dd,1H),7.18 (s ,1H), 7.60 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 10.62,14.05, 
22.60, 23.79, 26.93, 29.15, 30.05, 31.75, 45.86,  46.67, 47.04,  95.86, 96.12, 
107.99, 108.06, 108.23, 119.69, 119.79,125.00 ,129.16,136.14, 136.26,158.64, 
161.03.  LC-MS (ESI): m/z 333.42. [M+H]. +  
 
 
6-Fluro-1-octyl-3-piperidin-1-ylmethyl-1H-indole (1-18) Yellow oil. Yield: 
165mg. 47.8 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.10-1.42 
(m, 10 H), 1.85 (t, 4 H), 2.6-3.0 (br,8H), 4.1(m, 4 H), 6.8 (t,  1 H), 6.95 
(dd,1H),7.23 (s ,1H), 7.50 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 14.05, 22.60, 
23.92, 25.31, 26.93, 29.15, 30.05, 31.75, 46.77,  53.47, 53.81,  104.42, 104.61, 
105.75, 105.78,107.26, 117.12, 117.31,121.78, 129.01,138.76, 138.88,155.95, 







6-Fluro- 3-morpholin-4-ylmethyl-1-octyl-1H-indole (1-19) Yellow oil. Yield: 
215mg. 61.9 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.10-1.42 
(m, 10 H), 1.85 (t, 2 H), 2.5 (m,4H), 3.65-3.8(m, 6 H), 4.05 (t, 2H), 6.8 (t,  1 H), 
6.95 (m,2H), 7.55 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 14.05, 22.61, 23.79, 
26.97, 29.15, 30.05, 31.75, 46.45, 52.04, 53.91, 54.02, 81.70,  95.58, 95.84, 
107.52, 107.76, 110.85, 120.46, 120.56,124.91 ,127.58,127.61,136.34, 




6-Fluro- 3-(4-methyl-piperazin-1-ylmethyl-1-octyl-1H-indole (1-20) Yellow oil. 
Yield: 170mg.47.2 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.10-
1.42 (m, 10 H), 1.7 (br, 4H ), 1.85 (t, 2 H), 2.3 (s,3H), 2.4-2.6 (br,4H), 3.65 (s, 2 
H), 4.05 (t, 2H), 6.8 (t,  1 H), 6.95 (dd,1H), 7.01 (S,1H),  7.55 (m, 1H); 13C NMR 
(100 MHz, CDCl3): δ 14.05, 22.61, 26.98, 29.17, 30.05, 31.76, 46.00, 46.45, 
53.01, 53.47, 55.20, 95.77, 95.51, 107.44, 107.69,111.19, 120.46, 120.56,125.00 







Cyclopentyl-(6-fluoro-1-octyl-1H-indol-3-ylmethyl)–amine (1-22) Yellow oil. 
Yield: 208mg.60.3 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.10-
1.42 (m, 14 H), 1.7 (br, 2H ), 1.85 (m, 2 H), 2.2 (m,2H), 2.8 (m,1H), 4.01 (t, 2 H), 
4.15 (s, 2H), 6.8 (m,  2 H), 7.5 (S,1H),  7.65 (m, 1H); 13C NMR (100 MHz, CDCl3): 
δ 14.05,22.60, 24.53, 24.94, 26.94, 29.17, 29.63, 29.99, 31.76, 38.25, 46.77,  
54.74, 95.06, 96.32, 104.60, 108.65,108.90,119.51, 119.61, 120.56, 124.16, 




Diethyl-(7-fluoro-1-octyl-1H-indol-3-ylmethyl)–amine (1-23) Yellow oil. Yield: 
165mg. 49.5 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.10 (t,6H), 
1.20-1.42 (m, 10 H), 1.85 (t, 2 H), 2.65 (q,4H),3.8 (s,2H), 4.3(t, 2 H), 6.8 (m,  1 
H), 6.95 (m,1H),7.10 (s ,1H) ,7.50 (d, 1H); 13C NMR (100 MHz, CDCl3): δ 
11.74,14.10, 22.68, 26.77, 29.15, 29.23, 31.64,  31.82,46.63, 47.89,  48.91, 
48.95,  106.95, 107.13, 111.99, 115.25,115.28, 119.04, 119.11,124.08, 







7-Fluro-1-octyl-3-piperidin-1-ylmethyl-1H-indole (1-24) Yellow oil. Yield: 
200mg.  58 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.10-1.42 
(m, 10 H),1.5 (m, 2H), 1.65 (t, 4 H), 1.9 (m,2H), 2.5 (br,4H), 3.7(s, 2 H), 4.3 (t, 2 
H), 6.8 (t,  1 H), 6.95 (dd,1H), 6.90 (m-1H), 7.05 (s ,1H) ,7.50 (d, 1H); 13C NMR 
(100 MHz, CDCl3): δ 14.11, 22.67, 24.35, 25.91,  26.60, 26.77, 29.72, 31.63, 
31.81, 48.96,  53.81, 54.25,  106.90,107.08, 111.34, 115.30, 115.33, 
119.04,119.11,123.98, 124.07, 129.45, 132.95, 133.00,148.95, 151.37.  LC-MS 




7-Fluro- 3-(4-methyl-piperazin-1-ylmethyl-1-octyl-1H-indole (1-25) Yellow oil. 
Yield: 165mg. 45.8 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.10-
1.42 (m, 10 H), 1.5 (br, 2H ), 1.6-1.9 (br,7H), 2.0 (s,3H),3.3 (m,1H), 4.01 (s, 2 H), 
4.20 (t, 2H),5.8 (br,2H),  6.8 (t,  1 H), 6.95 (dd,1H), 7.20 (S,1H),  7.45 (m, 1H); 
13C NMR (100 MHz, CDCl3): δ 14.06, 22.61,24.20, 26.70, 29.17, 30.75, 31.76, 
40.97, 49.16, 57.53,  107.54, 108.06,114.42, 119.76, 119.82,123.93 , 








Cyclopentyl-(7-fluoro-1-octyl-1H-indol-3-ylmethyl)–amine (1-26) Yellow oil. 
Yield: 185mg.53.6 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =15 Hz, 3 H), 1.33-
1.42 (m, 12 H), 1.45 to 2.0 (m 8H,), 3.35 (m,1H), 4.1(s, 2 H), 4.2(t,2H), 6.8 (m,  1 
H), 7.0 (m,1H), 7.2 (s,1H), 7.49(d,1H); 13C NMR (100 MHz, CDCl3): δ 14.06, 
22.62, 24.11, 24.42,  26.58, 26.72, 29.17, 31.59, 31.81, 49.08,  56.92, 58.11,  
64.36, 107.27. 107.45, 110.00, 114.46, 114.49, 119.55, 119.61, 119.11, 123.98, 
124.07, 129.73,131.79, 131.85,148.95, 151.37.   LC-MS (ESI): m/z 345.23. 
[M+H] .+  
 
 
Series 2:  
 
(E)-1-(1-(3,7-Dimethylocta-2,6-dienyl)-5-fluoro-1H-indol-3-yl)-N,N-
dimethylmethanamine (2-1). Yellow oil. Yield: 37.2 %.1H NMR (300 MHz, 
CDCl3): δ 1.59 (s, 3 H), 1.67 (s, 3 H), 1.80 (s, 3 H), 2.09 (br, 4 H), 2.27 (s, 6 H), 
3.56 (s, 2 H), 4.65 (d, J = 6.3 Hz, 2 H), 5.07 (br, 1 H), 5.36 (t, J = 6.3 Hz, 1 H), 
6.90-6.96 (m, 1 H), 7.09 (s, 1H), 7.17-7.22 (m, 1 H), 7.31-7.34 (m, 1H). 13C NMR 
(75 MHz, CDCl3) δ 16.3, 17.7, 25.6, 26.2, 39.4, 44.2, 45.2, 54.4, 104.0, 104.3, 
109.5, 109.8, 109.9, 110.1, 111.6, 119.5, 123.6, 128.5, 128.8, 131.8, 132.9, 









ethylethanamine (2-2). Yellow oil. Yield: 43.4 %.  1H NMR (300 MHz, CDCl3): δ 
1.09 (t, J = 6.9 Hz, 6 H), 1.59 (s, 3 H), 1.67 (s, 3 H), 1.80 (s, 3 H), 2.09 (br, 4 H), 
2.55 (q, J = 6.9 Hz, 4 H), 3.72 (s, 2 H), 4.65 (d, J = 6.6 Hz, 2 H), 5.07 (br, 1 H), 
5.36 (t, J = 6.0 Hz, 1 H), 6.90-6.96 (m, 1 H), 7.08 (s, 1H), 7.17-7.21 (m, 1 H), 
7.35-7.38 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 11.8, 16.4, 17.7, 25.6, 26.2, 39.4, 
44.3, 46.5, 48.0, 104.3, 104.6, 109.4, 109.7, 109.9, 110.0, 111.8, 119.7, 123.6, 




methylpropan-1-amine (2-3). Yellow oil. Yield: 66.6 %.  1H NMR (300 MHz, 
CDCl3): δ 0.92 (t, J = 7.5 Hz, 3 H), 1.51-1.70 (m, 5 H), 1.72 (s, 3 H), 1.80 (s, 3 H), 
2.05-2.14 (m, 4 H), 2.21 (s, 3 H), 2.37 (t, J = 7.5 Hz, 2 H), 3.62 (s, 2 H), 4.65 (d, J 
= 6.6 Hz, 2 H), 5.05 (br, 1 H), 5.36 (t, J = 6.6 Hz, 1 H), 6.90-7.00 (m, 1 H), 7.11 






16.4, 17.7, 20.7, 25.7, 26.2, 39.4, 42.1, 44.2, 52.7, 59.5, 104.2, 104.5, 109.4, 
109.7, 109.9, 110.0, 111.8, 119.6, 123.6, 128.4, 128.9, 131.9, 132.9, 139.8, 
156.0, 159.2.  
 
N-Ethyl-N-((5-fluoro-1-octyl-1H-indol-3-yl)methyl)propan-1-amine (2-4). 
Yellow oil. Yield: 61.5 %.1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 7.5 Hz, 3 H), 
1.07 (t, J = 7.2 Hz, 3 H), 1.48-1.80 (m, 11 H), 2.05-2.11 (m, 4 H), 2.42 (t, J = 7.2 
Hz, 2 H), 2.53 (q, J = 7.2 Hz, 2 H), 3.71 (s, 2 H), 4.65 (d, J = 6.6 Hz, 2 H), 5.06 
(br, 1 H), 5.36 (t, J = 6.6 Hz, 1 H), 6.89-6.96 (m, 1 H), 7.06 (s, 1H), 7.16-7.21 (m, 
1 H), 7.35-7.39 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 11.8, 12.0, 16.4, 17.7, 20.2, 
25.7, 26.2, 39.4, 44.2, 47.1, 48.7, 55.1, 104.4, 104.7, 109.4, 109.7, 109.8, 110.0, 
112.1, 119.7, 123.7, 128.2, 128.9, 131.9, 132.9, 139.7, 156.0, 159.1. Elemental 
analysis: calc./found (C, H): 77.79, 9.52 ⁄ 78.26, 9.66. 
 
 (E)-N-Butyl-N-((1-(3,7-dimethylocta-2,6-dienyl)-5-fluoro-1H-indol-3-
yl)methyl) butan-1-amine (2-5). Yellow oil. Yield: 41.8 %.1H NMR (300 MHz, 
CDCl3): δ 0.88 (t, J = 7.2 Hz, 6 H), 1.23-1.35 (m, 4 H), 1.44-1.54 (m, 4 H), 1.67 
(s, 3 H), 1.72 (s, 3 H), 1.80 (s, 3 H), 2.05-2.12 (m, 4 H), 2.43 (t, J = 7.5 Hz, 4 H), 






6.89-6.95 (m, 1 H), 7.04 (s, 1H), 7.16-7.20 (m, 1 H), 7.34-7.38 (m, 1H). 13C NMR 
(75 MHz, CDCl3) δ 14.1, 16.4, 17.7, 20.7, 25.7, 26.2, 29.2, 39.4, 44.2, 49.4, 53.4, 
104.4, 104.7, 109.3, 109.7, 109.8, 110.0, 112.4, 119.7, 123.7, 128.2, 128.9, 
131.9, 133.0, 139.8, 156.0, 159.0. 
 
(E)-1-(3,7-Dimethylocta-2,6-dienyl)-5-fluoro-3-(piperidin-1-ylmethyl)-1H-
indole (2-6). Yellow oil. Yield: 14.7 %.1H NMR (300 MHz, CDCl3): δ 1.42 (br, 2 
H), 1.59 (br, 7 H), 1.66 (s, 3 H), 1.80 (s, 3 H), 2.08 (br, 4 H), 2.45 (br, 4 H), 3.64 
(s, 2 H), 4.65 (d, J = 6.3 Hz, 2 H), 5.06 (br, 1 H), 5.36 (t, J = 6.3 Hz, 1 H), 6.90-
6.96 (m, 1 H), 7.11 (s, 1H), 7.17-7.21 (m, 1 H), 7.33-7.36 (m, 1H). 13C NMR (75 
MHz, CDCl3) δ 16.4, 17.7, 24.3, 25.7, 25.9, 26.2, 39.4, 44.3, 53.9, 54.2, 104.2, 
104.5, 109.4, 109.8, 109.9, 110.1, 110.7, 119.6, 123.6, 128.9, 129.1, 129.3, 
131.9, 132.8, 156.1, 159.2.  
 
 (E)-4-((1-(3,7-Dimethylocta-2,6-dienyl)-5-fluoro-1H-indol-3-
yl)methyl)morpholine (2-7). Yellow oil. Yield: 58.6 %.1H NMR (300 MHz, 
CDCl3): δ 1.59 (s, 3 H), 1.67 (s, 3 H), 1.80 (s, 3 H), 2.05-2.13 (m, 4 H), 2.49 (br, 4 
H), 3.64 (s, 2 H), 3.70-3.73 (m, 4 H), 4.65 (d, J = 6.6 Hz, 2 H), 5.06 (d, J = 6.0 Hz, 






H), 7.36-7.40 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 16.4, 17.7, 25.7, 26.2, 39.4, 
44.3, 53.5, 54.0, 67.0, 104.3, 104.6, 109.6, 109.9, 110.0, 110.2, 110.4, 119.5, 
123.6, 128.6, 128.9, 131.9, 133.0, 140.0, 156.1, 159.2.  
 
(E)-4-((1-(3,7-Dimethylocta-2,6-dienyl)-5-fluoro-1H-indol-3-yl)methyl) 
thiomorpholine (2-8). Yellow oil. Yield: 43.2 %.1H NMR (300 MHz, CDCl3): δ 
1.59 (s, 3 H), 1.67 (s, 3 H), 1.80 (s, 3 H), 2.09 (br, 4 H), 2.68-2.69 (m, 4 H), 2.73-
2.75 (m, 4 H), 3.66 (s, 2 H), 4.65 (d, J = 6.6 Hz, 2 H), 5.06 (br, 1 H), 5.36 (t, J = 
6.6 Hz, 1 H), 6.90-6.97 (m, 1 H), 7.17 (s, 1H), 7.19-7.22 (m, 1 H), 7.34-7.38 (m, 
1H). 13C NMR (75 MHz, CDCl3) δ 16.4, 17.7, 25.7, 26.2, 28.0, 39.4, 44.3, 54.4, 
54.7, 104.4, 104.7, 109.6, 109.7, 109.9, 110.0, 110.4, 119.5, 123.6, 128.6, 128.9, 
131.9, 133.0, 139.9, 156.1, 159.2. 
 
 (E)-1-(3,7-Dimethylocta-2,6-dienyl)-5-fluoro-3-((4-methylpiperazin-1-
yl)methyl)-1H-indole (2-9). Yellow oil. Yield: 17.7 %.1H NMR (300 MHz, CDCl3): 
δ 1.58 (s, 3 H), 1.66 (s, 3 H), 1.79 (s, 3 H), 2.08-2.10 (m, 4 H), 2.28 (s, 3 H), 2.45 
(br, 8 H), 3.64 (s, 2 H), 4.63 (d, J = 6.3 Hz, 2 H), 5.06 (d, J = 6.3 Hz, 1 H), 5.35 (t, 
J = 6.3 Hz, 1 H), 6.89-6.96 (m, 1 H), 7.07 (s, 1H), 7.16-7.20 (m, 1 H), 7.34-7.38 






52.9, 53.4, 55.1, 104.3, 104.7, 109.5, 109.8, 109.9, 110.1, 110.7, 110.8, 119.6, 
123.6, 128.6, 128.9, 131.9, 132.9, 139.9, 156.1, 159.2. 
 
 (E)-1-(3,7-Dimethylocta-2,6-dienyl)-3-((4-ethylpiperazin-1-yl)methyl)-5-
fluoro-1H-indole (2-10). Yellow oil. Yield: 51.9 %.1H NMR (300 MHz, CDCl3): δ 
1.07 (t, J = 6.9 Hz, 3 H), 1.58 (s, 3 H), 1.66 (s, 3 H), 1.79 (s, 3 H), 2.01-2.12 (m, 4 
H), 2.37-2.53 (m, 10 H), 3.65 (s, 2 H), 4.63 (t, J = 6.63 Hz, 2 H), 5.06 (t, J = 6.0 
Hz, 1 H), 5.35 (t, J = 6.6 Hz, 1 H), 6.88-6.95 (m, 1 H), 7.06 (s, 1H), 7.15-7.20 (m, 
1 H), 7.34-7.38 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 11.9, 16.3, 17.7, 25.7, 26.1, 
39.4, 44.2, 52.2, 52.8, 52.9, 53.4, 104.3, 104.6, 109.5, 109.8, 109.9, 110.0, 
110.7, 110.8, 119.6, 123.6, 128.5, 128.9, 131.8, 132.9, 139.9, 156.0, 159.1.  
 
(E)-1-(3,7-Dimethylocta-2,6-dienyl)-5-fluoro-3-(pyrrolidin-1-ylmethyl)-1H-
indole (2-11). Yellow oil. Yield: 45.9 %.1H NMR (300 MHz, CDCl3): δ 1.58 (s, 3 
H), 1.66 (s, 3 H), 1.79 (br, 7 H), 2.04-2.12 (m, 4 H), 2.59 (br, 4 H), 3.78 (s, 2 H), 
4.65 (d, J = 6.6 Hz, 2 H), 5.06 (t, J = 6.3 Hz, 1 H), 5.36 (t, J = 6.6 Hz, 1 H), 6.89-
6.96 (m, 1 H), 7.14 (s, 1H), 7.17-7.21 (m, 1 H), 7.31-7.35 (m, 1H). 13C NMR (75 






109.4, 109.7, 109.9, 110.0, 111.8, 119.7, 123.6, 128.4, 128.9, 131.9, 132.9, 
139.8, 156.0, 159.2.  
Series 3:  
 
N,N-Dimethyl-1-(1-(3-methylbut-2-enyl)-5-m-tolyl-1H-indol-3-yl)methanamine 
(3-1). Yellow oil. Yield: 33.1 %.1H NMR (300 MHz, CDCl3): δ 1.79 (s, 3 H), 1.85 
(s, 3 H), 2.33 (s, 6 H), 2.45 (s, 3 H), 3.69 (s, 2 H), 4.70 (d, J = 6.6 Hz, 2 H), 5.41 
(t, J = 6.6 Hz, 1 H), 7.11-7.15 (m, 2 H), 7.32-7.38 (m, 2 H), 7.45-7.49 (m, 3H), 
7.86 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 18.0, 21.6, 25.6, 44.1, 45.2, 54.2, 
109.6, 111.8, 117.7, 119.9, 121.3, 124.6, 126.9, 127.7, 128.2, 128.5, 129.0, 
132.8, 135.7, 136.3, 138.1, 142.7. Elemental analysis: calc./found (C, H): 83.09, 
8.49 ⁄ 79.22, 8.87. 
 
N-Ethyl-N-((1-(3-methylbut-2-enyl)-5-m-tolyl-1H-indol-3-
yl)methyl)ethanamine (3-2). 1H NMR (300 MHz, CDCl3): δ 1.13 (t, J = 7.2 Hz, 6 
H), 1.79 (s, 3 H), 1.85 (s, 3 H), 2.46 (s, 3 H), 2.61 (q, J = 7.2 Hz, 4 H), 3.84 (s, 2 
H), 4.69 (d, J = 6.9 Hz, 2 H), 5.41 (t, J = 6.9 Hz, 1 H), 7.11 (s, 1 H), 7.13-7.16 (m, 






CDCl3) δ 11.9, 18.0, 21.6, 25.6, 44.1, 46.6, 47.8, 109.5, 112.1, 118.0, 120.0, 
121.2, 124.5, 126.9, 127.5, 128.2, 128.5, 129.2, 132.6, 135.7, 136.1, 138.1, 




1-amine (3-3). Yellow oil. Yield: 59.2 %.1H NMR (300 MHz, CDCl3): δ 0.94 (t, J = 
7.2 Hz, 3 H), 1.56-1.65 (m, 2 H), 1.78 (s, 3 H), 1.84 (s, 3 H), 2.42 (s, 3 H), 2.45-
2.47 (m, 5 H), 3.76 (s, 2 H), 4.69 (d, J = 6.6 Hz, 2 H), 5.41 (t, J = 5.7 Hz, 1 H), 
7.08-7.15 (m, 2 H), 7.32-7.37 (m, 2H), 7.44-7.48 (m, 3H), 7.88 (s, 1H). 13C NMR 
(75 MHz, CDCl3) δ 11.9, 18.0, 20.6, 21.6, 25.7, 42.0, 44.1, 52.5, 59.3, 109.6, 
111.6, 118.0, 119.9, 121.3, 124.5, 127.0, 127.7, 128.2, 128.5, 129.1, 132.7, 
135.7, 136.2, 138.0, 142.7. Elemental analysis: calc./found (C, H): 83.28, 8.95 ⁄ 










MHz, CDCl3): δ 0.93 (t, J = 7.2 Hz, 3 H), 1.11 (t, J = 7.2 Hz, 3 H), 1.54-1.66 (m, 2 
H), 1.79 (s, 3 H), 1.85 (s, 3 H), 2.42 (s, 3 H), 2.46-2.51 (m, 5 H), 2.59 (q, J = 7.2 
Hz, 2 H), 3.83 (s, 2 H), 4.69 (d, J = 6.6 Hz, 2 H), 5.42 (t, J = 6.3 Hz, 1 H), 7.08 (s, 
1 H), 7.14 (d, J = 7.5 Hz, 1 H), 7.32-7.37 (m, 2H), 7.45-7.49 (m, 3H), 7.93 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ 11.9, 12.0, 18.0, 20.3, 21.6, 25.6, 44.1, 47.1, 48.6, 
55.2, 109.5, 112.6, 118.2, 120.1, 121.1, 124.5, 126.9, 127.3, 128.2, 128.5, 129.2, 
132.5, 135.8, 136.1, 138.1, 142.8. Elemental analysis: calc./found (C, H): 83.37, 




amine (3-5). Yellow oil. Yield: 42.1 %.1H NMR (300 MHz, CDCl3): δ1H NMR (300 
MHz, CDCl3): δ 0.91 (t, J = 7.2 Hz, 6 H), 1.28-1.40 (m, 4 H), 1.49-1.59 (m, 4 H), 
1.79 (s, 3 H), 1.85 (s, 3 H), 2.45-2.52 (m, 7 H), 3.81 (s, 2 H), 4.69 (d, J = 6.6 Hz, 
2 H), 5.41 (t, J = 6.3 Hz, 1 H), 7.06 (s, 1 H), 7.14 (d, J = 7.5 Hz, 1 H), 7.32-7.36 
(m, 2H), 7.44-7.49 (m, 3H), 7.93 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 14.1, 18.0, 
20.8, 21.6, 25.6, 29.3, 44.1, 49.2, 53.5, 109.4, 112.8, 118.3, 120.1, 121.1, 124.4, 
126.8, 127.3, 128.2, 128.5, 129.2, 132.4, 135.8, 136.1, 138.0, 142.8. Elemental 








Yellow oil. Yield: 70.2 %.1H NMR (300 MHz, CDCl3): δ 1.43-1.44 (m, 2 H), 1.56-
1.64 (m, 4 H), 1.79 (s, 3 H), 1.85 (s, 3 H), 2.46-2.50 (m, 7 H), 3.74 (s, 2 H), 4.69 
(d, J = 6.6 Hz, 2 H), 5.41 (t, J = 6.6 Hz, 1 H), 7.11-7.16 (m, 2 H), 7.32-7.37 (m, 2 
H), 7.44-7.497 (m, 3H), 7.89 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 18.0, 21.6, 
24.4, 25.7, 26.0, 44.1, 53.8, 54.3, 109.6, 111.3, 118.0, 120.0, 121.2, 124.6, 
127.0, 127.9, 128.2, 128.5, 129.4, 132.7, 135.6, 136.1, 138.1, 142.8. Elemental 
analysis: calc./found (C, H): 83.82, 8.66 ⁄ 83.36, 8.66. 
 
4-((1-(3-Methylbut-2-enyl)-5-m-tolyl-1H-indol-3-yl)methyl)morpholine (3-7). 
Yellow oil. Yield: 34.2 %. 1H NMR (300 MHz, CDCl3): δ 1.72 (s, 3 H), 1.76 (s, 3 
H), 2.44 (s, 3 H), 2.45-2.51 (m, 4H), 3.58 (s, 2 H), 3.65-3.68 (m, 4H), 4.57 (d, J = 
6.9 Hz, 2 H), 5.28 (t, J = 6.9 Hz, 1 H), 7.00 (s, 1 H), 7.07-7.12 (m, 2 H), 7.20-7.24 
(m, 1 H), 7.39-7.41 (m, 3H), 7.80 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 18.0, 21.6, 
25.7, 44.2, 53.5, 53.8, 66.9, 111.0, 112.5, 119.4, 119.8, 122.1, 124.3, 127.0, 








8). Yellow oil. Yield: 52.9 %. 1H NMR (300 MHz, CDCl3): δ 1.79 (s, 3 H), 1.85 (s, 
3 H), 2.46 (s, 3 H), 2.68-2.71 (m, 4H), 2.80-2.81 (m, 4H), 3.77 (s, 2 H), 4.69 (d, J 
= 6.9 Hz, 2 H), 5.40 (t, J = 6.9 Hz, 1 H), 7.08 (s, 1 H), 7.15 (d, J = 7.2 Hz, 1 H), 
7.32-7.37 (m, 2 H), 7.45-7.47 (m, 3H), 7.89 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 
18.0, 21.6, 25.7, 28.0, 44.2, 54.3, 54.8, 109.7, 110.7, 118.1, 119.9, 121.4, 124.5, 
127.0, 127.8, 128.2, 128.5, 129.1, 132.8, 135.8, 136.3, 138.1, 142.7. Elemental 
analysis: calc./found (C, H): 76.88, 7.74 ⁄ 75.95, 7.57.  
 
1-(3-Methylbut-2-enyl)-3-((4-methylpiperazin-1-yl)methyl)-5-m-tolyl-1H-
indole (3-9). Yellow oil. Yield: 38.4 %.1H NMR (300 MHz, CDCl3): δ 1.78 (s, 3 H), 
1.84 (s, 3 H), 2.29 (s, 3 H), 2.45-2.60 (m, 11H), 3.77 (s, 2 H), 4.67 (d, J = 6.6 Hz, 
2 H), 5.39 (br, 1 H), 7.11-7.15 (m, 2 H), 7.33-7.36 (m, 2H), 7.44-7.47 (m, 3H), 
7.89 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 18.0, 21.6, 25.6, 44.1, 45.9, 52.8, 53.2, 






132.7, 135.7, 136.3, 138.1, 142.7. Elemental analysis: calc./found (C, H): 80.58, 
8.58 ⁄ 80.34, 8.75. 
 
1-(3-Methylbut-2-enyl)-3-((4-ethylpiperazin-1-yl)methyl)-5-m-tolyl-1H-indole 
(3-10). Yellow oil. Yield: 13.7 %.1H NMR (300 MHz, CDCl3): δ 7.92 (s, 1 H), 7.49-
7.44 (m, 3 H), 7.37-7.32 (m, 2 H), 7.16-7.10 (m, 2 H), 5.43-5.39 (m, 1 H), 4.68 (d, 
J = 6.6 Hz, 2 H), 3.77 (s, 2 H), 2.63-2.39 (m, 13 H), 1.85 (s, 3H), 1.79 (s, 3 H), 
1.09 (t, J = 7.2 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 142.65, 138.06, 136.16, 
135.68, 132.62, 129.20, 128.46, 128.15, 127.70, 126.91, 124.47, 121.20, 119.90, 




Yellow oil. Yield: 31.1 %.1H NMR (300 MHz, CDCl3): δ 1.78-1.81 (m, 7 H), 1.84 
(s, 3 H), 2.454 (s, 3 H), 2.63 (br, 4H), 3.88 (s, 2 H), 4.68 (d, J = 6.9 Hz, 2 H), 5.40 
(t, J = 6.9 Hz, 1 H), 7.12-7.17 (m, 2 H), 7.26-7.36 (m, 2 H), 7.44-7.48 (m, 3H), 






109.6, 112.3, 117.7, 119.9, 121.2, 124.5, 126.9, 127.4, 128.2, 128.5, 128.9, 
132.7, 135.6, 136.2, 138.1, 142.8 . 
Series 4:   
 
Diethyl-1-(1-octyl-5m-tolyl-1H-indol-3yl(methyl)-amine (4-1)  Yellow oil. Yield: 
110mg.  27%. 1H NMR (400 MHz, CDCl3 δ 0.85 (t, J =7 Hz ,3 H), 1.25-1.49 (m, 
16 H), 1.79 to 1.83 (m 2H),2.45 (s,3H) 3.00-3.35(m, 4 H),  4.12 (t , J =7 Hz, 2H), 
4.45 (s, 2H), 7.10 to 7.35 (m 3H), 7.40 to 7.55 (m 4H),  7.75 (s, 1 H);  13C NMR 
(100 MHz, CDCl3): δ 8.95, 14.07, 21.60, 22.61,  26.94, 29.12, 29.82, 30.06, 
31.76, 45.43, 46.85, 46.92, 101.74, 110.55, 116.11, 122.29, 124.63, 127.64, 
128.21, 128.34, 128.67, 128.75, 131.85, 134.38, 135.60, 138.43, 142.00, 184.49, 
LC-MS (ESI): m/z 405.40. [M+H] .+  
 
Diethyl-[5(2-Fluoro-phenyl)- 1-octyl-1H-indol-3yl methyl -amine (4-2)    
Yellow oil. Yield: 125mg. 30.5 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz ,3 
H), 1.25-1.49 (m, 16 H), 1.79 to 1.83 (m 2H), 3.00-3.35(m, 4 H),  4.12 (t, J =7 Hz , 
2H), 4.45 (s, 2H), 7.10to 7.35 (m 3H), 7.40 to 7.55 (m 4H),  7.75 (s, 1 H),     LC-







Diethyl-[5(3-Fluoro-phenyl)- 1-octyl-1H-indol-3yl methyl –amine (4-3)    
Yellow oil. 115mg.Yield: 28 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz, 3 
H), 1.25-1.49 (m, 16 H), 1.79 to 1.83 (m 2H), 3.00-3.35(m, 4 H),  4.12 (t, J =7 Hz , 
2H), 4.48 (s, 2H), 7.15 (t , J =6Hz, 2H), 7.40 to 7.60 (m 5H), 7.70 (s, 1 H).   13C 
NMR (100 MHz, CDCl3): δ 8.87, 14.05,  22.59,  26.92, 29.11, 30.05, 31.74, 
45.38, 46.83, 46.91, 101.86,110.63, 115.51, 115.72, 116.18,122.08, 128.63, 
128.82, 128.89,  131.93, 133.25, 135.59, 138.12, 160.98, 163.42 ,LC-MS (ESI): 
m/z 409.37. [M+H]. +  
 
Diethyl-1-(1-octyl-5-(2-trifluoromethyl-phenyl) -1H-indol-3ylmethyl-amine (4-
4)      brown oil. Yield: 75mg.16.3 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, 3 H), 
1.25-1.49 (m, 16 H), 1.85 to 1.95 (m 2H), 2.85-3.10(m, 4 H),  4.10-4.35 (m , 4H), 
7.15 (dd, , 1H), 7.40to 7.60 (m 4H), 7.70 (s, 1 H),7.80 (dd, 1H) .LC-MS (ESI): m/z 








5)     Yellow oil. Yield: 90mg.19.6 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, 3 H), 
1.25-1.49 (m, 16 H), 1.79 to 1.83 (m 2H), 3.00-3.35(m, 4 H),  4.12 (t , 2H), 4.55 
(s, 2H), 7.40 - 7.60 (m 5H), 7.70- 7.90 (m, 3 H). 13C NMR (100 MHz, CDCl3): δ 
8.83, 14.04,  22.59,  26.90, 29.10, 30.04, 31.74, 45.40, 46.88, 46.95, 
102.10,110.86, 116.45, 122.04, 122.95 , 123.37,123.40, 124.02,125.65, 128.69, 
129.31, 130.72,130.95,  131.27, 132.72, 135.94, 142.81, 163.42 ,LC-MS (ESI): 
m/z 459.33. [M+H]. +  
 
Diethyl-1-(1-octyl-5-(3-trifluoromethoxy-phenyl) -1H-indol-3ylmethyl-amine 
(4-6)   Reddish oil. Yield: 105mg. 22.1 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, 3 
H), 1.25-1.49 (m, 16 H), 1.79 to 1.83 (m 2H), 2.85-3.10(m, 4 H), 4.12 (t , 2H), 
4.33 (s, 2H), 6.70 – 6.80 (m 1H),  7.10 - 7.30 (m 2H), 7.40- 7.70 (m, 5 H). 13C 
NMR (100 MHz, CDCl3): δ 8.93, 14.03,  22.59,  26.86, 29.12, 30.14, 31.73, 






122.07, 125.67, 128.44,128.56,128.83, 130.10,131.29,  132.64, 135.87, 144.15, 
149.08, 150.04, 158.42 .LC-MS (ESI): m/z 475.50. [M+H]. +  
 
Diethyl- (1-octyl-3-pyridin-3-yl-1H-indol-3ylmethyl)-amine (4-7)  Yellow oil. 
Yield: 196mg.50.0 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz, 3 H), 1.15-
1.49 (m, 16 H), 1.80 to 1.93 (m 2H), 3.00-3.35(m, 4 H), 4.12 (t , J =7 Hz, 2H), 
4.55 (s, 2H), 7.40 – 7.65 (m 3H),  7.75 - 7.85 (m 1H), 8.05 (s, 1 H), 8.50- 8.80 (m, 
2 H), 9.15 (s, 1H).  13C NMR (100 MHz, CDCl3): δ 8.55, 14.03,  22.57,  26.88, 
29.09, 30.04, 31.71, 45.44, 47.01, 47.20, 103.10, 111.48, 117.95, 121.36, 
126.67, 128.58, 132.60, 136.92,140.06, 140.87, 141.11,162.13,162.49 .LC-MS 
(ESI): m/z 392.4. [M+H]. +  
 
Diethyl-[5(5-Fluoro-pyrdin-3yl)- 1-octyl-1H-indol-3yl methyl] -amine (4-8)  
Yellow oil. Yield: 128mg.31.2 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz ,3 
H), 1.15-1.40 (m, 16 H), 1.80 to 1.93 (m 2H,), 2.65-2.80(m, 4 H), 3.95 (s, 2H),  
4.12 (t , J =7 Hz, 2H), 7.00 (dd 1H),  7.25 - 7.45 (m 3H), 7.85 (s, 1 H), 8.05 (m, 1 
H), 8.45 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 11.19, 14.07,  22.62,  26.99, 






128.02, 129.07, 129.41, 136.09, 140.06, 139.94, 145.67, 162.13,164. 49.LC-MS 
(ESI): m/z 410.06. [M+H] .+ 
 
Diethyl-[5(3-nitro-phenyl)- 1-octyl-1H-indol-3yl methyl] -amine (4-9)   Yellow 
solid. Yield: 220mg. 50.2 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, 3 H), 1.15-1.40 
(m, 16 H), 1.80 to 1.93 (m, 2H,), 2.65-2.80(q, 4 H), 4.05 (s, 2H),  4.12 (t , 2H), 
7.35 (s 1H),  7.40 - 7.55 (m 2H), 7.60 (t, 1 H), 7.90 (s, 1 H), 7.95 (dd, 1H), 8.15 
(dd, 1H), 8.50 (s, 1H) .  13C NMR (100 MHz, CDCl3): δ 10.88, 14.08,  22.62,  
26.98, 29.18, 30.25, 31.76, 46.32, 46.66, 47.72, 110.37, 117.82, 
121.05,121.15,121.96, 128.97, 129.57, 129.98,133.27, 136.29, 144.21, 
148.73.LC-MS (ESI): m/z 438.39. [M+H]. +  
 
Diethyl-[5(4-methanesulfonyl-phenyl)- 1-octyl-1H-indol-3yl methyl] -amine 
(4-10)   Yellow oil. Yield: 281mg. 60.00 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, 
J =7 Hz, 3 H), 1.15-1.40 (m, 16 H), 1.70 to 1.90 (m 2H), 2.95-3.05(m, 4 H), 3.10 
(s,3H), 4.12 (t , J =7 Hz, 2H), 4.35 (s, 2H),   7.40-7.50 (m, 2H),  7.55 (s, 1H), 
7.75-7.95 (m, 5 H). 13C NMR (100 MHz, CDCl3): δ 9.31, 14.08,  22.59,  26.92, 






122.06, 125.98, 127.87, 128.09, 128.54, 131.67, 132.13, 136.32,138.31, 
147.54.LC-MS (ESI): m/z 469.39. [M+H] .+  
 
5-(3-Diethylaminomethyl-1-octyl-1H-indol-5-yl)-pyrimidin-2-ylamine (4-12) 
white solid. Yield: 85mg. 20.8 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, 3 H), 
1.15-1.40 (m, 16 H), 1.70 to 1.90 (m 2H), 2.85 (q, 4 H), 4.05 (s,2H), 4.12 (t, , 2H), 
5.25 (br, 2H),   7.25-7.35 (m, 1H), 7.40-7.50 (m, 2H),   7.75 (s, 1H), 8.55 (s, 2H). 
13C NMR (100 MHz, CDCl3): δ 10.55, 14.06,  22.60,  26.97, 29.17, 30.23, 31.75, 
46.06,46.69, 47.47, 110.52, 116.36, 120.41, 126.31,126.88,  129.05, 130.38, 
135.73,  156.58, 161.76,LC-MS (ESI): m/z 408.39. [M+H]. + 
 
Diethyl- (1-octyl-5-pyrimidin-5-yl-1H-indol-3ylmethyl)-amine (4-13)  brown oil. 
Yield: 105mg.  26.7 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz, 3 H), 1.15-
1.40 (m, 16 H), 1.75 to 1.90 (m 2H), 2.7 (q, 4 H), 3.9 (s,2H), 4.12 (t , J =7 Hz, 
2H), 7.25 (br, 1H), 7.4-7.5 (m,2H),   9.00 (s, 2H), 9.15 (s, 1H).  13C NMR (100 
MHz, CDCl3): δ 9.69, 13.88,  22.40,  26.77, 28.96, 29.98, 31.55, 45.67,46.56, 
47.17, 66.89,  110.46, 112.55, 117.00, 118.92, 121.25, 122.88, 128.61,129.71,  








amine(4-14)    Yellow oil. Yield: 128mg.29.4 %.1H NMR (400 MHz, CDCl3,): δ 
0.85 (t, J =7 Hz, 3 H), 1.15-1.40 (m, 16 H), 1.75 to 1.90 (m 2H), 2.9 (q, 4 H), 3.12 
(s,6H),  4.12 (t , J =7 Hz, 2H), 4.2 (s,2H), 6.6 (d, J =6 Hz, 1H),   7.40 (s, 2H), 7.60 
(s, 1H), 7.70-7.80 (m, 2 H),   8.45 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 9.96, 
14.08,  22.61,  26.98, 29.17, 30.22, 31.76, 38.30, 45.83,46.80, 47.28, 105.84, 
110.45, 115.57, 121.06, 125.64, 128.94, 131.02,131.28,  135.21, 136.23, 146.16, 
158.36. LC-MS (ESI): m/z 435.47. [M+H] .+  
 
5-(3-Diethylaminomethyl-1-octyl-1H-indol-5-yl)-pyrimidine-2-carbonitrile (4-
15)  Yellow oil. Yield: 78mg.18.6 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 
Hz, 3 H), 1.10 (t, J =7 Hz, 6 H), 1.15-1.40 (m, 10 H), 1.75 to 1.90 (m 2H), 2.65 (q, 
J =6 Hz 4 H), 3.85 (s,2H), 4.12 (t , J =7 Hz, 2H), 7.18 (s,1H),   7.35-7.50 (m, 2 H),   
8.00 (s, 1H), 9.10 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 11.64, 14.07,  22.61, 
24.88, 26.95, 29.15, 30.25, 31.74, 46.58, 48.09, 67.10, 75.05, 110.86, 
116.13,119.20, 120.22, 123.03, 129.16, 129.37, 137.22,  137.80, 142.19, 155.42. 







4-(3-Diethylaminomethyl-1-octyl-1H-indol-5-yl)-benzonitrile (4-16)   Yellow 
oil. Yield: 65mg.15.6 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz, 3 H), 
1.15-1.40 (m, 16 H), 1.75 to 1.90 (m 2H), 2.95 (m, 4 H), 4.05-4.2 (m,4H), 6.95- 
7.05 (m,2H),  7.20 (m, 1 H), 7.4- 7.6 (m,3H),  7.7- 7.85 (m,2H).  LC-MS (ESI): m/z 
416.53. [M+H] .+ 
 
3-(3-Diethylaminomethyl-1-octyl-1H-indol-5-yl)-phenol (4-17)   Colour less oil. 
Yield: 115mg. 28.25 %.1H NMR (400 MHz, CDCl3,): δ 0.85 (t, J =7 Hz, 3 H), 1.15-
1.40 (m, 16 H), 1.50 (br, 1H) 1.75 to 1.85 (m, 2H), 2.95 (m, 4 H), 4.05-4.2 (m,4H), 
6.30 (m, 1 H),  6.75- 6.8 (m,1H),   6.95 (m, 1 H), 7.0- 7.2 (m,3H),  7.3- 7.4 
(m,2H).LC-MS (ESI): m/z 407.50. [M+H] .+ 
 
4-(3-Diethylaminomethyl-1-octyl-1H-indol-5-yl)-N-methyl-






MHz, CDCl3,): δ 0.85 (t, J =7 Hz, 3 H), 1.15 (t, J =6 Hz 6 H), 1.20-1.40 (m, 10 H), 
1.75 to 1.90 (m, 2H,), 2.75 (m, 4 H), 2.85 (s, 3 H), 3.90 (s,2H), 4.12 (t , J =7 Hz, 
2H), 7.10 (d, J =6 Hz, 1H), 7.20 (m,1H), 7.30-7.45 (m, 4 H), 7.60-7.75 (m, 2H). 
LC-MS (ESI): m/z 484.47. [M+H].+  
Series 5 :  
 
2-[5-(2-Fluoro phenyl-1-octyl-1H-indol-3yl]-acetamide (5-1 ). White solid. 
Yield: 105mg, 58 %.1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 1.33-
1.39 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 3.80 (s, 2 H), 4.14 (t, J = 15 Hz, 2 H), 
5.80 (br,1H) 6.10(br,1H) , 7.11 (s, , 1 H), 7.21-7.19 (dd-1H) , 7.37-7.45 (m, 2 H), 
7.50-7.57 (m, 3 H), 7.80 (s, 1 H); 13C NMR (100 MHz, CDCl3): δ 14.1,  22.6, 27.0, 
29.1, 29.2, 30.3, 31.8, 32.9, 46.5, 108.0, 109.66. 115.91, 116.13,119.5,123.48 , 
123.5, 124.35,127.38 127.66, 127.88, 128.24. 128.32, 129.95, 130.08.4, 131.19, 
131.22, 136.03, 158.64, 161.09, 174.51 ; LC-MS (ESI): m/z 381.17 [M+H] .+  
 
2-[5-(3-Fluoro phenyl-1-octyl-1H-indol-3yl]-acetamide (5-2)  White solid. Yield: 
305mg, 66 %.1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 1.33-1.42 






(br,1H), 6.20(br,1H) , 7.11 (s, , 1 H), 7.21-7.19 (dd-1H) , 7.37-7.45 (m, 2 H), 7.50-
7.57 (m, 3 H), 7.80 (s, 1 H); 13C NMR (100 MHz, CDCl3): δ 14.15, 22.6, 27.0, 
29.2, 29.25, 30.3, 31.8, 32.9, 46.5, 108.0, 109.66,115.91, 116.14,119.5,123.46, 
124.33, 124.36,127.34 127.69, 127.90, 128.23, 128.31, 129.97, 130.10, 131.21, 
131.24, 136.03, 158.65, 161.1, 174.68; LC-MS (ESI): m/z 381.17 [M+H] .+   
 
2-[5-(4-Fluoro phenyl-1-octyl-1H-indol-3yl]-acetamide ( 5-3) White solid. Yield: 
110mg, 62.0 % 1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 1.33-1.42 
(m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 3.80 (s, 2 H), 4.14 (t, J = 15 Hz, 2 H), 5.80 
(br,1H), 6.20(br,1H) ,7.11-7.22 (m, , 3 H), 7.40-7.55 (m, 2 H), 7.60-7.57 (m, 2 H), 
7.80 (s, 1 H); 13C NMR (100 MHz, CDCl3): δ 14.15,  22.6, 27.0, 29.2, 29.25, 30.3, 
31.8, 32.9, 46.5, 108.08, 110.10, 116.14, 115.4, 115.60., 117.27, 121.75, 128.01, 
28.25, 128.38, 128.78, 128.86, 131.39, 131.49, 132.23, 136.00, 138.36, 160.85, 
163.29, 174.61; LC-MS (ESI): m/z 381.17 [M+H] +. 
 
2-[5-(2-Trifluoromethyl  phenyl-1-octyl-1H-indol-3yl]-acetamide (5-4)  White 
solid. Yield: 110mg, 55.0 %1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 






H), 5.80-5.90 (br,2H), 7.11 (s,  1 H), 7.21-7.19(dd-1H), 7.37-7.55 (m, 3 H), 7.57-
7.65 (m, 2 H), 7.80 (d, 1 H); 13C NMR (100 MHz, CDCl3): δ 14.15,  22.6, 27.0, 
29.2, 29.25, 30.3, 31.8, 32.9, 46.5, 107.9,108.92., 119.38, 123.45, 126.01, 
126.06, 126.90, 126.93., 127.84, 131.16, 131.42. 132.74, 135.94, 142.38, 
174.40; LC-MS (ESI): m/z 431.16 [M+H] .+  
 
2-[5-(3-Trifluoromethyl  phenyl-1-octyl-1H-indol-3yl]-acetamide (5-5) White 
solid. Yield: 130mg, 65.0 %1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 
1.33-1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 3.77 (s, 2 H), 4.14 (t, J = 15 Hz, 2 
H), 5.80 (br,1H), 6.10 (br,1H), 7.11 (s,  1 H), 7.4-7.4 (m-4H),7.75-7.85 (m, 2 H), 
7.90 (s 1 H); 13C NMR (100 MHz, CDCl3): δ 14.15, 22.6, 27.0, 29.2, 29.25, 30.3, 
31.8, 32.9, 46.5, 100.01, 102.48, 108.24, 110.31, 119.38, 124.03, 124.07, 
124.11, 125.70, 128.03, 128.20, 128.41, 129.16, 130.58, 130.66, 130.90, 131.22, 







2-[5-(3-Trifluoromethoxy  phenyl-1-octyl-1H-indol-3yl]-acetamide (5-6) 
Yellow oil. Yield: 90mg, 43.0 %1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 
H), 1.33-1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 3.77 (s, 2 H), 4.14 (t, J = 15 Hz, 
2 H), 5.70 (br,1H), 6.10(br,1H), 7.11 (s,  1 H), 7.20 (m-1H),  7.4-7.52(m-4H), 7.6-
7.65 (m, 1 H), 7.80 (s 1 H); 13C NMR (100 MHz, CDCl3): δ 14.10,  22.6, 27.0, 
29.2, 29.25, 30.3, 31.8, 32.9, 46.5, 108.26,110.24,116.80,117.54,118.67, 119.90, 
121.69, 121.97, 124.46, 125.72, 128.17,  129.97, 131.60, 136.35,144.41, 149.7, 
174.46; LC-MS (ESI): m/z 447.15. [M+H] .+  
 
2-[5-(2-Fluoro-4-methyl- phenyl-1-octyl-1H-indol-3yl]-acetamide (5-7) White 
solid. Yield: 110mg, 60.0 %.1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 
H), 1.33-1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 2.4(s.3H), 3.77 (s, 2 H), 4.14 (t, 
J = 15 Hz, 2 H), 5.60 (br,1H), 5.85 (br,1H), 6.9-7.05 (m,2H),7.11 (s,  1 H), 7.4-
7.52(m-3H), 7.70 (s 1 H); 13C NMR (100 MHz, CDCl3): δ 14.15, 21.02, 22.6, 27.0, 
29.2, 29.25, 30.3, 31.8, 32.9, 46.5, 108.05,109.62,116.44, 116.66, 119.31, 
123.46, 125.09,126.89, 127.02,127.44,  127.7, 130.81,130.85, 135.90,138.66 







2-[5-(4-Fluoro-4-pyridin-3-yl)-1-octyl-1H-indol-3yl]-acetamide (5-8) Brown 
solid. Yield: 100mg, 57.0 %1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 
1.33-1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz),2.4(s.3H), 3.77 (s, 2 H), 4.14 (t, J = 
15 Hz, 2 H), 5.60-5.85 (br,2H), 6.9-7.05 (m,1H),7.11 (s,  1 H), 7.4-7.52(m-2H), 
7.70 (s 1 H) 8.0 (t,1H),8.45 (s,1H); 13C NMR (100 MHz, CDCl3): δ 14.09,  22.6, 
27.0, 29.2, 29.25, 30.3, 31.8, 32.9, 46.59, 108.22,109.05, 109.42,110.45, 117.55, 
121.41, 128.13, 128.30,  128.4, 135.86,135.90, 136.31,139.94, 145.64, 145.79, 
161.49,163.86, 174.36;  LC-MS (ESI): m/z 382.55. [M+H] +. 
 
2-(1-Octyl -3-pyridin-3-yl-1H-indol-3yl)-acetamide (5-9)  Yellow solid. Yield: 
110mg, 65.0 %. 1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 1.33-1.42 
(m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 2.4(s.3H), 3.77 (s, 2 H), 4.14 (t, J = 15 Hz, 2 
H), 5.60-5.85 (br,2H), 7.15 (s,  1 H), 7.35-7.42(m-1H), 7.45-7.55 (m, 2 H), 7.8 
(S,1H), 8.00 (dd,1H), 8.6(dd,1H), 8.9 (S,1H); 13C NMR (100 MHz, CDCl3): δ 
14.09,  22.6, 27.0, 29.2, 29.25, 30.3, 31.8, 32.9, 46.61, 108.21,110.45, 117.64, 
121.59, 123.55,128.11, 128.22,129.62, 134.56,136.35,147.64,148.48, 174.19; 







2-[5-(3-Nitro phenyl)-1-octyl-1H-indol-3yl]-acetamide (5-10) Yellow solid. 
Yield: 130mg, 68.0 % 1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 1.33-
1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 3.77 (s, 2 H), 4.14 (t, J = 15 Hz, 2 H), 
5.90 (br,1H),6.45 (br,1H), 7.15 (s,  1 H), 7.35-7.55(m-3H), 7.8 (S,1H), 7.90 
(d,1H), 8.10 (d,1H), 8.5(s,1H); 13C NMR (100 MHz, CDCl3): δ 14.09,  22.6, 27.0, 
29.2, 29.25, 30.3, 31.8, 32.9, 46.61, 108.42,110.41, 117.71, 121.06 ,121.40, 
121.83, 128.14,128.38, 129.54,130.32 ,133.23,136.52,143.91,148.63, 174.19; 
LC-MS (ESI): m/z 408.20. [M+H] +. 
 
 
2-[5-(4-Methane sulfonyl)-1-octyl-1H-indol-3yl]-acetamide (5-11) Brown Oil. 
Yield: 130mg, 63.0 %. 1 H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 
1.33-1.42 (m, 10 H), 1.90 (t, 2 H,) 3.10(s.3H), 3.77 (s, 2 H), 4.14 (t, J = 15 Hz, 2 
H), 5.60-5.85 (br,2H), 7.15 (s,  1 H), 7.4-7.55(m-2H), 7.8 (br-s,3H), 8.00 (d,2H); 
13C NMR (100 MHz, CDCl3): δ 14.09,  22.6, 27.0, 29.2, 29.25, 30.3, 31.8, 32.9, 
44.71,46.61, 118.42. 121.73,127.84,127.99, 128.08,128.36, 130.85, 136.68, 







2-(1-Octyl -5-(1H-pyrazol-3-yl)-1H-indol-3yl)-acetamide (5-12)   Yellow Oil. 
Yield: 85mg, 52.0 %. 1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 1.33-
1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 3.77 (s, 2 H), 4.14 (t, J = 15 Hz, 2 H), 
5.50 (br,1H), 5.80 (br,1H), 7.15 (s,  1 H), 7.35-7.50(m-2H), 7.7 (S,1H), 7.90 
(s,2H); 13C NMR (100 MHz, CDCl3): δ 14.09,  22.6, 27.0, 29.2, 29.25, 30.3, 31.8, 
33.0, 46.52, 107.63, 110.18, 115.80, 120.89, 127.84,127.93,135.62, 174.19; LC-
MS (ESI): m/z 353.16. [M+H]. +  
 
 
Series 6 :  
 
N-Methyl-2-(1-octyl -5-m-tolyl-1H-indol-3yl)-acetamide (6-1) White solid. Yield: 
240mg, 60.0 %.1H NMR (400 MHz, CDCl3,): δ 0.90 (t, J =15 Hz, 3 H), 1.33-1.42 
(m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 2.45 (s,3H), 2.75(d,3H), 3.77 (s, 2 H), 4.14 (t, 
J = 15 Hz, 2 H), 5.70 (br,1H), 7.15 (s,  1 H), 7.2 (d,1H), 7.35 (t,1H), 7.4-7.60 (m-
3H), 7.7 (S,1H) ; 13C NMR (100 MHz, CDCl3): δ 14.09, 22.78, 26.8, 27.0, 28.1, 
29.73, 30.3, 31.66, 31.80, 33.40,  39.32, 46.55, 107.89, 109.95, 117.39,121.93, 
124.44,128.05, 128.13,128.63, 133.30,136.04, 138.28,142.12, 171.53;  LC-MS 







N-Methyl-2-(1-octyl -5-pyridin-3-yl-1H-indol-3yl)-acetamide (6-2) Yellow oil. 
Yield: 235mg, 60.0 %. 1H NMR (400 MHz, CDCl3,): δ 0.96 (t, J =15 Hz, 3 H), 
1.33-1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 2.8(d,3H),  3.77 (s, 2 H), 4.14 (t, J = 
15 Hz, 2 H), 5.50 (br,1H), 7.15 (s,  1 H), 7.35-7.50(m-3H), 7.7 (S,1H), 7.95 
(dd,1H), 8.55(d,1H), 8.85(s,1H); 13C NMR (100 MHz, CDCl3): δ 14.09,  22.6, 
26.42, 27.0, 29.15, 29.20, 30.3, 31.75, 33.1, 46.56,108.05,110.39, 117.59, 
121.45, 123.45,128.27, 128.39, 129.41, 134.58, 136.33, 137.71, 147.42,148.28, 
172.19;  LC-MS (ESI): m/z 378.18. [M+H] .+   
 
N-Ethyl-2-(1-octyl -5-m-tolyl-1H-indol-3yl)-acetamide (6-3)  White solid. Yield: 
120mg, 59.0 %. 1H NMR (400 MHz, CDCl3,): δ 0.90 (t, J =15 Hz, 3 H),1.03(t,3H) 
1.33-1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz), 2.45 (s,3H), 3.3(q,2H), 3.77 (s, 2 H), 
4.14 (t, J = 15 Hz, 2 H), 5.70 (br,1H), 7.15 (s,  1 H), 7.2 (d,1H), 7.35 (t,1H) ,7.4-
7.60(m-3H), 7.7 (S,1H) ; 13C NMR (100 MHz, CDCl3): δ 14.09,14.95,  22.6, 27.8, 
29.10, 30.2, 31.8, 33.15,34.43 ,46.56, 107.58, 109.56, 117.25,121.80, 124.20, 
128.05, 128.23,128.53 ,133.30,136.14, 138.28,142.12, 171.2 ; LC-MS (ESI): m/z 







N-Ethyl-2-(1-octyl -5-pyridin-3-yl-1H-indol-3yl)-acetamide (6-4)  Yellow oil. 
Yield: 82mg, 40.5 %.1H NMR (400 MHz, CDCl3,): δ 0.90 (t, J =15 Hz, 3 H),1.05 (t, 
J =15 Hz, 3 H), 1.33-1.42 (m, 10 H), 1.90 (t, 2 H, J = 15 Hz),3.3(q,2H) , 3.77 (s, 2 
H), 4.14 (t, J = 15 Hz, 2 H), 5.70 (br,1H), 7.15 (s,  1 H), 7.35-7.50(m-3H), 7.7 
(S,1H), 7.95 (dd,1H), 8.55 (d,1H), 8.85 (s,1H); 13C NMR (100 MHz, CDCl3): δ 
14.09,14.87,  22.6, 27.0, 29.20, 30.3, 31.75, 33.1,34.43 ,46.56,108.05,110.39, 
117.59,121.45, 123.45, 128.27, 128.39,129.58, 134.53,136.35,137.67, 
147.63,148.45, 171.23.  LC-MS (ESI): m/z 392.18. [M+H] .+  
 
N-Propyl-2-(1-octyl -5-m-tolyl-1H-indol-3yl)-acetamide (6-5)  White solid. 
Yield: 130mg, 62.2%1H NMR (400 MHz, CDCl3,): δ 0.90 (t, J =15 Hz, 3 
H),1.04(t,3H) 1.33-1.42 (m, 12 H), 1.90 (t, 2 H, J = 15 Hz), 2.45 (s,3H), 3.3(q,2H), 
3.77 (s, 2 H), 4.14 (t, J = 15 Hz, 2 H), 5.70 (br,1H), 7.15 (s,  1 H), 7.2 (d,1H), 7.35 
(t,1H), 7.4-7.60(m-3H), 7.7 (S,1H) ; 13C NMR (100 MHz, CDCl3): δ 11.30,14.19 ,  
22.45, 22.83, 27.2, 29.20, 30.25, 31.70, 33.35,  41.20, 46.65, 107.92, 109.90, 
117.28,121.75, 124.36,128.08, 128.18, 128.50, 133.32, 136.08, 138.36, 142.12, 







N-Propyl-2-(1-octyl -5-pyridin-3-yl-1H-indol-3yl)-acetamide (6-6) Yellow oil. 
Yield: 90mg, 45.9 % 1H NMR (400 MHz, CDCl3,): δ 0.90 (t, J =15 Hz, 3 H),1.05 (t, 
J =15 Hz, 3 H), 1.33-1.42 (m, 12 H), 1.90 (t, 2 H, J = 15 Hz),3.2(q,2H), 3.77 (s, 2 
H), 4.14 (t, J = 15 Hz, 2 H), 5.70 (br,1H), 7.15 (s,  1 H), 7.35-7.50(m-3H), 7.7 
(S,1H), 7.95 (dd,1H), 8.55(d,1H), 8.85(s,1H); 13C NMR (100 MHz, CDCl3): δ 
11.20, 14.09 ,  22.6, 22.79 , 27.0, 29.20, 30.3, 31.75, 33.35,  41.25, 46.60, 
108.11,  110.42, 117.65, 121.56,  123.61,128.27, 128.39,129.54, 134.61, 
136.37,137.72,147.51,148.32, 171.37 ; LC-MS (ESI): m/z 392.18. [M+H] .+  
 
N-Butyl-2-(1-octyl -5-m-tolyl-1H-indol-3yl)-acetamide (6-7)  White solid. Yield: 
340mg, 41.3 %1H NMR (400 MHz, CDCl3,): δ 0.80 (t, J =15 Hz, 3 H),0.90 (t, J 
=15 Hz, 3 H), 1.33-1.42 (m, 14 H), 1.90 (t, 2 H, J = 15 Hz), 2.45 (s,3H),3.2(q,2H), 
3.77 (s, 2 H), 4.14 (t, J = 15 Hz, 2 H), 5.70 (br,1H), 7.15 (s,  1 H), 7.2 (d,1H), 7.35 
(t,1H), 7.4-7.60(m-3H), 7.7 (S,1H), ; 13C NMR (100 MHz, CDCl3): δ 13.69,14.09, 






107.89, 109.95, 117.39,121.93, 124.44,128.05, 128.13,128.63 ,133.30,136.04, 









Purity of final compounds 
Purities were determined using Waters 2695 Separations Module on a Waters 
Xterra C18 column (3.5 µm,  3.0 × 50 mm) at a flow rate of 2.0 mL/min. Mobile 
phases   were (i) H2O with 0.1% TFA, and  (ii) acetonitrile with 0.1% TFA. 
Detection was made at 254 nm using a Waters 2996 photodiode array detector. 
Two gradient systems were used. In A, solvents (i) and (ii) were mixed in the 
proportion of 99.5% (i) -0.5% (ii)  to 5% (i)-99.5% (ii).  In B,  solvents (i) and (ii) 
were mixed in the proportion of 99.5% (i) -0.5% (ii)  to 70 % (i)-30% % (ii).   The 
chromatogram was run for 6 min for the detection of major peak.Area %  = [Area 










Appendix:1-2  HPLC Purity Determination of synthesized compounds1 
Cpd No Gradient  A Gradient -B 
RT (min) Area (%) RT(min) Area(%) 
Cysmethynil  2.64 99.78 4.71 99.66 
1-1 3.104 99.29 4.46 97.42 
1-2 3.17 99.38 4.59 99.51 
1-3 2.94 98.32 4.25 96.86 
1-4 3.13 99.62 4.53 97.53 
1-5 2.48 97.79 3.46 94.64 
1-6 3.07 98.39 4.44 97.45 
1-7 2.05 96.18 3.28 95.20 
1-8 3.36 96.61 4.58 99.11 
1-16 3.17 97.43 4.60 97.43 
1-17 3.09 99.21 4.51 97.44 
1-18 3.40 98.89 5.00 99.0 
1-19 2.99 97.32 4.24 97.69 
1-20 2.70 95.91 4.73 95.14 
1-21 3.40 97.92 4.56 94.62 
1-22 3.16 99.19 4.47 97.65 
1-23 3.16 98.18 4.55 93.63 
1-24 3.18 99.49 4.65 95.72 
1-25 3.26 95.37 4.71 99.0 






4-1 0.70 98.52 1.17 95.42 
4-2 3.44 97.03 4.82 86.19 
4-3 2.10 99.9 4.79 99.9 
4-4 ND  ND  
4-5 3.61 91.50 4.89 89.60 
4-6 5.03 98.22 2.51 98.66 
4-7 1.02 99.90 2.20 99.76 
4-8 1.23 91.68 3.02 93.49 
4-9 2.20 96.56 3.57 98.73 
4-10 3.09 95.31 3.01 95.54 
4-12 2.50 98.88 4.74 99.19 
4-13 0.26 97.85 2.65 99.16 
4-14 0.28 91.45 2,28 93.59 
4-15 1.190 91.02 3.02 97.12 
4-16 1.29 95.36 3.29 93.46 
4-17 1.19 93.16 3.15 95.73 
4-18 1.17 96.06 3.05 96.00 
5-1 2.61 99.05 4.59 98.32 
5-2 2.60 98.76 4.60 98.70 






5-4 2.74 99.42 4.74 98.95 
5-5 2.81 99.87 4.79 99.62 
5-6 2.86 99.43 4.81 100.0 
5-7 2.73 99.12 4.73 97.05 
5-8 2.38 99.89 4.03 99.23 
5-9 2.02 99.18 4.56 95.18 
5-10 1.73 97.14 2.53 97.14 
5-11 2.02 99.39 3.20 98.94 
5-12 2.00 99.44 3.19 99.34 
6-1 2.77 95.88 3.93 96.53 
6-2 1.80 95.14 4.12 99.0 
6-3 2.88 99.46 No peak 
crashed 
- 
6-4 1.73 99.88 2.52 99.0 
6-5 3.153 98.24 4.57 99.0 
6-6 1.99 98.73 3.12 98.10 
6-7 3.04 97.96 4.89 99.37 
7-3 2.21 97.19 3.61 93.73 











































































































Appendix 2  




Regression Equation: y = 4.66e-006 x + 0.000817 (r = 0.9810) 








Regression Equation: y = 12.1 x + 7.85e+003 (r = 0.9982) 













2,000.00 788.42 89.4 
5,000.00 6053.95 121.1 
7,500.00 7002.28 93.4 
10,000.00 12279.67 122.8 
50,000.00 47459.60 94.9 
75,000.00 74183.44 98.9 
100,000.00 79509.39 79.5 
Appendix 2-3 : Cysmethynil standard calibration 
Comparison of theoretical versus experimentally determined concentrations of 








75,000.00 73880.120 98.51 
10,000.00 8905.714 89.06 
50,000.00 51598.541 103.20 
100,000.00 84942.716 84.94 
2,000.00 2391.215 119.56 
7,500.00 6504.885 86.73 
5,000.00 5823.271 116.47 













2,000.00 1997.90 99.9 
10,000.00 9869.37 98.7 
25,000.00 25930.60 103.7 
75,000.00 76642.40 102.2 
100,000.00 105523.16 105.5 
2.000e+05 179952.05 90.0 
Appendix 2-5 : 4.12 Standard calibration 








25,000.00 27512.087 110.05 
75,000.00 85210.504 113.61 
100,000.00 128670.454 128.67 
2.000e+05 199263.704 99.63 










Calculated sample concentration:  
Cysmethynil-20mg/kg 
Time Conc  ng/mL Mean  Stdev 
h Mice 1 Mice 2 Mice 3 ng/mL ng/mL 
0.083 84000 188000 120400 130800 52774.24 
0.25 283200 122400 224400 210000 81361.42 
0.75 26700 331000 273000 210233.3 161568.4 
1.5 115000 188000 243000 182000 64210.59 
3 74500 94700 87600 85600 10247.44 
8 8970 15700 15900 13523.33 3944.57 
24   7.51   7.51   
48     25.5 25.5   
Appendix 2-7 : Cysmethynil 20mg/kg  Peak area. 
Cysmethynil-100mg/kg 
Time Conc  ng/mL Mean  Stdev 
h Mice 1 Mice 2 Mice 3 ng/mL ng/mL 
0.083 40400 54600 289000 128000 139610.7 
0.25 97200 109200 128000 111466.7 15524.6 
0.75 595000 1650000 1240000 1161667 531844.3 
1.5 753000 583000 632000 656000 87504.29 
3 213000 557000 643000 471000 227534.6 






24 9290 839 9780 6636.333 5026.612 
48   809 353 581 322.4407 
Appendix 2-8: Cysmethynil 100mg/kg  Peak area 
 
4.12-10mg/kg 







3 ng/mL ng/mL 
0.083 8630 6630 1750 5670.00 3539.04 
0.25 4840 38500 10200 17846.67 18085.98 
0.75 7170 9980 13700 10283.33 3275.55 
1.5 8540 4050 7000 6530.00 2281.60 
3 1100 1350 915 1121.67 218.31 
8 339   99.8 219.40 169.14 
24           
48           
4.12-25mg/kg 







3 ng/mL ng/mL 
0.083 25800 11000 321 12373.67 12794.92 






0.75 21300 20000 10900 17400.00 5666.57 
1.5 6400 6670 9600 7556.67 1774.72 
3 2200 822 11200 4740.67 5636.22 
8 313 290   301.50 16.26 
24           
48           
Appendix 2-9: 4-12   10 and 25mg/kg  Peak area 










Rsq 0.9985 0.9643 0.9251 0.9923 
Rsq_adjusted 0.9978 0.9554 0.9002 0.9846 
Corr_XY -0.9993 -0.982 -0.9618 -0.9961 
No_points_lambda_z 4 6 5 3 
Lambda_z 0.4482 0.1627 0.5545 0.5096 
Lambda_z_lower 1.5 0.75 0.25 1.5 
Lambda_z_upper 24 48 8 8 
HL_Lambda_z 1.5464 4.2602 1.25 1.3603 
Tlag 0 0 0 0 
Tmax 0.75 0.75 0.25 0.75 
Cmax 210233.3333 1161666.667 17846.6667 17400 
Cmax_D 0.0105 0.0116 0.0018 0.0007 
Tlast 24 48 8 8 
Clast 7.51 581 219.4 301.5 
AUClast 842785.9133 7692164.467 24627.8633 40805.735 
AUCall 842785.9133 7692164.467 24627.8633 40805.735 
AUCINF_obs 842802.6675 7695735.352 25023.5278 41397.4224 
AUCINF_D_obs 0.0421 0.077 0.0025 0.0017 
AUC_%Extrap_obs 0.002 0.0464 1.5812 1.4293 
Vz_F_obs 52.9405 79.8637 720.679 1185.1456 
Cl_F_obs 23.7303 12.9942 399.6239 603.9023 
AUCINF_pred 842803.8019 7694471.648 24925.4965 41420.8808 
AUCINF_D_pred 0.0421 0.0769 0.0025 0.0017 
AUC_%Extrap_pred 0.0021 0.03 1.1941 1.4851 
Vz_F_pred 52.9404 79.8768 723.5134 1184.4744 
Cl_F_pred 23.7303 12.9963 401.1956 603.5603 






AUMCINF_obs 2396979.073 46003848.28 36589.5834 80113.1398 
AUMC_%Extrap_obs 0.0183 0.4203 10.601 7.3579 
AUMCINF_pred 2397008.828 45935423.64 35628.5441 80346.844 
AUMC_%Extrap_pred 0.0196 0.272 8.1895 7.6274 
MRTlast 2.8436 5.9555 1.3282 1.8188 
MRTINF_obs 2.8441 5.9778 1.4622 1.9352 
MRTINF_pred 2.8441 5.9699 1.4294 1.9398 
 
Appendix-2-10: Winnonlin calculated parameters for Cysmethynil  and 4.12. 
Appendix 3 
Metabolic stability of 4-12 in rat liver microsomes 
 
Appendix3-1: Percentages of remaining cpd 4-12 and PC relative to initial 
amounts (t = 0) in rat liver microsomes upon incubation at 37 OC for 5, 10, 15, 30 









in vitro system k (1/min) T1/2 (min) 





RLM 0.061±0.003 11.3±0.4 204.0±9 24.7±1 
Cpd 4-12-
Female RLM 0.040±0.004 17.6±2.1 132.1±15 16.1±1.7 
Appendix 3-2: The parameters of k, T1/2, Clint, in vitro and Clint, app values (mean + 
std. dev.) of cpd 4-12 (6 μM) upon incubation at 37 OC for 45 min  
Metabolic stability of cysmethynil in rat liver microsomes 
 
Appendix-3-3: Percentages of remaining cysmethynil and PC relative to initial 
amounts (t = 0) in rat liver microsomes upon incubation at 37 OC for 5, 15, 30 and 
























system k (1/min) T1/2 (min) 





Male RLM 0.0153±0.003 44.0±8 53.6±9 6.5±1 
Cysmethynil-
Female RLM 0.0101±0.0003 65.8±5 35.2±3 4.3±0.3 
Appendix-3-4: The parameters of k, T1/2, Clint, in vitro and Clint, app values (mean + 
std. dev.) of cysmethynil (3 μM) upon incubation at 37 OC for 45 min  
Apendix 4 
Survival of Data 1:Survival proportions


















































0 100 100 100 100 100 
4         87.5 
6   87.5       
8     87.5   75 
10     75     
18         62.5 
22     62.5     
23 87.5         
24   62.5   87.5   
25 87.5 62.5 62.5 87.5 62.5 
 
Appendix 4-2: Xenograft study mice Survival proportion 
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